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Abstract 
 
Shortages in deceased organ donation have necessitated widespread 
acceptance of living donor kidney transplantation, which offers better 
outcomes in terms of graft survival, life expectancy and quality of life for 
many patients with end-stage kidney disease, compared with deceased 
donor kidney transplantation and dialysis. However, there are barriers 
and challenges that exist in the current practice of living kidney donor 
transplantation. Overall, the rates of living kidney donor transplantation 
have decreased or plateaued, with ethical and socio-economic disparities 
in access to living kidney donation reported in many countries, that 
remain largely unexplained. Living donors must accept risks associated 
with undergoing nephrectomy, despite the evidence on the long-term risks 
of living kidney donation remaining uncertain. In response, there have 
been efforts to identify and describe the barriers and disparities in living 
kidney donor transplantation, and to assess a range of outcomes for living 
donors. Yet, little is known about the donors’ priorities for outcomes. A 
comprehensive understanding of the values, beliefs, experiences, priorities 
and preferences of the key stakeholders, including donors and health 
professionals involved in their care, is needed to ensure that research, 
clinical practice and policy in living kidney donations address their needs 
and priorities.  
The first part of this thesis (Chapters 3 to 6) consists of qualitative studies 
that describe in-depth the perspectives and experiences of kidney 
transplant recipients, living kidney donors and nephrologists. These 
studies address recipient decision-making, donors’ experiences of the 
evaluation process, and nephrologists’ perspectives on recipient eligibility 
and disparities in living kidney donor transplantation.  
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Chapter 2 provides an overview of qualitative health research methods 
and principles including participant selection, data collection and analysis. 
The approaches used to demonstrate rigour are discussed in terms of 
credibility, confirmability, dependability and transferability. 
In Chapter 3, to understand recipient expectations and attitudes 
regarding living kidney donor transplantation, a systematic review and 
thematic synthesis of primary qualitative studies that examined recipient 
perspectives was conducted. Six themes were identified, including 
prioritising own health, guilt and responsibility, ambivalence and 
uncertainty, seeking decisional validation, needing social support, and 
cautious donor recruitment. A new conceptual schema of the barriers and 
facilitators was developed, highlighting the need to address patients’ 
concerns regarding donor outcomes, guilt, relationship tensions and donor 
recruitment.  
Chapter 4 examines how donors sustain commitment to donation during 
the evaluation period, including their experiences with informed consent, 
and their medical and psychosocial assessment. From focus groups 
conducted in Australia and Canada, themes were identified that reflected 
the challenges they experienced, including underlying fears for their 
health, obstructive system shortfalls and lifestyle interference. Their 
emotional investment, feeling undeterred by low risks, and mental 
preparation for possible donation outcomes sustained their commitment 
throughout the evaluation process, despite facing these challenges.   
Chapter 5 describes nephrologists’ attitudes towards recipient eligibility 
and access to living kidney donor transplantation. Nephrologists from 
Australia and New Zealand participated in a semi-structured interview 
study. The themes identified reflected nephrologists’ competing priorities -  
to achieve optimal recipient outcomes, ensure the risk to the donor was 
justified, and to protect their transplant unit’s integrity. Nephrologists 
also considered disparities to be entrenched and difficult to address within 
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their roles and limited resources. This analysis led to recommendations to 
promote more equitable decision-making and help nephrologists address 
disparities and advocate for disadvantaged patients.  
The second part of this thesis (Chapters 6 and 7) is focussed on outcomes 
for living kidney donors. These studies sought to identify the outcomes 
most important to donors and evaluate the spectrum and consistency of 
outcomes reported in trials and observational studies of living kidney 
donors.  
In Chapter 6, outcomes most important to living kidney donors and the 
reasons for their choices were elicited using nominal group technique – a 
mixed methods approach that incorporates quantitative ranking and 
qualitative focus group discussion. The top five most important outcomes 
included kidney function, time to recovery, surgical complications, donor-
recipient relationship and lifestyle restrictions. The themes that explained 
their rankings included unfulfilled expectations, heightened susceptibility, 
confidence and empowerment, downplaying risks and harms, and 
worthwhile sacrifice. 
Chapter 7 presents the scope and frequency of outcomes reported in recent 
trials, and observational studies in living kidney donors based on a 
systematic review. The top five most frequently reported domains were 
kidney function, time to discharge, blood loss/transfusion, operative time 
and blood pressure. There was also large heterogeneity in the measures 
used to assess the same outcomes. 
The latter two chapters highlight a mismatch between outcomes that were 
most frequently reported in contemporary studies in living kidney donors 
and outcomes explicitly identified to be most important to donors, such as 
time to recovery, clinical outcomes including pain and mortality, and 
psychosocial outcomes including the donor-recipient relationship, lifestyle 
restrictions, life satisfaction and family life.   
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In conclusion, this thesis identifies potential strategies to address the 
tensions and challenges in the pathway to living kidney donor 
transplantation for recipients, donors and nephrologists. The findings 
highlight the need for culturally sensitive, family-oriented educational and 
psychosocial support to resolve recipient ambivalence, and help patients 
find an acceptable approach to engaging in discussions with potential 
donors. They also highlight the need to help nephrologists to better 
advocate for their patients. To facilitate equitable decision-making, and 
resolve tensions and uncertainties for nephrologists, it was demonstrated 
that there is a need for greater consensus and standardized practice 
regarding complex medical psychosocial cases, and greater transparency 
of centre practices. Focus groups with living donors showed that more 
attention is needed to the psychosocial challenges of live donor evaluation; 
including preparing donors for surgery and recovery, minimising anxiety 
and lifestyle burdens, ensuring donors feel comfortable expressing their 
fears and concerns, and making explicit the responsibilities of donors in 
their assessment process.   
This thesis also provides greater understanding of the outcomes that are 
most important to donors, and a framework for improving the relevance of 
outcomes reported in trials and observational studies to clinical and donor 
decision-making. It was demonstrated that consistent reporting of 
outcomes relevant to decision making is needed to better inform and 
prepare donors for outcomes after donation.  Overall, the acknowledgement 
of stakeholder perspectives in guidelines, education, research and practice 
needs to address the real tensions faced by nephrologists, recipients and 
donors, to ensure equitable decision-making, alleviate barriers and 
disparities, and improve outcomes for recipients and their donors.   
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Chapter 1: Introduction  
1.1 Overview 
“A rising demand for organs exists without enough organs to meet it, making the 
urgency for those willing and able to donate even more critical and the need for 
innovation and support even more imperative.” 
- Barak Obama, April 1st 2016 
This thesis is presented as a series of papers that address the overall aim 
of improving access and outcomes in living kidney donor transplantation. 
In this chapter, background literature is reviewed to provide an overview 
of living kidney donor transplantation. This is followed by a discussion of 
important gaps in research and practice in addressing barriers and 
disparities in living kidney donor transplantation, and ways to improve 
the donation pathway and outcomes for living kidney donors. This chapter 
also includes justification for this research, the value of qualitative 
research methods, and an outline of the aims of each study.  
1.2 Living kidney donor transplantation 
The first successful living kidney donor transplantation was performed in 
1954 in Boston Massachusetts, between identical twin brothers. Living 
kidney donor transplantation is now the preferred treatment option for 
many patients with end-stage kidney disease, as it is associated with 
superior graft survival, patient survival and quality of life outcomes.1,2 
Moreover, the unresolved shortages in deceased organ donation have 
necessitated widespread acceptance of living kidney donor 
transplantation.3 In 2014, 23,233 transplants were made available by 
living kidney donors, comprising 42% of all kidney transplants 
worldwide.4 
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The rate of living kidney donor transplantation varies widely across 
countries, and differences in transplant policy and practice are apparent.5 
In high income countries, including Australia, Canada, the United 
Kingdom and the United States, living kidney donor transplantation 
comprises up to 40% of kidney transplants.6 Spain’s highly successful 
deceased donor program has resulted in a very low proportion of living 
kidney donors, at less than 10%.7 In contrast, living donors comprise 90% 
of all kidney transplantations in Japan, due to legal restrictions on 
deceased donation (which were revised in 2010).3 In Saudi Arabia, high 
rates of living donation are thought to be related to a large uptake of 
unrelated donors.3 In Hong Kong and Taiwan, emotionally related 
donation is restricted. Furthermore, living unrelated donation is 
prohibited in many countries in Asia.8  
Reimbursement practices for donors differ substantially, ranging from the 
provision of paid leave (e.g. Australia), reimbursement for out-of-pocket 
expenses (e.g. Canada) and government regulated compensation in Iran.9 
In most countries, payment for donation is illegal10, although organ 
trafficking and transplant tourism are still practised11.  
Major innovations in transplantation have transformed and improved 
access and outcomes in living kidney donor transplantation for both 
patients and donors. Advances in immunosuppression and recipient 
desensitization techniques have enabled unrelated donors, who are blood-
type or human leukocyte antigen incompatible, to donate.12,13 However, 
immunologically matched donor-recipient pairs are preferable as these 
techniques come with increased risk of infection and rejection for the 
recipient.12 Laparoscopic nephrectomy, introduced in 1995, improved 
surgical outcomes for donors by reducing the length of stay in hospital, the 
size of their incision and their overall convalescence period. Many 
countries have introduced a living kidney donor exchange scheme.3,12 
Incompatible donors, and in recent times also compatible donors, enter the 
Chapter 1: Introduction and overview of the thesis   
3 
 
paired donation scheme and ‘swap’ donors in order to receive a compatible 
or better matched kidney.  
There are various types of kidney donors. ‘Directed donation’ refers to 
donation between relatives or friends, wherein there is an emotional or 
biological relationship.12 In many countries the demographic of living 
donors is changing, to include unrelated donors from the patient’s broader 
social network.14 There has been substantial growth in non-directed 
(altruistic) donors in recent years, particularly in the United States, the 
Netherlands and the United Kingdom.15 Kidney donations from non-
directed donors are usually allocated to a recipient on the waiting list, as 
determined by a computer algorithm16, or to a recipient to initiate a chain 
in a paired exchange program, allowing a kidney to be allocated to 
someone on the waiting list13. Many transplant centres do not accept non-
directed donors due to concerns about the psychosocial impact of donation, 
ulterior motives and commercialisation.15 More recently, the process of 
donating directly to a stranger has been allowed, often identified through 
social media or public pleas, whereby a donor can respond to the request 
for a kidney donation of a specific person with whom they have no prior 
connection.12 This has been legalised in the United Kingdom and United 
States but is not currently practised in many other countries, including 
Australia.  
1.3 Ethical considerations  
The practice of living kidney donation entails unique ethical issues. Living 
kidney donor transplantation requires a healthy person to undergo 
surgery for the benefit of the patient17, who is  thus exposed to the risks 
associated with nephrectomy. For clinicians, the practice of living kidney 
donation can be perceived to be in tension with the fundamental principle 
of medical ethics, to do no harm (primum non nocere). However, the 
transplant community recognises that there are not only benefits for the 
patient, but also a range of non-medical benefits for the donor.18 
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Ultimately, clinicians must make decisions to ensure that the risks to 
donors are sufficiently small, and at the same time may have to trade off 
these potential risks with the potential benefits for the recipient and the 
donor.19,20  
The ethical principles of autonomy, justice, beneficence and non-
maleficence are often used as a framework to guide practice in living 
kidney donor transplantation.21,22 Autonomy, the right of individuals to 
make their own decisions, is actualised by obtaining  informed consent 
from potential donors.22 However, patient and donor autonomy must be 
balanced or tempered by medical judgement.20  
Beneficence refers to the need to protect the welfare and interests of the 
donor and recipient, while non-maleficence entails the protection from 
harm, and minimisation of risk.20 Rigorous medical screening and 
assessment, informed consent incorporating education about long-term 
outcomes, and access to long-term health care are critical to ensuring 
these principles are upheld.    
1.4 The living kidney donor transplant pathway 
This thesis examines the living kidney donor transplant pathway to 
understand barriers and disparities in living kidney donation, and 
determine strategies to better donors for surgery and recovery and 
satisfaction with the donation process. An overview of the main 
components of the pathway to living kidney donor transplantation is 
provided in this section, and are summarised in Figure 1.1.   
In most jurisdictions, living kidney donor transplant programs are 
organised and overseen by individual transplant centres, without the 
same level of oversight as deceased donor transplant programs, which are 
typically governed by nationally or regionally operated waiting lists and 
allocation criteria.23 This, in part, explains the substantial variability 
across centres and countries in the practices and policies in living kidney 
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donor transplantation, particularly in terms of eligibility criteria and 
assessment practices.  
 
Figure 1.1. Key steps in the living kidney donor transplantation pathway*  
*Adapted from Renal Resource Centre. An introduction to kidney donation by live donors 
Kidney Health Australia. (http://kidney.org.au/cms_uploads/docs/rrc-kidney-donation-by-
live-donors.pdf ) Published 2010. Accessed January 1st 2017. 
Live donor evaluation  
Comprehensive evaluations involving medical and psychosocial screening 
and informed consent are necessary to safeguard donor voluntarism and 
minimise harm for living kidney donors.21,23 The Kidney Disease 
Improving Global Outcomes (KDIGO) guidelines state that the primary 
goal of the live donor evaluation is to determine individual suitability for 
donation, ensure donors are making an informed choice, and determine 
whether their kidney is suitable for the intended recipient.24 
National guidelines for live donor assessment are available, but practices 
differ substantially among different units.12 It is widely recommended that 
Suitable candidate referred 
to transplant centre
Patient completes pre-
transplant work-up
Potential donor offers to 
donate
Patient accepts offer from 
potential donor 
Patient enters waiting list 
for deceased donor
Donor completes initial 
workup 
Completes medical, and 
psychosocial assessment 
and sustains commitment
Completes living kidney 
donor transplant surgery
Multidisciplinary team 
makes eligibility decision 
throughout assessment 
Clinician’s role
Potential recipient’s role
Potential donor’s role
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the team evaluating the potential donor should be independent from the 
team evaluating the potential recipient, to minimise a conflict of 
interest.18 The duration of assessment varies substantially, due to the 
available resources at each unit. A generic example of the live donor 
evaluation is provided below in Table 1.1: 
Table 1.1: Living kidney donor evaluation and education 
Assessment stage Details  
1. Initial assessment  Blood group and tissue typing compatibility 
 Full medical assessment 
2. Education  Informed consent – understand risks and benefits 
3. Live donor cross-
matching 
 HLA leukocyte antigen typing 
 ABO compatibility testing 
 Cross-matching by two different methods  
4. Assessment of renal 
function 
 24-hour urine collection and/or nuclear medicine 
scan and/or renal laboratory test 
 Renal ultrasound 
5. General health 
assessment 
 Chest x-ray and ECG, sometimes echocardiogram 
and stress test 
 Blood tests (electrolytes, liver function, full blood 
count, fasting glucose, lipids, oral glucose tolerance 
test) 
 Blood tests for transmissible disease, Epstein-Barr 
virus and CMV 
 Females > 50 require pap smear and mammogram, 
males > 50 require PSA  
6. Renal angiogram  3D Helical CT angiogram, magnetic resonance 
imaging MRI, angiogram or formal arteriogram 
7. Psychosocial 
evaluation 
 Social worker: emotional support, advice on 
practical, organisational, and financial matters 
 Psychologist/psychiatrist: assesses capacity to cope 
with process or a poor outcome 
8. Surgical assessment  Surgeon provides information about operation and 
risks, reviews CT renal angiogram and obtains 
informed consent  
9. Review by renal 
physician 
 Renal physician discusses test results, answers 
questions, notifies recipient’s renal physician that 
workup complete, plans surgery date 
* Adapted from Renal Resource Centre. An introduction to kidney donation by live donors 
Kidney Health Australia. (http://kidney.org.au/cms_uploads/docs/rrc-kidney-donation-by-
live-donors.pdf ) Published 2010. Accessed January 1st 2017; HLA: Human Leukocyte 
Antigen; ECG: Electrocardiography; CMV: Cytomegalovirus; PSA: Prostate-specific 
antigen; CT: Computed tomography scan; MRI: Magnetic resonance imaging.  
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Donor eligibility criteria 
Guidelines specify some absolute and relative contraindications to living 
kidney donation. Most countries require donors to be over the age of 18 
years.12 Caution with respect to donors under 30 years of age is often 
applied due to a lack of evidence on lifetime risks.25 In Australia, relative 
and absolute contraindications include cancer, diabetes, high blood 
pressure, infection disease, lung and heart disease, kidney disease, 
obesity, psychiatric disorder and major abdominal surgery.26 Obesity and 
lifestyle related problems are generally considered to be relative 
contraindications that can be addressed.18 Lack of evidence for 
determining risk factors for medical and psychosocial outcomes may 
explain some of the variability in assessment and acceptance of donors, 
particularly regarding age, measured glomerular filtration rate (GFR), 
body mass index and hypertension.27,28 The Kidney Disease: Improving 
Global Outcomes (KDIGO) guidelines recommend that each centre “strives 
to develop and communicate a quantitative threshold of ‘acceptable risk’ 
for each post-donation adverse outcome they wish to avoid”.29  In practice, 
the decision to accept a donor is complex and involves weighing the risks 
to the donor against the benefits for the donor and the intended 
recipient.21  
Informed consent 
Informed consent aims to ensure that donors are making a voluntary, 
intentional decision and understand the potential consequences of 
donating. The most recent KDIGO guidelines indicate that potential 
donors should understand the “likely medical, psychological, social and 
economic outcomes of donation, potential risks and benefits to themselves, 
and anticipated outcomes for the recipient”.24 Moreover “uncertainty in 
the risk estimates should be discussed when risk cannot be accurately 
quantified based on available data”. Informed consent practices have been 
shown to vary widely.30 The information conveyed to donors is complex, 
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and may be difficult for donors to process and completely comprehend 
prior to donation.  
Various strategies have been used to implement informed consent. To 
ensure donors make a considered decision, some transplant programs 
implement a ‘cooling off period’ and deliberately delay the process.27 Dew 
et al31 designed a motivational interviewing intervention to address donor 
ambivalence prior to donation, which showed reductions in ambivalence, 
fatigue, physical symptoms, pain, shorter recovery times, anxiety 
symptoms, and family-related problems after donation. Since 2007, the 
Organ Procurement and Transplant Network in the United States has 
mandated the independent living donor advocate to assist with informed 
consent by providing education, support and advocacy to potential 
donors.32 Home-based education programs have been developed to improve 
education about living kidney donor transplantation, particularly among 
ethnic minority groups.13,33,34   
Psychosocial evaluation  
Psychosocial evaluation assesses how the donation will potentially impact 
on the donor’s life and wellbeing i.e. the non-medical aspects of donation.21 
The gift of a transplant can impact the donor’s sense of self, their roles, 
and their relationships.35,36 The psychosocial assessment ultimately aims 
to ensure donors are prepared for the challenges they may face, and 
donors are ruled out if they are deemed unlikely to cope.  
Specific components of the psychosocial evaluation include an assessment 
of donors’12,37:  
 motives for donation (reasons for volunteering, decision-making 
process, coercion or inducement, ambivalence) 
 relationship with the recipient (nature of existing relationship, 
degree of closeness, perceived obligations and expectations) 
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 knowledge about surgery/recovery (understanding and expectations 
of risks and outcomes) 
 social support (emotional and practical support, pressure or 
opposition from family, social network and workplace), and 
 financial status (financial stability, insurance coverage, resources 
for unexpected expenses). 
Many of the issues explored in the psychosocial evaluation are considered 
relative contraindications that can be overcome prior to donation.30 
However, guidelines offer limited advice regarding specific tools to conduct 
psychosocial assessments and address these issues.26  
Previous studies have shown that the donor evaluation process can be 
lengthy, invasive and anxiety provoking.28,38-40 Donors have reported a 
fear of being deemed ineligible, uncertainty about their eligibility status 
and surgery date, and difficulty navigating an unfamiliar healthcare 
system.38-40 These experiences can cause considerable stress during the 
evaluation. Many donors report anxiety and residual ambivalence about 
undergoing surgery.31,41,42 Previous studies have found that donors 
attempt to manage how they are perceived throughout evaluation, to 
ensure that they are accepted as donors.43 There are, therefore, concerns 
that donors may not disclose their apprehensions and anxieties in order to 
protect their eligibility.43 
1.5 Barriers and disparities in living kidney donor 
transplantation 
Living kidney donor transplant programs are an important strategy to 
improve access to kidney transplantation. In recent years, the number  of 
living kidney donor transplants has decreased or plateaued, particularly 
among disadvantaged populations44, prompting concerted efforts to 
understand and reduce disparities and inequities in  transplantation45. 
This problem was highlighted in the quote by Barak Obama at the start of 
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this chapter, who called for increased support and innovation in 
transplantation. Such strategies to increase living kidney donor 
transplantation require greater understanding of the barriers preventing 
uptake of living kidney donation.  
While the term ‘disparities’ describes health differences between 
subgroups, equity is an ethical concept.46 The World Health Organisation 
defines health inequities as “differences in health that are unnecessary, 
avoidable, unfair and unjust”.47 Health equity, therefore, entails the 
dismantling of systematic health disparities between social groups with 
different degrees of social advantage or disadvantage.46 While poor health 
outcomes may relate to biological variation between populations, it is 
argued that we have a responsibility to do something about the health 
gaps that are caused by systematic disparities.48  
Disparities in the rates of living kidney donation have been reported both 
within and across countries worldwide, but the reasons remain largely 
unexplained.44,45 Ethnic minority status, socio-economic disadvantage, 
female gender and older age have been associated with a lower probability 
of living kidney donor transplantation.49-51 However, the associations 
between cultural, demographic and socio-economic factors with living 
kidney donor transplantation are not completely understood.52  
Living kidney donor transplantation involves the private gift exchange 
between two individuals; therefore, the barriers are thought to be different 
to those relevant to deceased donor transplantation.53 Patients must be 
deemed eligible for transplantation and be able to navigate the transplant 
pathway, but they also depend on the eligibility and willingness of a 
healthy donor.54 A clear understanding of the range of barriers to living 
kidney donation and reasons for disparities is needed to inform strategies 
to overcome them. Importantly, it is important to identify solutions “that 
do not require ‘encouraging’ people to donate who would otherwise be 
unwilling or unlikely to consider donation”.55  
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Theoretical framework 
The socio-ecological model56 adapted from Bronfenbrenner’s ecological 
systems theory (1998) informs the aims of this thesis, to describe barriers 
and facilitators impacting on access to living kidney donor transplantation 
from different perspectives. This model examines the influence of personal 
values, family, extended social network, health care system, and cultural 
or societal (including government regulations and policy) values on health 
care decision-making and behaviour. Barriers and disparities in living 
kidney donor transplantation are complex, and multifactorial, thus many 
studies have utilised this model.57 The ‘pathway approach’ to 
understanding disparities in living kidney donor transplantation was also 
utilised, which emphasises the importance of understanding barriers in 
the context of the entire disease and transplant process.48 The pathway to 
living kidney donor transplantation was outlined above in Figure 1.1 
(section 1.3).  
Patient perspectives 
Patients with chronic kidney disease (CKD), the potential transplant 
recipients, have various attitudes and beliefs that can pose barriers to 
receiving a living donor transplant. Previous studies have identified 
patients’ reluctance to ask someone to donate a kidney, or to accept a 
relative’s offer to donate, as a common barrier to pursuing living kidney 
donor transplantation.58,59 Surveys have found that potential recipients 
would feel guilty accepting a kidney from a living donor because they have 
concerns for the donor’s health and wellbeing, financial implications and 
fear that the graft might fail. Potential recipients may also lack knowledge 
about living kidney donor transplantation.59-61 
In general, cultural perspectives on living kidney donor transplantation 
are not well understood.62 A willingness to approach potential living 
kidney donors has been found to be lower among ethnic minorities and 
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uneducated, older and female populations.59,63 Qualitative studies and 
surveys, mostly conducted in North America and Europe, suggest that a 
patient’s cultural background may influence their communication with 
clinicians64, their trust of medical information64, their propensity to 
actively seek information65 and their willingness to communicate with 
their family and potential donors about living donation59,63,66-68. Within 
some cultures, decision-making is a family-oriented process which 
operates according to rules of family hierarchy.69 Discussions about 
disease and illness are sometimes considered unacceptable and taboo.65 
Concerns about the donor’s reproductive and marriage potential may be 
more prevalent among certain communities.69,70 Poor health literacy may 
also limit comprehension of information among patients of ethnic minority 
background.62  
Although most religions are not actually opposed to living or deceased 
donor transplantation, religion is still thought to be a potential barrier to 
receiving or undergoing living kidney donor transplantation.71 For 
example, a patient may perceive their kidney disease as fate or spiritual 
punishment, and therefore not feel worthy of receiving a kidney from a 
donor.63,69 Some religions believe in maintaining bodily integrity and being 
buried whole; therefore, some people view kidney donation as 
incompatible with this principle.72 However, many religions also espouse 
the principles of altruism and saving a life, which are often used to justify 
kidney donation.71  
Donor perspectives 
The ‘differential access’ hypothesis to explain disparities in living kidney 
donor transplantation is prominent in the literature, suggesting that 
ethnic disparities are primarily underpinned by the lesser availability of 
medically suitable or compatible potential donors.73,74 However, this has 
only been demonstrated in single-centre studies, and these studies have 
only included the potential donors who approach the transplant unit for 
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evaluation.73 Research suggests that many people, including people of 
ethnic minority backgrounds, may face some modifiable barriers to 
becoming a donor.  
Most studies have found that living kidney donors have a high tolerance 
for medical risks associated with donation, such that they are willing to 
accept more risk and uncertainty on medical outcomes, including kidney 
disease, cardiovascular disease and hypertension, than health 
professionals.75,76 Donors are usually highly motivated to donate, and their 
decisions are instantaneous and stable, compelled by moral duty, 
perceived responsibility and social expectation, spiritual confirmation, and 
personal benefits including improved quality of life, relationship and 
lifestyle.36,40,77,78 Non-directed donors report a similar resoluteness and 
determination to their decision.79 They believe they are able to live with 
one kidney, trust in the medical system, perceive themselves to be 
genetically and physically resilient, and are willing to accept mild 
inconvenience.79 Simmons et al (1987) identified that some donors undergo 
a more deliberative and postponed decision-making process.80  
It is estimated that up to 22% of candidates undergoing assessment for 
donation choose to opt-out.81 Some of the key barriers are thought to 
include education and misconceptions about donation, financial burdens, 
and concerns about the health risks of donation.81 Financial barriers may 
be a deterrent for potential donors of low socio-economic status, as 
donation assessment and recovery can incur travel and accommodation 
expenses, time away from work, unpaid leave, lost income and, in some 
countries, medical costs for assessment and post-operative care.82-84 
However, research on donor decision-making mostly includes retrospective 
studies on those who actually donate.36 Donors who have gone on to 
complete the donation have reported feelings of ambivalence and anxiety 
prior to the donation, and inadequate knowledge of donation procedures 
and outcomes.31,41,42  
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Clinician perspectives  
Nephrologists play a central role in facilitating access to kidney 
transplantation, through educating patients about transplant options, 
referring them to a transplant program, completing transplant 
evaluations and participating in recipient acceptance meetings.48,54,85 In 
the absence of a standardised pre-transplant assessment pathway and 
eligibility criteria, nephrologists’ recommendations and eligibility 
decisions may vary according to their attitudes, preferences, ethical 
values, priorities and competing responsibilities.86  
Nephrologists are generally in favour of living kidney donation, but may 
have differential views regarding thresholds for patient and donor 
eligibility and their suitability for living kidney donor transplantation.87,88 
Their decision to accept a donor and recipient involves a number of 
tensions and challenges: to adhere to ethical principles; increase access to 
transplantation; ensure equitable access; ensure donor safety and 
voluntariness; and provide optimal outcomes for the patient.88  
Decision-making about transplantation may be more complex in 
disadvantaged populations which are more likely to present with medical 
and psychosocial risk factors.48,57,86,89-91 Previous research suggests that 
clinicians’ interactions with disadvantaged patients may reflect their 
inherent biases regarding patients’ interest in transplantation, their 
likelihood of finding a donor, completing evaluations or adhering to 
treatment, and the expected survival benefit of transplantation compared 
to dialysis.90,91 Clinicians also report difficulties in communicating and 
establishing trust with people from different backgrounds to them, and 
completing their referral and evaluation processes.90,92   
Nephrologists’ decisions and promotion of living kidney donation may also 
be influenced by the centres in which they work. In 2014, the proportion of 
living kidney donor transplants in Australian hospitals ranged from 16-
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52%.93 Many countries have demonstrated inter-unit variability in the 
utilization of living kidney donor transplantation, after adjusting for the 
characteristics of a centre’s patient population.52,94,95 Previous research 
has identified various centre factors associated with higher rates of living 
kidney donor transplantation, including a higher annual volume of 
transplant candidates, longer waiting times for deceased donor 
transplantation, higher percentages of laparoscopic donor nephrectomy, 
greater use of unrelated donors, and programs to overcome biological 
incompatibility.49,52,95-97  Centres with higher rates of living kidney donor 
transplantation are likely to have mechanisms that particularly encourage 
living kidney donation, such as better education programs, formalised 
procedures to help patients and donors complete transplant evaluations 
and more support to alleviate financial burdens.52,94 
1.6 Outcomes of living kidney donation 
This thesis also addresses problems relating to research and the 
assessment and discussion of living kidney donor outcomes, particularly 
during donor evaluation and post-donation care. Living kidney donors 
undergo a “medically unnecessary procedure”98; therefore, their safety and 
long-term outcomes are a primary concern for donors, recipients and their 
clinicians. Living donor transplantation has long been thought to incur 
minimal risk to donors who are deemed to be healthy and suitable to 
donate, and the social and emotional benefits to the donor have been 
considered to outweigh the risks for a medically suitable donor. 18 Recent 
evidence supports the view that short term risks of morbidity and 
mortality after donation are very low.99,100  In a recent study of 80,347 
donors in the United States, the 90-day all-cause mortality rate was 
0.03%, and 2.5% of donors experienced major complications.100 Donors are 
usually advised of the minimal risks associated with surgery, and that 
they can expect to live a long and normal life. However, an understanding 
of long-term donation outcomes is evolving, with recent publication of 
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more robust longitudinal data.21,23 These studies suggest a small increase 
in the absolute risk of end-stage kidney disease, hypertension, 
hypertension in pregnancy and all-cause mortality in the three years after 
donation, compared to the general or healthy population.12,101-106 Despite 
some methodological limitations, these studies have changed how risk is 
discussed with living donors to include discussion of uncertainty regarding 
individualised risk and long-term outcomes.24 
Limitations of living donor outcomes research  
Our knowledge of long-term risks is considered incomplete due to several 
limitations in the evidence currently available. Observational studies have 
obtained less than ten years follow-up data on long-term outcomes, and 
been limited to retrospective data collection, recall bias, insufficient 
sample sizes to estimate effects, significant loss to follow-up and 
inappropriate control groups.21,107,108 Therefore, the lifetime risks of long-
term health outcomes are uncertain and cannot be accurately extrapolated 
to young donors. Prospective studies which include a healthy non-donor 
control group are needed to determine the risks attributable to living 
kidney donation23 as this control group can simulate life without 
donating109. There is also limited data to estimate risks on an individual 
level based on specific risk-factors. This is becoming increasingly 
important as criteria for donation have been expanding, such that donors 
with comorbidities and older candidates are increasingly being accepted as 
donors.12  
Long-term data collection and monitoring of living donors remains a 
challenge for transplant units, globally. More recently, emerging data 
from larger donor databases and linkage to population databases have 
enabled longer follow-up, larger samples and comparison with matched 
controls.13,23,110,111  
 
Chapter 1: Introduction and overview of the thesis   
17 
 
Long-term clinical outcomes  
After nephrectomy, the donor’s remaining kidney adapts by undergoing 
hyper filtration, which may adversely impact kidney function and blood 
pressure in the long-term.108 Two large registry studies from North 
America and Europe indicate that the relative risk of kidney failure is 
higher among donors compared to healthy matched non-donors.101,112 In a 
US study, 96,000 donors were followed for a median of 7.6 years, and 
compared to 20,000 healthy non-donors. Living donors had eight times the 
risk of end-stage kidney disease (ESKD) compared to healthy non-donors; 
however, the absolute risk was 0.3%.105 In a Norwegian study, living 
donors had 11 times the risk of ESKD compared to healthy non-donors, 
and a similar absolute risk of 0.47% for non-donors.101 However, there is 
considerable uncertainty in these estimates due to issues with the 
analysis and comparison cohorts.21 Most studies have found that donors 
have similar mortality risks to healthy matched non-donor controls.103 The 
Norwegian study reported a higher mortality rate in kidney donors 
compared to healthy controls, and a 5% increase in all-cause mortality 
after 25 years, attributable to donation.101 Table 1.2 provides a summary 
of the recent evidence on other outcomes in living kidney donors compared 
with healthy controls. 
Table 1.2. Recent evidence on donor outcomes compared to healthy controls   
Outcome N 
donors 
N healthy 
matched 
donors 
Median 
donor 
follow-up 
(years) 
Incidence 
donors (%) 
Incidence 
controls 
(%) 
HR (95% CI) 
All-cause mortality      
Mjoen et al. 
(2014)101  
1901 32,621 15.1 11.8 7.4 1.30 (1.11-
1.52) 
Reese et al. 
(2014)103 
3,368 3,368 7.8 3.4 4.5 0.90 (0.71-
1.52) 
End-stage kidney disease     
Mjoen et al. 
(2014) 101 
1901 32,621 15.1 0.47 0.067 11.38 (4.37 – 
29.63) 
Muzaale et al. 96,217 96,217 7.6 0.10 0.037 Not reported 
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(2014)105 
Hypertension       
Garg et al. 
(2008)113 
1,278 6,369 6.0 16.3 11.9 1.4 (1.2-1.7) 
Major cardiovascular events     
Garg et al. 
(2012)104 
2,028 20,280 6.8 1.3 1.4 0.85 (0.57-
1.27) 
Pre-eclampsia or gestational hypertension    
Garg et al. 
(2015)106 
85 510 11.0 11.5 4.8 2.4 (1.2-5.0) 
Gout         
Lam et al. 
(2015)114 
1,988 19,880 8.8 3.4 2.0 1.6 (1.2-2.1) 
 
Donor-reported outcomes  
There is also a range of possible psychosocial and surgical related 
outcomes that can result after donation.  Previous studies have generally 
shown that quality of life is good or better for living donors compared to 
the general population, and few donors regret their decision to donate.115 
Some qualitative studies support the view that donors gain a number of 
benefits from donation, including a new appreciation of life, personal 
growth and self-worth, and strengthened relationships with the donor and 
family.36 Many studies have found that only a minority of donors (5-25%) 
experience negative psychological outcomes after living kidney 
donation.116 The majority  of donors report no depression or anxiety, but 
instead an improved relationship with the recipient, increased self-esteem 
and no change or improvement in their psychosocial health.117 
However, qualitative research indicates that some donors experience 
challenges in their relationships and emotional wellbeing, particularly 
related to recipient death, recipient non-adherence and a lack of medical 
follow up.36 An Australian study found evidence of psychological distress 
or a diagnosable psychiatric disorder in 25% of living donors, including 
donors with no prior history of mental illness.118 After donation, up to 25% 
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of kidney donors report financial hardships attributable to donation. The 
financial impacts include out-of-pocket expenses related to travel to the 
transplant centre, lost wages, lost employment, and difficulties 
obtaining/retaining health or life insurance.119 Up to one third of donors 
report that their health is poor or worse after donation, complaining of 
fatigue and pain.119 Recent studies have also suggested that donors who 
experience medical complications, or their recipient, have an adverse 
outcome, and may be more likely to experience negative psychosocial 
impacts. The Renal and Lung Living Donors Evaluation (RELIVE) Study, 
found that pre-donation psychiatric diagnoses, younger age, a longer 
recovery from surgery and dissatisfaction with medical attention were 
associated with worse mental health after donation.120 A prospective study 
from the Netherlands found that donor or recipient medical complications 
were associated with a decline in donors’ mental health up to 12 months 
post-donation.121 Adverse outcomes may lead to depression and feelings of 
disappointment, guilt, conflict in the donor recipient relationship.117 
However, it is likely that differences in psychosocial reactions among 
donors also reflect donors’ different coping styles.121  
There are some limitations of research on post-donation psychosocial 
outcomes. These studies have typically only assessed psychosocial 
outcomes in the short-term (i.e. less than twelve months). The surveys 
used are usually generic, facilitating obtaining data from general 
population controls, but lacking donation-specific items.117 In most 
studies, population-based surveys were used as controls, rather than 
matching for health and demographic characteristics; therefore, 
psychosocial morbidity may be underestimated among donors. 
Additionally, donors have been found to be reluctant to express negative 
feelings in regard to their donation experience, possibly due to social 
desirability bias.117  
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Which outcomes are important to donors? 
Living donors undergo rigorous medical screening and assessment; they 
must provide informed and voluntary consent and have access to long-
term health care.21,29,102 Informed consent assumes that donors receive 
reliable data about the outcomes they regard as important and relevant to 
their decision. Living kidney donors experience a broad range of outcomes 
that span their health, physical function, relationships, wellbeing and 
livelihood. Follow-up care may not address the outcomes that are most 
important to donors.122 Donor priorities for outcomes have not been 
systematically identified.  
Research may also not include outcomes that are important to donors, 
making it difficult to provide reliable and useful information to donors, 
and provide appropriate clinical care after donation.122 Various initiatives 
have been developed to improve the selection and reporting of outcomes in 
trials and observational research123,124, including the aim to ensure they 
are more relevant to consumers, clinical and policy decisions. These 
groups have worked towards establishing a minimum set of outcomes to 
be measured and reported across research in specific health areas e.g. 
kidney transplantation, dialysis and rheumatology.125 The process 
typically involves steps to identify priorities for key stakeholders, the 
scope of the outcomes frequently measured in research, and consensus 
methods to reach agreement on the most important ‘core’ outcomes. The 
Outcome Measures in Rheumatology (OMERACT)  initiative, led by 
independent international health professionals,  has demonstrated 
improvements in the reporting and measurement of outcomes in trials.123   
1.7 Justification for the study  
The perspectives of kidney transplant recipients, living kidney donors and 
nephrologists are fundamental to improving access and outcomes in living 
kidney donor transplantation. However, the values, perspectives and 
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beliefs that shape their decisions and actions have not been studied in-
depth, particularly in the areas of donor recruitment by potential 
recipients, nephrologists’ decisions on recipient eligibility and donors’ 
perceptions of donation risks and experiences of the evaluation process. 
Nephrologists are also uniquely placed to provide insight to understand 
barriers and disparities across the transplant pathway. In addition, little 
is known about what outcomes are critically important to donors, and 
whether research, informed consent, education, and follow-up care address 
these outcomes. This study needed to ensure that these standard-of-care 
processes address outcomes and provide information that is meaningful 
and relevant to kidney donors.  
As well, these perspectives of donors, recipients and nephrologists need to 
be considered when planning and delivering ethical and equitable 
strategies to improve access, outcomes and satisfaction with the donation 
process. Qualitative research is a powerful tool for eliciting stakeholder 
perspectives, utilizing rigorous and systematic methods with practical 
recommendations for living kidney donor transplantation clinical care and 
policy. 
1.8 Qualitative research methods used in the study 
In this thesis, qualitative research methods were used, including thematic 
synthesis of qualitative studies (Chapter 3), focus groups (Chapter 4), 
semi-structured interviews (Chapter 5) and the nominal group technique, 
a mixed-methods approach (Chapter 6). A systematic review of patients’ 
perspectives was performed, given the plethora of existing research, 
including patients’ perspectives on living kidney donor transplantation. 
Primary interviews were performed with clinicians to gain in-depth 
insight into their perspectives on barriers and disparities in living kidney 
donor transplantation, and to understand varying individual perspectives. 
There were no pre-existing studies addressing the research questions 
posed in this study. Focus groups were considered more appropriate for 
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living donors because rapport among participants can encourage more 
open and honest discussion about the donation experience. The nominal 
group technique was also used with living donors to elicit their priorities 
for outcomes. Adapted grounded theory and thematic analysis/synthesis 
were applied to the qualitative studies in this thesis, as they are suited to 
questions around health care problems and solutions, and their results are 
directly applicable to practice and policy development.126 
Chapter 2 contains an overview of qualitative research methods, including 
interview and focus groups methods. Grounded theory and thematic 
analysis, synthesising qualitative research in systematic reviews, and the 
use of the nominal group technique (NGT) for focus groups are expanded 
upon below. 
Use of grounded theory and thematic analysis 
Grounded theory is a commonly used methodological approach in 
qualitative health research, due to its focus on problems and how 
participants resolve them.127 Grounded theory describes a theory that was 
derived from the data, and gathered and analysed in a systematic and 
inductive process.128 Strauss and Corbin (1990) describe theory as “a set of 
well-developed concepts related through statements of relationship, which 
together constitute an integrated framework that can be used to explain or 
predict phenomena”.128 The data analysis process is an iterative process, 
such that the data is analysed concurrently with data collection, and 
subsequent participants are chosen due to their potential to confirm or 
test the emerging theory (i.e. theoretical sampling).128 Through the 
constant comparative method data are continuously compared across 
participants, to enable a deeper level of interpretation and development of 
more analytical themes from descriptive categories.128 The research 
question or the interview questions may also change throughout the data 
collection process.129 
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 Thematic analysis is commonly used to analyse grounded theory 
studies127, because it is “theoretically flexible” i.e. not linked to a specific 
methodological approach.126 Thematic analysis is a systematic approach to 
developing themes that identify “patterns of meaning” in the data and 
generate models of human attitudes, experiences and behaviours.130 These 
themes answer a specific research question, and are developed into more 
analytical concepts through interpretation and comparison within the 
data set.126,131 A thematic analysis can generate results that are accessible 
to lay persons and useful for policy development. 
Synthesising qualitative research  
A synthesis of qualitative research is presented in this thesis. Methods for 
synthesising qualitative research are not as developed and standardised 
as they are for quantitative research, with many different approaches 
emerging and evolving.132 However, there has been increased recognition 
of their value in providing evidence to inform patient-centred care, and 
implementing and evaluating health care interventions.133 A qualitative 
systematic review involves systematically searching for qualitative studies 
that address a specific research question, and synthesising their 
findings.134 Their findings are useful for identifying research gaps, and 
generating comprehensive models of a phenomenon, with broad and in-
depth insight from various cultural and health care contexts.134  
Meta-ethnography135 was the first proposal for the synthesis of qualitative 
research that informed the development of various other approaches, 
including thematic synthesis, grounded theory synthesis and critical 
interpretive synthesis. Each is associated with different methods and 
approaches for searching and selecting studies to include in the review, for 
appraising the quality of the included studies, synthesising findings from 
the included studies, and determining the type of output that is produced. 
Thematic synthesis developed by Thomas and Harden132 was used in this 
thesis. A thematic synthesis is suited to questions of participants’ 
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experiences and perspectives, supports a systematic and transparent 
approach, and produces practical recommendations.132 Other 
methodologies, such as  critical interpretive synthesis and meta-
ethnography, often produce more complex, “conceptually rich”, theoretical 
findings which may require further interpretation of readers to directly 
apply their findings to policy or practice.133,136  
Focus groups using the nominal group technique  
Focus groups and NGT are used in the studies in this thesis. The NGT is a 
variation of a focus group, utilizing both quantitative and qualitative 
components (i.e. mixed-methods). The NGT was first developed to identify 
strategic problems and develop strategies to solve them137 and has been 
used to identify consumers’ preferences and priorities138-140, and reach 
group consensus.141 It involves a highly structured face-to-face meeting 
lasting up to two hours.142 The process begins with a structured 
‘brainstorming’ discussion to develop ideas, followed by individual voting 
on the prioritised list of options.141 Finally, reasons for divergent and 
similar opinions are explored through group discussion. By voting 
confidentially as an individual, each participant is able to offer their own 
viewpoint without the pressure to converge to the mainstream 
viewpoint.141 Generally speaking, the quantitative analysis of the NGT 
involves analysing the scores or rankings of participants, as well as the 
frequency of votes for each outcome.142 Thematic analysis is often used to 
analyse the qualitative discussion from the NGT.137 The qualitative data 
should be compared to the priority scores (quantitative data) to 
contextualise and explain group priorities, explore where they converge or 
contract each other, and inform policy implications.137,143   
1.9 Aims of the research  
This thesis can be divided into two related parts, reflecting the aims of the 
studies:  
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a) the pathway to living kidney donor transplantation (chapters 3 to 
5), and  
b) living kidney donor outcomes (chapters 6 and 7).  
The specific aims of each study are:  
1. to identify and describe the beliefs, attitudes and expectations of 
patients with CKD (stages 1-5) regarding living kidney donation 
(Chapter 3) 
2. to describe kidney donors’ experiences of the evaluation process 
(Chapter 4) 
3. to describe nephrologists’ perspectives on barriers to living kidney 
donation and disparities in access to living kidney donor 
transplantation (Chapter 5) 
4. to identify living kidney donors’ priorities for outcomes and describe 
the reasons for their choices (Chapter 6), and 
5. to determine the scope and heterogeneity of outcomes in adult living 
kidney donors reported in randomised trials and observational studies 
(Chapter 7). 
1.10 Structure of the thesis  
This chapter, Chapter 1, includes a summary of existing literature 
regarding the pathway to living kidney donor transplantation (including 
barriers and disparities and the evaluation process), and outcomes for 
living kidney donors. An overview of the thesis structure is provided in 
Figure 1.2. The studies presented in this thesis are identical copies of the 
published peer-reviewed articles (Chapters 2, 3, 4, 5), and submitted 
articles (Chapters 6 and 7).  
Chapter 2 provides an overview of qualitative research methods and the 
principles of rigour.  
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Chapters 3 to 5 include qualitative studies on the perspectives of patients, 
living kidney donors and nephrologists on different aspects of the pathway 
to living kidney donor transplantation. In Chapter 3, the expectations and 
attitudes of patients with CKD regarding living kidney donor 
transplantation are described, based on a systematic review and thematic 
synthesis of qualitative studies. Chapter 4 presents donors’ experiences of 
the evaluation process elicited through focus groups in Australia and 
Canada. Chapter 5 provides in-depth insights on nephrologists’ attitudes 
and perspectives regarding recipient eligibility and access to living kidney 
donor transplantation, which were generated through semi-structured 
interviews.  
Chapters 6 and 7 focus on donor outcomes. Chapter 6 elicits living kidney 
donors’ priorities for outcomes using the nominal group technique, and 
describes the reasons underpinning their preferences as derived from the 
focus group discussion. Chapter 7 provides a comprehensive, systematic, 
and detailed evaluation of the scope, consistency and measurement of 
outcomes reported in randomised trials and observational studies on 
living kidney donor outcomes.    
In Chapter 8, the concluding chapter of this thesis, the key findings from 
each study are integrated and considered as a whole. These findings were 
compared with existing literature. The strengths and limitations of 
studies are discussed. Finally, the implications of these studies for 
improving access and outcomes in living kidney donor transplantation are 
outlined.  
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Figure 1.2. Thesis chapter outline  
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 Introduction 2.1
Qualitative research aims to describe, understand or explain social 
phenomena using a systematic and scientific process.1 Qualitative 
methods are designed to answer ‘why’ questions. For example, to explain 
why adolescent kidney transplant recipients do not take 
immunosuppression medications as prescribed, particularly given their 
higher rates of graft loss due to non-adherence during transition.2,3 While 
quantitative research tests hypotheses, qualitative research generates 
hypotheses and provides detailed and nuanced understandings about 
health behaviours, decisions and experiences. Qualitative methods may 
also be conducted in a mixed-methods framework (i.e. combined with 
quantitative research), for example, to inform survey design or explain 
survey responses, or used in process evaluations to guide the design, 
conduct, evaluation, and implementation of clinical trials. 
Qualitative research is a broad term for various approaches of inquiry. 
Depending on the research question, researchers may use a 
methodological framework to guide their choice of methods used to collect 
and analyse data (e.g. grounded theory, phenomenology or ethnography).1 
Common methods used in qualitative research are outlined in Figure 2.1. 
In the following section, we describe the methods of participant selection, 
data collection and analysis in qualitative research. 
 Participant selection and recruitment  2.2
In qualitative research, participants are sampled for meaning, not for 
statistical power. Typically, purposive sampling (e.g. to include a range of 
demographic, clinical characteristics, experience and backgrounds) of 
information-rich informants, is used to gain a broad insight relevant to the 
phenomenon being investigated.4,5 Qualitative interview studies generally 
include 20 to 50 participants, while focus group studies usually report 
around 6 or more groups, with 6-8 participants per group to optimize 
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participant interaction. Generally, recruitment will cease when data 
saturation is achieved i.e. when subsequent data collection does not 
provide new insights.5 Unlike quantitative studies, qualitative findings 
are not ‘generalisable’ or ‘representative’ across all patients, however, the 
findings (or concepts) may be transferable to other contexts.1    
 Data collection  2.3
Interviews and focus groups are commonly used in qualitative health 
research. Semi-structured or in-depth interviews are suited to research 
that aims to understand individual perspectives, for example, a person’s 
decision-making about medicine taking or the impact of disease on their 
identity. Semi-structured interviews use a flexible question guide, which 
can evolve during data collection. The question guide includes open-ended 
questions related to the study topic, and prompts to encourage 
participants to elaborate and clarify their responses. In-depth interviews 
are unstructured, inviting participants to share their narratives with 
occasional prompts from the researcher. In contrast, focus groups harness 
the dynamics of group interaction to elucidate reasons for similar or 
disparate views and experiences, or to brainstorm ideas, for example to 
develop a new transition program. Audio-recording and transcription 
ensure accuracy and allow researchers to concentrate on interacting and 
engaging with participants. Field notes on contextual information and 
non-verbal communication may be recorded.  
 Data analysis  2.4
The aim of qualitative data analysis is to develop a description or 
explanation of a phenomenon that captures the breadth and depth of the 
data collected.  The output is usually themes (e.g. thematic analysis), or a 
theory (e.g. grounded theory analysis). Coding is the basis of most forms of 
qualitative data analysis, involving an iterative process of data reduction 
by identifying and interpreting the meaningful sections of text and 
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synthesizing the data into themes or concepts. Usually, the concepts are 
identified inductively. However, content analysis involves coding of the 
data into pre-defined categories or existing theories and is usually done 
when there is a meaningful denominator (e.g. the number of websites with 
a focus on specific pre-determined topics). Coding can be performed within 
a software program to facilitate analysis of qualitative data. Multiple 
investigators may be involved to ensure the analysis is comprehensive 
(investigator triangulation). Researchers may identify conceptual 
relationships and patterns among the concepts or themes identified.  
Figure 2.1. An outline of common methodologies and methods used in 
qualitative research 
 Appraising qualitative research  2.5
Several guidelines suggest criteria for appraising qualitative research 
though this remains contentious as there is no empiric basis to 
demonstrate that a given approach (e.g. use of software) improves the 
quality of a qualitative study.5-7 To guide the appraisal of qualitative 
research, we suggest the use of four constructs proposed by Guba and 
Lincoln8: credibility (are the findings trustworthy?), confirmability (are 
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the interpretations linked to the data?) dependability (is the process 
logical and auditable?), and transferability (are the findings relevant to 
other settings and contexts?). 
Credibility: The credibility of a study’s findings considers how 
comprehensive, truthful and reasonable the findings and interpretations 
are. Qualitative data collection involves the co-construction of meaning 
among the researchers, participants and research process9,10; and is not 
designed to measure a single objective reality. Providing a detailed 
description of the research team and their roles, study setting, question 
guide and findings can help readers determine whether these may have 
influenced participant responses and the researchers’ interpretations. The 
question guide should be relevant to the research question and designed to 
facilitate in-depth discussion. Purposive sampling and data saturation 
ensures that sufficient data has been collected to captures the diversity of 
views and experiences relevant to the research question. Triangulation 
using multiple methods of data collection, or multidisciplinary 
investigators in the analysis can ensure more comprehensive insight and 
interpretations.5 Member-checking (obtaining participant feedback on the 
results) can also ensure that the findings reflect the complete range and 
depth of opinions.6   
Confirmability: The confirmability of a study convinces the readers that 
the findings reflect the participant’s perspectives, rather than the 
researcher’s predetermined assumptions or agenda. Reflexivity involves 
researchers recognizing any undue influence on the their interpretations 
of the data.6 Strategies to demonstrate confirmability include independent 
coding by multiple investigators who are familiar with the data (e.g. by 
reading all the transcripts), and presenting raw data such as participant 
quotations to support themes and concepts that are developed.5,11   
Dependability: Dependability establishes that the study followed a 
rigorous and systematic approach by demonstrating a coherent link 
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between the findings and the methods and methodology. Qualitative 
research methods are iterative and interpretive, and impossible for 
another researcher to replicate12, therefore the concept of ‘reliability’ is not 
applicable6. Audio recording, transcription of data, and use of software for 
coding can ensure a transparent and auditable documentation of the 
research process. This can allow the raw data, and analysis process to be 
reviewed by others.  
Transferability: Transferability describes the extent to which the themes 
or concepts can be considered relevant to other settings.5,13 Details about 
the study setting, participant characteristics, and health care framework 
can help readers to ascertain whether the findings are applicable to their 
own context.6 Also, demonstrating some similarities to other studies 
conducted in different regions and populations, or to existing theory can 
help demonstrate the broader relevance of their findings.14  
The Consolidated Criteria for Reporting of Qualitative Research (COREQ) 
13 provide a framework for reporting qualitative studies using interviews 
or focus groups, so readers can assess study quality. 
 Conclusions 2.6
In summary, qualitative methods are valuable for providing in-depth 
understanding the values, beliefs, attitudes, priorities and preferences of 
the key stakeholders involved in living kidney donor transplantation. 
Authors can ensure the value of qualitative studies by demonstrating the 
principles of credibility, confirmability, dependability and transferability. 
Qualitative research is also useful for developing hypotheses, for example, 
to develop interventions to address disparities in living kidney donor 
transplantation.12 By using rigorous and systematic qualitative research 
methods, the research in this thesis intends to gain in-depth insight into 
donor, recipient and nephrologists perspectives to identify strategies to 
Chapter 2: Qualitative research: methods and rigour   
46 
 
improve access, outcomes and satisfaction with living kidney donor 
transplantation.   
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3.1.   Abstract 
Background: Living kidney donation offers superior outcomes over 
deceased organ donation, but incurs psychosocial and ethical challenges 
for recipients because of the risks imposed on their donor. We aimed to 
describe the beliefs, attitudes, and expectations of patients with chronic 
kidney disease toward receiving a living kidney donor transplant.  
Methods: We conducted a systematic review of qualitative studies of 
patients’ attitudes toward living kidney donation using a comprehensive 
literature search of electronic databases to February 2013. The findings 
were analysed using thematic synthesis. 
Results: Thirty-nine studies (n = 1791 participants) were included. We 
identified six themes: prioritising own health (better graft survival, 
accepting risk, and desperate aversion to dialysis), guilt and responsibility 
(jeopardising donor health, anticipating donor regret, and causing donor 
inconvenience), ambivalence and uncertainty (doubting transplant 
urgency, insufficient information, confronted by unfamiliarity, and 
prognostic uncertainty), seeking decisional validation (a familial 
obligation, alleviating family burden, reciprocal benefits for donors, 
respecting donor autonomy, external reassurance, and religious approval), 
needing social support (avoiding family conflict, unrelenting indebtedness, 
and emotional isolation), and cautious donor recruitment (self-advocacy, 
lacking self-confidence, avoiding donor coercion, emotional vulnerability, 
respecting cultural, and religious taboos). 
Conclusion: Enhanced education and psychosocial support may help 
clarify, validate, and address patients’ concerns regarding donor outcomes, 
guilt, relationship tensions, and donor recruitment. This may encourage 
informed decision-making, increase access to living kidney donation, and 
improve psychosocial adjustment for transplant recipients. 
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3.2.   Introduction 
Critical shortages in the rates of deceased organ donation have 
necessitated widespread acceptance of living organ donors for 
transplantation.1,2 In 2011, 42% of the 76,118 kidney transplants 
registered across more than 80 countries were from living donors.3 Ethnic 
and socioeconomic variations in access to living donor kidney 
transplantation have been reported in many countries4-8, but the barriers 
are poorly understood.  
While living donor kidney transplantation offers optimal recipient 
survival outcomes, 9-11 the risks posed to their living donor make decision-
making ethically and emotionally complex for potential recipients 1,9,12. 
Patients report concerns about the long-term health problems and 
financial burdens for their donor, the possibility of graft failure, family 
conflict, feelings of guilt and indebtedness and initiating discussions with 
potential donors.13-19 
Guidelines offer limited recommendations to address the psychosocial 
issues faced by potential recipients20,21, and educational and psychosocial 
resources vary considerably among transplant centres. 22,23  We aimed to 
describe the attitudes and expectations of patients with chronic kidney 
disease (CKD) regarding living kidney donation, to inform strategies to 
support decision-making that addresses patients’ perspectives and 
priorities. 
3.3.   Methods 
We followed the Enhancing Transparency of Reporting the Synthesis of 
Qualitative Research (ENTREQ) framework.24  
Selection criteria 
Qualitative studies were included that explored the perspectives of adult 
patients (≥ 18 years of age) with CKD (stages 1-5, 5D, and 5T) towards 
Chapter 3: Patients’ perspectives on living kidney donor transplantation   
51 
 
living kidney donation (including related, unrelated, altruistic, 
commercial, and paired exchange donation). Non-English articles were 
excluded to avoid misinterpretation of meaning.  
Data sources and searches 
The search strategy is provided in Appendix A.1. The searches were 
performed in MEDLINE, Embase, PsycINFO, and CINAHL from 
inception to the 19th February 2013. Google Scholar and reference lists of 
relevant articles were also searched. CSH screened the titles and abstracts 
and discarded articles that did not meet the inclusion criteria. Full-text 
articles of potentially relevant studies were obtained and assessed for 
eligibility.  
Quality of reporting assessment  
For each study, two reviewers (CSH/AFR) independently assessed the 
explicitness of reporting of each study using the Consolidated Criteria for 
Reporting Qualitative Health Research (COREQ) framework for interview 
and focus group studies.25 Disagreements were resolved through 
discussion. This framework enables readers to assess the transferability of 
each study to their own setting.  
Data analysis 
Thematic synthesis, the inductive generation of analytical themes, was 
used to synthesise the findings.26 All text in the “results/findings” and 
“discussion/conclusion” sections were extracted and entered into 
HyperResearch (ResearchWare, INC 2009 version 3.5.2), software for 
qualitative data management. CSH performed line-by-line coding of all 
text relating to patients’ perspectives regarding receiving a living kidney 
donation, to identify preliminary concepts. These concepts were translated 
between studies by coding data into existing or new themes as they 
emerged. AT independently reviewed these themes to ensure they 
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incorporated all of the concepts. We mapped relationships between themes 
to develop a conceptual analytical framework.  
3.4.   Results 
Literature search and study characteristics  
Our search yielded 1325 articles. We included 39 studies (n≥1791) 
involving participants with CKD stages 1-5 (n = 108), 5D (n = 912), 5T (n = 
766) and unspecified (n = 5) (Figure 3.1). At least 444 (60%) of the 
transplant recipients had received (or were undergoing evaluation for) a 
living donor transplantation. At least 39 (5%) of the transplant recipients 
received a pre-emptive transplant. Persons of ethnic minority status were 
recruited by purposive sampling in 16 (46%) studies. Data was collected 
using in-depth or semi-structured interviews, focus groups and open-
ended surveys. The studies were conducted across 13 countries. The study 
characteristics are provided in Table 3.1. 
Comprehensiveness of Reporting 
Studies reported between 6 and 21 of the 27 items included in the COREQ 
framework (Table 3.2). Twenty-four studies described the participant 
selection strategy, 24 studies provided the questions or topic guides, and 
all studies included participant quotations. Eighteen studies reported 
researcher triangulation, and four reported on theoretical saturation.  
Synthesis 
We identified six major themes: prioritising own health, guilt and 
responsibility, ambivalence and uncertainty, needing social support, 
seeking decisional validation and cautious donor recruitment.  Selected 
quotations for each theme are provided in Table 3.3. Conceptual links 
among themes are depicted in Figure 3.2. Perceived urgency and 
desperation fostered a pro-active pursuit of a living donor. Participants 
were conflicted between choosing the best treatment to improve their 
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survival and quality of life (QOL), and their concerns regarding their 
donor’s health, the emotional challenge of asking someone to donate, the 
burdens of guilt, responsibility, indebtedness and family conflict. These 
concerns were minimised with emotional support and reassurance, 
internal and external decisional validation and shared responsibility.  
Prioritising own health 
Better graft survival: Living donor kidney transplantation was perceived 
to be the “best way forward”27, as the graft was expected to last longer 
than a deceased donor graft, particularly a related donor which could 
provide “the best match”14. Participants’ derived comfort from knowing the 
origin and quality of a living donor kidney. 
Accepting risk: The risks to the donor were perceived to be minimal, and it 
was thought that a person could spare one kidney. Some coped with 
uncertainty by avoiding focussing on risks that “may never happen”28 or 
identifying “standby donors”29 in case the graft failed.  
Desperate aversion to dialysis: Some felt desperate for a living donor, 
believing they were waiting “in vain”30 on the transplant list, facing 
imminent death on dialysis, or could no longer cope with dialysis. Pre-
dialysis participants hoped for a pre-emptive living donation to avoid 
dialysis. Some participants considered paying for a kidney from an 
overseas donor.  
Guilt and responsibility  
Jeopardising donor health: Participants expected that guilt would 
constantly play “at the back of [their] mind”13 if their donor was harmed. 
Older participants felt it was “selfish”13 to potentially shorten a young 
person’s life. Parents believed it was their inherent duty to protect their 
children from harm.  
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Anticipating donor regret: Participants feared that their donor might 
blame and resent the recipient for their “bad decision”15 if the donor 
experienced health problems. The donor might regret their unnecessary 
sacrifice if the graft failed. Some were reluctant to accept their partner’s15 
kidney in case their children ever needed a transplant, particularly if 
polycystic kidney disease was diagnosed in the family.  
Causing donor inconvenience: Participants would feel guilty for causing 
their donor to incur financial loss, career disruption, dietary restrictions, 
pain or impaired self-esteem due to scarring. They believed that those 
with a “busy job”17, young children or sporting aspirations should not risk 
their health and take time away from their commitments.  
Ambivalence and uncertainty  
Doubting transplant urgency: Some found it difficult to consider pre-
emptive transplantation if they were asymptomatic, still producing urine, 
and living a normal life. Some believed their “kidney [function] might be 
coming back”31 with adherence to medication or dialysis. A living kidney 
donation could be a “last resort”32 if their illness became “life 
threatening”.33  
Insufficient information: Some felt there was insufficient information 
about donor acceptance criteria, financial and insurance issues, risks to 
the donor, the surgical procedures, the exchange program, and the 
possibility of overseas donors. Participants from diverse cultural and 
linguistic backgrounds felt that the information provided was difficult to 
understand and could be more culturally sensitive. Turkish, Moroccan and 
Cape Verdean patients from the Netherlands explained that they would 
not “dig any further for information”33 and relied on clinicians to provide 
information. Participants did not feel they had enough time with their 
doctor to discuss their concerns. Families could help them to comprehend 
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information, but some thought family members may be unwilling or 
unable to attend education sessions.  
Confronted by unfamiliarity: Living donation was unfamiliar and 
confronting to Mexican participants, portrayed as “strange”, “outside of 
[their] world”, and “something for rich people”.31 Some felt uneasy about 
incorporating a living person’s kidney into their own body.34 African and 
Turkish patients felt their communities were unfamiliar with living 
donation, thus discussions with family members were met with 
resistance.33,35  
Prognostic uncertainty: Despite knowing that the risks to the donor were 
low, the potential consequences were considered severe. Some were 
concerned that their donor might die during surgery, have a shortened life 
expectancy, or develop kidney failure and require dialysis.36 They feared 
that donation might cause fertility and pregnancy complications. Some 
preferred a deceased donor transplant to spare their loved one from 
possible harms.  
Seeking decisional validation     
A familial obligation: Donation between blood relatives was perceived to 
be “fair”37 and obligatory, and participants with volunteering relatives 
thought that there was a mutual understanding that the participant 
would have donated if the roles had been reversed.  
Alleviating family burden: Living kidney donation was expected to 
alleviate the restrictions and caregiver burdens placed on family members, 
enabling the flexibility to travel and socialise. 
Reciprocal benefits for donors: Some believed their donor might experience 
increased self-esteem from helping a loved one.38 Spousal donors were 
thought to benefit from alleviated caregiver burdens and improved QOL. 
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Some recipients felt these benefits for the donor could be better 
communicated during decision-making.39  
Religious approval: Muslim, Christian and Buddhist participants believed 
that living kidney donation aligned with the altruistic values of their 
religion.33,40,41 Some were concerned that their religious community might 
condemn interfaith or unrelated living donation. Some Muslim 
participants argued that their beliefs did not prohibit living donation, and 
the notion of bodily integrity was irrelevant as “it’s the soul which goes to 
God not the body”.40 
Respecting donor autonomy: Participants believed that motivated donors 
had the “right to donate”42, and would feel disappointed if their offer was 
rejected or were deemed ineligible. Refusing an offer would therefore be 
perceived as “selfish”42.  
External reassurance: Participants wanted reassurance from their doctor 
that their donor was going “to be ok”.33 Patient advocates were described 
as a valuable source of emotional support.  
Needing social support  
Avoiding family conflict: Some felt that accepting or rejecting a relative’s 
offer could ignite family conflict. Refusal to donate created resentment and 
tension. Some participants concealed their feelings to preserve 
relationships. Participant’s valued decisional-support from their families, 
fearing blame for potentially harming their loved one or losing their 
kidney.  
Unrelenting indebtedness: Participants expected to feel eternally indebted 
to their donor, particularly sibling donors, and be unable to refuse what 
their donor might ask of them, for fear of appearing ungrateful. Young 
participants felt that accepting their parent’s kidney meant their parents 
would have even greater control over their lives. Some rejected offers 
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which they suspected came with “strings attached”43 such as financial 
obligations. They preferred the “neutrality”43  and anonymity of deceased 
donation.  
Emotional isolation: Participants felt there was limited support to cope 
with depression, anxiety about uncertain donor or graft outcomes, guilt, or 
accept their diagnosis. Participants explained that they concealed their 
“miseries”30 from their donor, family or health care providers. Refusal 
from family members to donate led some participants to feel isolated, as 
they felt their friends and family withdrew from them.  
Cautious donor recruitment 
Self-advocacy: Participants believed that being honest and informing 
family members about the possibility for living kidney donation was 
respectful, but would also maximise their chances of finding a donor. Some 
believed that clinicians could convey the “legitimate”33 need for donation 
to potential donors more effectively. Some felt they had to “promote” their 
own cause with “a really good story”33 or by offering incentives33.  
Lacking self-confidence: Participants lacked confidence in finding a willing 
living donor, particularly if they had been refused in the past. Participants 
were unsure how to approach the topic and were worried about misleading 
or misinforming potential donors. Pre-dialysis patients were uncertain 
about their ability to justify the need for pre-emptive transplantation to a 
potential donor without immediate medical urgency. Some were willing for 
clinicians to hold family information sessions, mediate discussions or 
make requests on their behalf.   
Avoiding donor coercion: Some participants preferred to “wait and see”33 if 
a donor volunteered, in case the donor might feel too guilty to refuse. 
Others preferred an indirect approach like using humour, providing 
information, or “cautiously [dropping] the subject”.44 Providing 
information to potential donors early was thought to facilitate informed 
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decision-making. Some believed that donors were nominated and 
pressured by other family members, and participants sought reassurance 
that their motives were genuine.  
Emotional vulnerability: Initiating discussions with potential donors was 
expected to be “emotionally excruciating”31 as participants expected 
refusal to be devastating. Asking would feel like “beg[ging]”33, and was 
considered “pathetic”33, “awkward”33 and embarrassing. Clinician-
mediated discussions were suggested.  
Respecting cultural and religious taboos: Turkish, Dutch Antillean, 
Moroccan and Surinamese patients expressed that discussing illness was 
considered to be “taboo”33, and thus donation requests would be considered 
disrespectful. African participants mentioned that they had to seek 
permission from their senior relatives prior to discussing donation with 
family.35,41  
3.5.   Discussion 
For patients with CKD, decisions regarding living donor kidney 
transplantation involve complex tensions between prioritising their own 
health and concerns about the risks to their living donor. A preference for 
living kidney donation was based upon maximising graft survival, a 
desperate aversion to dialysis, and confidence in the transplant 
community to protect their donor from harm. Patients justified accepting a 
donation from a living donor to reduce caregiver burdens and to 
demonstrate respect for the donor’s choice to donate. However, decision-
making can be challenging for patients’ harbouring concerns about the 
donor’s vulnerability to physical harm, coercion and financial hardship. 
Patients anticipated bearing burdens of guilt, responsibility and 
indebtedness, and causing conflict among family members. They also faced 
the challenge of initiating sensitive discussions about live donation with 
friends and family. Patients who were unable to accept or understand 
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their diagnosis of CKD were reluctant to contemplate pre-emptive 
transplantation. The inability to communicate and resolve these anxieties 
intensified decisional-conflict in potential recipients.  
The themes identified in our review might explain some of the 
psychosocial and cultural barriers underpinning ethnic disparities in 
living donor kidney transplantation.5,6 Previous studies have found that 
patients from minority ethnic backgrounds are less likely to initiate 
discussions with potential living donors than non-minority patients 19,45. 
Our findings indicate that patients emphasise various cultural values 
which underpin reluctance to seek potential donors including the 
impropriety of discussing illness, rules of family hierarchy, and suspected 
community unfamiliarity and ambivalence about living donation. A sense 
of medical urgency and desperation mobilised patients to initiate 
discussions with potential donors. Previous studies, however, have found 
that African American patients have difficulty accepting their diagnosis of 
renal failure and the need for transplantation.4,19,45-47  
Our study has certain strengths. We performed a comprehensive 
literature search and an independent appraisal of study reporting9,25, and 
used software to facilitate the auditable development of themes. A novel 
conceptual schema was developed depicting the facilitators, barriers and 
challenges influencing patients’ decisions about living donor kidney 
transplantation. This review included participants from a range of clinical, 
ethnic, cultural and religious backgrounds. However, the exclusion of non-
English studies, and the predominance of studies from high income 
countries with a high human development index (HDI)48 may limit the 
overall transferability of our findings.  
Education directed at potential living kidney donor transplant recipients 
should seek to identify and address patients’ valid concerns and mitigate 
misconceptions. Patients are anxious about donors having an increased 
risk of ESKD36, perioperative mortality13, a shortened life expectancy13, 
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pregnancy complications17, erectile dysfunction41, pain13, and facing long-
term lifestyle modifications49. Evidence-based information about the 
potential risks and benefits should be communicated to patients.  Recent 
data suggests that donors may be at an increased risk of ESKD50,51, 
gestational hypertension during pregnancy52, and have a 0.03% risk of 
perioperative mortality53. Studies also show that living donors can derive 
various personal benefits  from donation including an improved 
relationship with the recipient, increased quality of life due to reduced 
caregiver burdens, and gain an increased sense of self-worth.54 
Informing patients about efforts to safeguard donors such as independent 
donor advocates, reimbursement schemes, psychological evaluation, and 
rigorous donor acceptance criteria may provide reassurance to patients. To 
help patients engage in discussions about pre-emptive transplantation, 
transplant education should emphasise the benefits of pre-emptive 
transplantation and ensure that patients understand that while CKD can 
be asymptomatic, the disease can progress to ESKD requiring renal 
replacement therapy. Clinicians may also be confronted with the patient’s 
preference for commercial or deceased donor transplantation due to 
desperation, or to avoid exposing their loved ones to the possible risks 
associated with living donation; and resources to educate patients about 
the risks of commercial transplantation are available.55 
Interventions should be evaluated that specifically address patients 
concerns about guilt, indebtedness, family conflict, donor coercion, 
uncertain donor outcomes and donor recruitment. Quality of life therapy, 
which aims to identify specific areas of dissatisfaction and problem-solving 
strategies, can improve QOL and psychological functioning for patients 
awaiting living donor kidney transplantation.56 Our findings can inform 
possible coping-strategies such as sharing responsibility for possible risks. 
Mediated open-communication between patients, their family and 
potential donors might resolve interpersonal concerns and facilitate family 
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support, shared responsibility and decisional validation.29,57  A 
randomised controlled trial58,59 found that a culturally-sensitive home-
based family education  program improved patients knowledge and 
willingness to discussion living kidney donation, decreased patients 
concerns about living donor kidney transplantation, and led to increased 
donor inquiries, evaluations and actual living kidney donor transplant 
rates. Family-oriented interventions may be particularly effective for 
culturally and linguistic diverse patients to facilitate social support, 
information comprehension and address family ambivalence.57,60  
Reticence to initiate discussions with potential donors is one of the most 
frequently reported barriers among patients waitlisted for 
transplantation.19,61 Indirect discussions about donation, rather than 
direct requests to donate, have been found to be effective for donor 
recruitment32, and may alleviate concerns about disrespecting, pressuring 
potential donors. This might be achieved through family-oriented 
education, led by a health professional independent from the transplant 
team57,60,62. The Talking about Living Kidney Donation Educational and 
Social Worker intervention encourages patients to identify and resolve 
self-identified barriers to discussing and pursuing pre-emptive living 
kidney donor transplantation. This intervention increased discussions 
about living kidney donation with family and clinicians, and the 
identification of potential donors.57,60 Boulware and colleagues60 developed 
model conversations to help patients initiate such discussions with 
potential donors (http://diseasemanagementboulware.org/talk-materials/). 
Similarly, a rubric with example phrases and role-playing exercises could 
be offered to potential recipients for making direct donation requests. The 
provision of a medical ‘alibi’ to excuse unwilling potential donors has been 
widely advocated63, and may also protect the patient’s self-esteem and 
preserve family relationships. We also recommend providing patients 
access to counselling to cope with the disappointment of refusal to donate 
and develop resilience for making subsequent requests. 
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Research is needed to inform strategies for identifying and addressing the 
specific challenges experienced by living donor kidney transplant 
recipients. We suggested further adaptation to validated psychosocial 
screening tools, for example The Stanford Integrated Psychosocial 
Assessment for Transplantation (SIPAT)21 to capture additional domains 
identified in our review such as guilt, indebtedness and donor 
recruitment. Identifying the priorities and preferences of patients from 
ethnic minorities is needed to inform culturally sensitive interventions. 
Further research is needed in low and middle HDI countries where 
treatment is less readily available. Previous studies have identified 
socioeconomic disparities in access to living donor kidney 
transplantation6,7,64, but barriers from the patients’ perspective require 
more in-depth exploration. Also, more understanding is needed about 
patients’ attitudes towards pre-emptive transplantation, paired kidney 
exchange, altruistic living donation and the perspectives of patients who 
are likely to face a longer waiting time for a deceased donor kidney, for 
example highly sensitised patients.  
Living donor kidney transplantation is appreciated by patients as the 
optimal treatment for CKD, but carries inherent psychosocial and ethical 
challenges implicated in asking another person to accept risks on their 
behalf, as well as coping with guilt, responsibility, indebtedness, potential 
coercion and family resistance. We propose culturally sensitive, family-
oriented educational and psychosocial strategies to resolve guilt, 
ambivalence, decisional-conflict and interpersonal problems and help 
patients find a personally acceptable approach to engaging in discussions 
with potential donors. Recognising and addressing patients’ concerns may 
encourage informed decision-making, increase access to living kidney 
donation, and improve recipient’s psychosocial wellbeing.  
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Figure 3.1. Search Results 
* Minimum 1769 CKD 1-5, dialysis and transplant patients (Gill 2008 and 2012; Gordon 2001a and 2001b; Ismail 2010, 2011 and 2012; Mazaris 2012a and 2012b used 
the same participants in each study).   
MEDLINE
507 citations 
Embase
458 citations
PsycINFO
308 citations 
CINAHL
41 citations
citations
1325
Title and abstract review
Excluded (n = 1199)
Epidemiology studies (trials, registry data, case reports, diagnosis, pilot studies, cohort studies) 
Duplicate articles
No patient views elicited (only donors, family, community, non-adults, healthcare professionals)        
Not relevant to live donor kidney transplantation (deceased donor kidney transplantation only)
Only quantitative analysis (surveys, questionnaires)                                                                                            
Non-primary research (commentary, review, guidelines, ethics, conference report/abstract)                
Surgical techniques 
Basic science
Full text analysis
Excluded (n = 87)
Qualitative not relevant to live donor kidney transplantation 
Only quantitative analysis 
No patient views elicited
Non-primary research
Non-English article   
Epidemiology studies
Experiences of living donor kidney transplantation post-transplant 
citations
126
Included in systematic review 
39 studies
(n = 1791*)
Other sources
11 citations  
441
183
167
156
138
103
6
5
29
25
9
11
5
3
5
Chapter 3: Patients’ perspectives on living kidney donor transplantation   
64 
 
 
Figure 3.2. Thematic schema representing adult CKD patients’ expectations and attitudes towards living kidney donor 
transplantation 
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Table 3.1. Characteristics of included studies (grouped by country) 
Study Country 
 
n Age 
range  
(years) 
Gender 
M:F 
CKD stage  Data collection Methodologic
al framework 
Analysis  Research questions relating 
to living kidney donor 
transplantation 1-5 5
D 
DD LD Pre- 
Martin-
McDonald 2003  
Australia 10 22-68 5:5  ●    Face-to-face, in-depth interview  Narrative 
inquiry 
Thematic  Medical concerns for donor   
Tong 2009  Australia 63 20-78 31:32 ● ● ● ●  Focus groups  - Thematic Psychosocial considerations  
Barnieh 2011  Canada 145 - 83:62 ● ●    Survey with open-ended 
response 
- Thematic  Knowledge, psychosocial barriers  
Hilton 1994 Canada  10 20-60 -    ●  Interviews  Grounded 
theory 
Content  Family decision-making  
Schweitzer 2003  Germany 67 - 40:27    ●  Prospective, face-to-face open-
ended interview 
- Content Psychosocial and medical 
concerns 
Lock 1999  Japan 21 - -   ● ●  Face-to-face open-ended 
interview 
- - Cultural beliefs and attitudes  
Crowley-Matoka 
2005  
Mexico 50 17-62 28:22   ● ●  Prospective, face-to-face, in-
depth interview 
Ethnography Content   Socio-cultural, political and 
economic issues   
Martin 2013  New Zealand  193 19-77 104:87  ●   ● Open-ended survey - - Barriers to finding a donor  
Alnaes 2012 (15)  Norway 18 - 
 
- 
 
   ●  Face-to-face, semi-structured 
interview 
Narrative 
inquiry 
Gift theory 
- 
 
Psychosocial and cultural 
barriers among ethnic minority 
patients  
Alnaes 2012 (21) Norway 18 - -    ●  Prospective, face-to-face, 
unstructured interview 
Narrative 
inquiry 
- 
 
Psychosocial and cultural 
barriers for Asian and African 
immigrants  
Frade 2011   Portugal 35 - 22:13    ●  Open-ended survey - - Psychosocial concerns  
Ndlovu 1998  South Africa 14 19-48 6:8   ● ●  Face-to-face, semi-structured 
interview 
- - Religious and cultural beliefs   
Ekelund 2010 Sweden 39 26-84 30:9  ●    Face-to-face and phone semi-
structured interview 
- Thematic Psychosocial issues  
Sanner 2003  Sweden 12 46-59 7:5    ●  Face-to-face open-ended 
interview 
- Content Preferences, psychological 
barriers  
Sanner 2011  Sweden 214 - 124:90   ● ● ● Survey with open-ended 
responses  
- Content  Experiences during evaluation 
de Groot 2012   The 
Netherlands 
27 - 17:10   ● ●  Focus groups I-change model  Content Motivations. social concerns   
Ismail 2010* The 
Netherlands 
50 21-74 26:24  ●    Focus groups, In-depth 
interview 
Grounded 
theory  
- Attitudes, communication and 
knowledge among ethnic 
minorities  
Ismail  2012* The 
Netherlands 
50 21-74 26:24  ●    Focus groups 
In-depth interview 
Grounded 
theory 
- Religious attitudes among ethnic 
minority patients  
Ismail  2013* The 
Netherlands 
50 21-74 26:24  ●   ● Focus groups 
In-depth interview 
Grounded 
theory  
- Cultural barriers among ethnic 
minority patients 
Kranenburg 
2005   
The 
Netherlands 
61 - 35: 26  ●    Face-to-face, semi-structured 
interview 
- - Preferences, medical and 
psychosocial concerns  
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Kranenburg 
2007 (20)  
The 
Netherlands 
48 - 25: 23    ●  Face-to-face and phone 
structured interview  
- - Psychosocial issues for patients 
in kidney exchange program    
Kranenburg 
2007 (27) 
The 
Netherlands 
151 18-75 95:49  ●    Face-to-face, in-depth structured 
interview 
- Content Psychological and communication 
barriers  
Kranenburg 
2009  
The 
Netherlands 
84 19-76 61:23  ●    Face-to-face, semi-structured 
interview 
- Thematic Barriers to finding a living donor  
Franklin 2003  United 
Kingdom 
20 - 8:12    ●  Face-to-face, semi-structured 
interview 
Phenomenology Content Beliefs about risks to the donor 
and expected relationship 
changes  
United 
Kingdom 
30 - 14:16    ●  Face-to-face, semi-structured 
interview 
Ethnography Content  
Thematic  
Socio-cultural barriers  
Gill 2008* United 
Kingdom 
11 32-63 6:5    ●  Face-to-face, semi-structured 
interview 
Phenomenology 
hermeneutical  
Thematic  
 
Psychosocial issues related to gift 
exchange  
Gill  2012* United 
Kingdom 
11 32-63 6:5    ●  Face-to-face, semi-structured 
interview 
Phenomenology 
hermeneutical 
Thematic  Stressors and coping mechanisms 
Mazaris 
2012(44)* 
United 
Kingdom 
16 - -  ● ● ●  Focus groups  Grounded 
theory  
- Pre-surgical experiences  
Mazaris  
2012(27)* 
United 
Kingdom 
16 - -  ● ● ●  Focus groups Grounded 
theory  
- Donor recruitment  
Boulware 2011 United States 8 34-71 5:3 ●    ● Structured group interview - Thematic Communication barriers among 
African American patients 
DePasquale 
2012   
United States 29 37-72 12:17  ●   ● Face-to-face, semi-structured 
interview 
- Content Medical, psychological and 
economic barriers 
Gordon  
2001(15)* 
United States 79 19-73 39:40  ●    Face-to-face, semi-structured 
interview 
Ethnography Content Medical, social and cultural 
issues and personal attitudes  
Gordon  2001* 
(53) 
United States 79 19-73 39:40  ●    Face-to-face, semi-structured 
interview 
Ethnography Content Socio-cultural issues and medical 
concerns  
Humphreys 2011  United States 9 39-64 5:4  ●    Face-to-face, semi-structured 
interview 
Grounded 
theory 
 Cultural attitudes and personal 
beliefs   
Murray 1999  United States 115 26-75 63:51**  ●    Face-to-face, semi-structured 
interview 
Constant 
comparative 
method 
Thematic Knowledge, preferences and 
expectations  
Pradel 2003  United States 13 26-72 6:7 ● ●  ●  Focus groups  Phenomenology Content Expectations and beliefs about 
laparoscopic nephrectomy  
Simmons 1972 United States  83 - -   ● ●  Prospective, face-to-face 
interview 
- - Family communication patterns 
in the search for a kidney donor  
Waterman 2006  United States  26 - 14:12    ●  Focus groups  - Content Psychological concerns, donor 
recruitment, educational needs.  
Wilson 2012 United States 12 - 7:5   ● ●  Focus groups - Content Improvements to education  
(-) not stated, unclear, or unable to ascertain; (*) Other studies included in this review have used the same sample  ; (**) One participant in this sample did not indicate gender Abbreviations: CKD 1-5, not 
undergoing renal replacement therapy; CKD-5D, dialysis patients (peritoneal or haemodialysis patients, and those undergoing transplant evaluation or waitlisted); LD, received, or being evaluated for a living donor 
transplant; DD, received or are being evaluated for a deceased donor transplant; Pre, received, or being evaluated for a pre-emptive transplant. Definitions: I-change model, predisposing social factors determine a 
person’s self-efficacy, intention and motivation to carry out certain behaviours; gift theory, gift exchange is a cycle bound by three key obligations i.e. giving, receiving and reciprocating.  
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Table 3.2. Comprehensiveness of reporting of included studies  
Items Studies reporting each item  n(%) 
Personal characteristics   
Interviewer/facilitator identified 13,17,27,28,30,31,33-35,40,41,43,44,65-70 19(54) 
Occupation 15,27-29,36,40,57,65,67,69-73 14(40) 
Gender 17,27,28,30,31,35,41,43,65,67,72 11(31) 
Qualitative research experience 14,15,33,36,40,44,71 7(20) 
Relationship with participants  
Relationship established prior to 
study commencement 
17,27,28,31,44,65,67 7(20) 
Participant selection   
Selection strategy (snowball, 
purposive, convenience) 
17,27,28,30,31,33-37,40-44,65,67,69-75 24(70) 
Method of recruitment 14,15,17,27,28,31,33-38,40-42,44,65,67,69,70,73-76 24(70) 
Sample size 13-15,17,27,28,30,31,33-38,40-44,57,65,67-79 34(97) 
Number/reasons for non-
participation 
14,15,17,30,34-37,42,44,57,70,74,75 14(40) 
Setting   
Venue for data collection 13-15,17,27-31,33-37,40-43,67-70,73,75,77 25(71) 
Presence of non-participants 15,27-31,33,40-42,44,57,70-75 18(51) 
Description of the sample 13-15,17,27-31,33-38,40-42,44,57,65,67-77,79 33(94) 
Data collection   
Questions or topic guide 13-15,17,27-30,34-36,40,42,44,57,65,67,69,71-75,77 24(69) 
Repeat interviews 13-15,27-31,33,34,37,40-44,57,65,67,69-71,73-75,77,78 27(77) 
Audio/visual recording 13-15,17,27-31,33-35,38,40-42,44,57,67,70,71,74,76,79 24(69) 
Field notes 13,31,33,35,41-43,65,67,70,74,79 12(40) 
Duration 13,15,17,28,31,33-37,40,44,57,65,67,69,71,72,74 19(54) 
Data/theoretical saturation 33,40,44,74 4(11) 
Transcripts returned   41,67,69 3(9) 
Data analysis   
Researcher triangulation  14,15,27-29,33,36-38,42,44,57,65,71,72,74,76,79 18(51) 
Derivation of themes or findings 13-15,17,27-31,33,34,36-38,40,42,44,57,65,67,69-
72,74,76,79 
27(77) 
Protocol for translation  33,37 2(6) 
Protocol for data preparation and 
transcription 
13-15,17,27,28,30,31,33,34,38,40-44,57,67,69,71,73-76 24(69) 
Use of software 31,33,40,42,44,67,74 7 (20) 
Participant feedback on findings 17,34,41,67,69,73,75 7 (20) 
Reporting   
Participant quotations or raw 
data provided 
13-15,17,27-31,33-38,40-44,57,65,67-79 35(100) 
Range and depth of insight into 
participants perspectives 
13-15,28,33,35-37,40,41,44,57,70-72,74,79 17(49) 
Note: References Barnieh (2011), Frade (2011), Martin (2013) and Sanner (2011) were not included as COREQ is 
not applicable to survey studies. 
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Table 3.3. Illustrative quotations  
Themes Participants quotations (italicised) and/or authors’ explanations References 
Prioritising own health  
Better graft 
survival 
When my wife offered to give me her kidney, it’s not that you’re ungrateful but I didn’t want her to go through that for me. But we talked it over and 
eventually decided that it was the best way forward and reluctantly, but gratefully, I’ve accepted it. – UK 27  
One can keep the kidney from a living donor longer than that of a deceased. – The Netherlands 33  
He’s flesh of my flesh and blood of my blood. Half my gene set comes from her. – Sweden 37 
13,14,27,28,33,37,44
,66,74,77,79 
Accepting 
risk 
The worst-case scenario is very rare. – UK 76   
We’ve been both guilty of heads in the sand approach, until we’ve needed to come to the next hurdle and then we cope with it and move on. But we try not to 
worry too much about things that may never happen. – UK 28  
Some had developed “emergency plans” such as selecting a second “standby donor”. – Germany 29 
13,28,29,76 
 
Desperate 
aversion to 
dialysis  
One patient commented that he would accept a kidney “even from my worst enemy”. – The Netherlands 17  
I did not want my children to see their father this way. I was prepared to go to great lengths for that. – The Netherlands 74  
I am tired of that whole dialysis thing. I hate those needles and such; sometimes it hurts so much that I do not want to go to the dialysis centre anymore. – 
The Netherlands 33 
13,14,17,31,33,36,41
,44,49,57,70,74,80 
Guilt and responsibility  
Jeopardising 
donor health 
I’ve had a pretty full life, so I wouldn’t want to take a kidney, like, from my daughter or my wife, which might shorten their life. – US 57  
It’s a selfish thing of me to ask of my family or others to give me what God gave them to survive. I had my kidney... – US 34 
… He’s having an operation he doesn’t need. If anything happens to him by giving me a kidney, I’d never forgive myself. – UK 28  
My son is healthy and [has] my same blood type, but he has two young children. How could I, when they tell us the risks involved…  - US 79 
To take a transplant from either of my two daughters is anathema to me because I don’t want to violate their bodies. – Australia 42  
13-15,17,27-
29,33,34,36,37,42-
44,49,57,61,65,68,77
,79 
Anticipating 
donor regret 
I didn’t want to increase their likelihood of having problems in the future and then have them say, “Oh my God! I gave my dad my one kidney”. – US 15 
We’re all young and we’re all just getting married and looking at starting families and…I wouldn’t want any of my friends to have this resentment if they 
had a child that needed it for a husband or another family member of theirs. – US 15 
I know for myself that what I have is hereditary, and my concern was if my husband was my donor and I had a child who needed it and who happened to 
match him as well, would there be an issue? You have no more spares. – US 15  
I would be more upset [if the kidney failed] because I put them through all that … I’d be afraid they would think they made a bad decision. – US 15  
I’m afraid that the donor someday will ask for his kidney back – The Netherlands 44 
13-
15,17,28,29,33,36,42
-44,49,57,66,68,70 
 
Causing 
donor 
inconvenienc
e  
You know, most of them are younger and have little kids, you know my parents are too old at this point… so, you know what I’m saying… like everybody 
has such busy lives, so having to bring it up, it’s just so, you know, it’s disrupting their life so much… – US 49 
Because I heard it's really hard for the donor (they break the ribs [to get to the kidney]), the donor is in the hospital longer than the recipient, and I don't 
want him to go through that. – US 13  
I’ve told my two daughters that they should maintain their health so that they can take care for their own children. – The Netherlands 44 
13-15,38,42-
44,49,80 
 
Ambivalence and uncertainty 
Doubting 
transplant 
However, if an emergency arises and I really need a kidney, then I will ask someone to donate. – US 13 
Maybe when I’m really sick! – US 36  
13,14,17,28,31,33,34
,36,41,44,49,57,80 
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urgency I’ve been doing really well on dialysis and I think there is a chance that my kidneys might be coming back… so I think maybe I’m getting better and I won’t 
even need one. – Mexico 31 
I didn’t want to accept it… I was in denial, I refused to believe my kidneys were packing up… I thought maybe I’ll feel better tomorrow.  – UK 28 
Insufficient 
information 
You have questions that come up and you are so overwhelmed by what is going to be happening to you that when you go finally to see the doctor and he 
gives you 3 minutes of his time, you don’t have time to ask all of these questions. – US 15  
The collaboration between the hospital and foreign people is bad; they do not give us all the information we need. – The Netherlands 33  
I do not think that they [my family] would come to such a meeting, it would really help them understand my situation.  – The Netherlands 33  
My wife was with me, and then she turned out to be the living donor. So her education was far more important than mine. – US 79 
I’m more interested on like if you have a donor somewhere else, like a different country. That wasn’t really covered.  – US 79 
15,33,40,79 
Confronted 
by 
unfamiliarity  
My doctor mentioned the idea of a transplant to me when I was first diagnosed, but I thought, that’s not for me, I suppose it seemed like something for rich 
people, movie stars, people who can go up there [to the US] not for me. – Mexico 31  
The Mosque isn’t negative about it; it’s the people that are. Because they are not experts on this issue… – The Netherlands 40 
31,33-35,40 
Prognostic 
uncertainty  
I have to talk to her doctor. What would be her health down the road? Is that extra kidney going to help her along better? – US 13 
As I look back on it... the actual event wasn’t anywhere near as bad as the anticipation – US 13 
I’m afraid that I will get to live and the donor will die, I heard that it already happened once, so I’ve heard. – The Netherlands 44 
I’m afraid to take it from my family because a friend of mine gave a kidney and now she’s on the machine. I don’t want that for my family. – US 36 
Uncertainty and waiting are big problems, but I also feel split regarding the question of whether I really do want to receive a living organ. – Sweden  30  
13-15,17,27-
30,33,34,36,37,42-
44,57,61,65,67-
70,72-77,79,80 
 Seeking decisional validation   
A familial 
obligation  
I think my brothers and sisters had gone through their life having a slightly ill little sister but not quite realising how ill and when I had a total collapse 
they just sort of said, ‘‘wow’’ and so they all just came in and offered instantly. – UK 65  
In our community children and parents are very close. So if they can donate they will donate! This works both ways. –  The Netherlands 33  
She knows that if she had been the one in need I would have been there. – UK 65 
17,33,37,65,70 
Alleviating 
family 
burden 
I will be able to work and take care of my family. – Mexico 31  
I just want to be a normal woman. I want to be a mother and a real wife, so that is why we are going through all this now, so that we can be a family. – 
Mexico 31 
29,31,38,42 
Reciprocal 
benefits for 
donors 
 When potential donors are not allowed to donate, they feel sad. – UK 38  
There was also a very strong emphasis, particularly in spousal transplantation, of “being in it together”, with donors and recipients supporting each other 
through the process. – UK 28  
Ask her also, would you prefer to be a donor or a carer? Because her life may improve without you on dialysis, you can go on those holidays that you wanted 
to go on. – Australia 42 
It seems to me it’s important that you express the donor benefits to the recipients. If I take anything from this.. that’s where we’re not communicating very 
well, is to the recipients. – US 15  
13,14,28,29,31,33,37
,38,42-
44,49,65,66,72-
74,76,77,81 
 
Religious 
approval 
I know Islam quite well and I know what the principles are. Islam is not against it. – The Netherlands 40  
In Buddhism it’s literally stated that you should save a life when you get the chance. – The Netherlands 40 
No, religion wouldn’t make a difference, people are people, and they help each other. – The Netherlands 40 
I thought that because of religion it can only be someone from your own family, but isn’t allowed from someone else, that’s what I thought. – The 
Netherlands 40 
33,40,41 
Chapter 3: Patients’ perspectives on living kidney donor transplantation   
70 
 
Respecting 
donor 
autonomy  
If you were in her situation, would you want her to accept your kidney? Would you be happy? – Australia 42 
They said, “your mother would do anything for you and by saying no, you’re actually hurting her.” So I suddenly realised, hang on, I’m almost selfish for 
saying no to such a gift, and it’s for that reason I will accept... – Australia 42   
It was up to my father [the donor] and I to make the decision, and it was not for her [doctor] to tell us what to do, it was not as if she knew me. I hate that 
soppy interference. I have seen other people coming out of her room crying. I wasn’t going to have any of that. – UK 65 
My mother was ready to donate before she was influenced by my sister. – The Netherlands 33  
They would feel more reassured that they were not at fault if the decision to donate had been made voluntarily by the donor. – The Netherlands 73 
14,33,42,65,79,81 
External 
reassurance 
I want a great deal of certainty that my donor is going to be ok. – The Netherlands 33   
I needed their (family) support. – UK 72 
It would be really nice to discuss everything with your family. In this way they will get to know your miseries. – The Netherlands 33 
33,72,79 
 Needing social support   
Avoiding 
family 
conflict 
My sisters said that they do not want to have family problems in the future because of the donation. – The Netherlands 44 
In many ways I would have liked to have refused but that would have caused so much conflict... – UK 72  
I will not let this situation spoil my relationship with my family (I am really going to need them in the future), but I am disappointed. – The Netherlands 17 
No one really asked me, it just happened and I never really liked him that much… – UK 72 
We did not really discuss it. It is not something we talk about – The Netherlands 17 
13,14,29,33,37,38,42
-44,65,72-
74,76,77,81 
Unrelenting 
indebtedness 
You can keep your organ, I don't want you to run my life. – US 13 
Gina refused to accept the offer because her daughter “kept talking about [me] covering her expenses while in the hospital and paying her wages”, which 
made Gina feel like her daughter was “selling her kidney”’. – US 13  
[She] felt the offer was an act of manipulation by her sister so that she could “become the martyr and take centre stage.” –  UK 72   
I was afraid that in case of an argument the kidney would be brought up, even just as a joke. I didn’t want that. – The Netherlands 74  
I knew what it would be like afterwards – eternal gratitude. – UK 72   
May I still argue with the donor? I was afraid not – The Netherlands 74 
13-15,27-
29,33,37,42,43,65,68
,72,74,75,77 
 
Emotional 
isolation 
I’m disappointed with my brothers and sisters… Getting a kidney would solve lots of problems for me. – Sweden 30 
Most informants were reluctant to reveal their anxiety about the donation and the donor, and they seldom spoke with their doctors about this, only 
occasionally with the ward staff and the hospital chaplain. – Sweden 37  
I don’t think there is any focus or not enough focus on the psychological things you go through. – US 15  
I just go through it by myself.  –  US  13 
I don’t really want a transplant right now. But I don’t tell that to the doctors, I go along with the tests, just in case. – Mexico 31 
13,15,17,30,31,35,37
,42,49,82 
 Cautious donor recruitment   
Self-advocacy  You cannot just wait for someone to give his kidney away. You should promote yourself and get to the point! – The Netherlands 33   
You should come up with a really good story, so that they cannot turn down your request. – The Netherlands 33  
If a doctor asks it, it would be seen as a legitimate request.  – The Netherlands 33 
I would make a joke about it: if I for example pick your name you will lose a kidney! – The Netherlands 33  
I said to a young acquaintance that if he would donate his kidney to me, I would arrange a marriage and buy a house for him in Turkey – The Netherlands 
33 
15,33,76 
Lacking self- The whole thing about asking….It’s not like just saying, you know, “Can I borrow your car?” or “Will you lend me fifty bucks?” It’s a whole life thing that 13-15,17,30,33,36-
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confidence  can effect someone forever. – US 15  
I also think it’s easier to talk to people about it and ask these things when there’s a sense of urgency… – US 57  
I talked to them about it. Most of the family has kidney problems. So when I asked them about donating, then they had problems too. – US 67 
They didn’t cover approaching [others about LDKT] even of your family members. They said it could be done  - US 79 
It’s hard to ask somebody. If you don’t have family and real close friends, how do you come up to somebody and say, are you willing to be my donor? - US 79 
Any the funny thing about it is my whole life, I’ve always had my driver’s licence checked, even before I ever got sick, that I wanted to be a donor. And I 
would step up like that to give anybody else a kidney, but for me to ask somebody, I couldn’t do that.  - US 79 
38,40,41,44,49,57,61
,65,67,68,73,74,76,7
7,79,80 
Avoiding 
donor 
coercion  
It's a totally voluntary thing. It's a gift. It's not something to ask someone. – US 13  
We live the whole time with the hope that one of our siblings will offer to provide us a kidney sooner or later. – Sweden 30 
Everyone that knew me, knew I was very sick… People knew this and if they weren’t volunteering then they must not want to donate. – US 15  
They all know I’m here. They all know I’m going to have a transplant. If they were going to donate, wouldn’t they have called by now? – US 78 
You would feel guilty, they would not dare to say no, and then, if something happens, you would feel even more guilty. – The Netherlands 17  
If somebody wants to do that, they’ll offer. I wouldn’t want to put somebody in that position if they didn’t really want it. – US 13 
The social worker can act as an arbitrator … and lay out all of the costs on the table and the benefits, so that everybody knows what they’re getting into – 
US 49    
13-15,17,27,28,30-
33,35-38,41-
44,49,57,65,66,72-
74,76,78,80 
Emotional 
vulnerability  
I do not want to bother my family with this; it would feel like I want to bring them together to show them how sad I am. – The Netherlands 44  
If I ask they may get angry, or try to avoid me. I do not want that, I really need them. – The Netherlands 73 
Rather than ask and get my feelings hurt, I didn’t even ask. – US 15 
I was alarmed by my daughter’s reaction. [After that] I have not asked anyone else. I might lose them. – The Netherlands 17 
14,15,17,31-
33,41,49,73,80 
Respecting 
cultural and 
religious 
taboos 
I would not expect someone else to ask me such a question, so I would not ask anybody either. – The Netherlands 33 
It is still a taboo to talk about your illness in the Antillean community. – The Netherlands 33   
It would be unseemly for them to get to know about my illness through an intermediary like the doctor. – Norway 41   
13,17,33,35,40,41,49
,65,66 
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4.1 Abstract 
Background and objectives: Comprehensive evaluations are required to 
safeguard voluntarism and minimise harm to living kidney donors. This 
process is lengthy, invasive, and emotionally challenging, with up to one-
fifth of potential donors opting-out. We aimed to describe donors’ 
experiences of the evaluation process.  
Design, setting and participants: We conducted 14 focus groups involving 
123 kidney donors, who completed donation, from three transplant centres 
(Australia and Canada). Transcripts were analysed thematically.  
Results: We identified six themes reflecting donors’ experiences of 
evaluation. The themes that related to perseverance included emotional 
investment (prioritising the recipient’s health, desperation for a normal 
life, protecting eligibility, shame of disappointing others, overcoming 
opposition); undeterred by low-risks (medical confidence and protection, 
worthwhile gamble, inherent invincibility, normalising risks); and mental 
preparation (avoiding regret, resolving decisional ambivalence, managing 
expectations of recovery). The challenges included underlying fears for 
health (processing alarming information, unsettling uncertainty, pre-
operative panic); system shortfalls (self-advocacy in driving the process, 
stressful urgency, inconsistent framing of safety, unnerving bodily 
scrutiny, questioning risk information, draining finances); and lifestyle 
interference (living in limbo, onerous lifestyle disruption, valuing 
flexibility).   
Conclusions: Previous donors described an emotional investment in 
donating and determination to protect their eligibility, despite having 
concerns for their health, financial and lifestyle disruption, and opposition 
from their family or community.  Our findings suggest the need to prepare 
donors for surgery and recovery, minimise anxiety and lifestyle burdens, 
ensure donors feel comfortable expressing their fears and concerns, reduce 
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unnecessary delays, and make explicit the responsibilities of donors in 
their assessment process. 
4.2 Introduction 
Living kidney donor transplantation offers the best outcomes for many 
patients with end-stage kidney disease (ESKD), but their donors must 
accept potential risks and uncertainty regarding long-term outcomes.1-3 
Informed consent and comprehensive evaluations are necessary to 
safeguard donor voluntarism, exclude unsuitable donors, minimise harm 
and risk factors, and organise support for living donors.1,4,5 The evaluation 
can be lengthy, invasive and anxiety-provoking6-9, and it is estimated that 
up to 22% of potential donors opt-out of evaluation.10 
Donors undergo rigorous assessment of their mental and physical health, 
their relationship with the recipient, motivations, expectations, lifestyle, 
finances, social support and their understanding of risks.11,12 Difficulty 
navigating an unfamiliar healthcare system can cause considerable 
stress.6-8 Many donors report anxiety and ambivalence about undergoing 
surgery.13-15 Some donors are very intent on donating and therefore unable 
to fully comprehend the risks, or conceal their concerns in order to protect 
their eligibility.16  
There are sparse data on the reasons why donors accept health risks, their 
experiences of being assessed, and how they persevere with evaluation. 
We aimed to describe kidney donors’ experiences of the evaluation process 
to inform strategies to prepare donors for the donation and possible 
outcomes.  
4.3 Methods 
This is study is part of a larger study examining donors’ priorities for 
outcomes.17 We reported our study according to the consolidated criteria 
for reporting qualitative studies (COREQ) framework.18  
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Participant selection 
Participants were recruited from three transplant units in Australia 
(Westmead Hospital, and Monash Medical Centre) and Canada (St Paul’s 
Hospital). A researcher phoned donors to invite them to participate. 
Purposive sampling was used, whereby donors were selected to include 
diverse demographic and donation characteristics.  All adult kidney 
donors, from the past 20 years, who were English-speaking, and able to 
provide informed consent, were eligible to participate. Participants were 
reimbursed AUD/CAD $50. Ethics approval was obtained from the 
Western Sydney Local Health District, Monash Health, and the University 
of British Columbia and Providence Health Care Research Ethics Board.  
Data collection 
The question guide (Appendix B.1) was based on a systematic review of 
donors’ experiences19, and discussion among the research team. The two-
hour focus groups were conducted in a hotel meeting room. One facilitator 
(CSH/AT/AFR) moderated the groups and a co-facilitator recorded notes. 
Each group was audio-recorded and transcribed verbatim. Focus groups 
were ceased when saturation was achieved (no new information was 
elicited in subsequent groups) within each country.20   
Analysis 
Grounded theory and thematic analysis were used to analyse the data.21 
CSH initially read through the transcripts to inductively identify 
preliminary concepts. The transcripts were coded using HyperRESEARCH 
(ResearchWare Inc. version 3.5.2) software, in which CSH reviewed the 
transcripts line-by-line and assigned themes to each segment. The themes 
were iterated by comparing within and across groups and with feedback 
from AFR, KM and AT, who ensured all data were captured.  
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4.4 Results 
We convened fourteen focus groups with 123 donors from July 2015 to July 
2016 (median = 9 participants per group, IQR = 8-10, min = 5, max = 12). 
The demographic and donation characteristics are provided in Tables 4.1-
4.2. The participants were aged from 27-78 years (mean 55 years, SD = 
11.5), including 78 (63%) women. The time since donation ranged from two 
months to sixteen years (mean 3.6 years, SD = 3.1). One hundred and one 
(82%) participants donated to a family member, nine (7%) to an unrelated 
recipient, six (5%) were non-directed (anonymous) donors, and nineteen 
(15%) donated through a paired-exchange.  
Six themes were identified. The relationships among themes are depicted 
in Figure 4.1. Quotations are provided in Table 4.3.  
Emotional investment 
Desperation for a normal life: Donation was seen as a “privilege” that 
provided the chance to “fix” their recipients health and family life. Even if 
they had risk factors, they believed there was “no other choice”. 
Incompatible donors were relieved to find “a plan B” through paired 
exchange. 
Shame of disappointing others: Directed donors felt a responsibility to 
“pass” their assessments to avoid disappointing the recipient and the 
recipient’s family. At the final psychosocial evaluation, participants felt it 
was too late to let the recipient down. Non-directed donors became 
“emotionally connected” to being a donor.  
Prioritising the recipient’s health: Participants felt “blind[ed]” to 
information about risks - “I didn’t care if I lived or died, because it was my 
daughter”. Some were willing to “live with” short-lived and “manageable” 
consequences, like pain. Some were so “focused” on the recipient, that 
post-donation outcomes were “an afterthought”. 
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Protecting eligibility: The possibility of being ineligible caused anxiety. 
Some maintained a strict diet and exercise regimen to ensure they were 
accepted. Donors were careful to say “all the right words” to “pass” the 
evaluation. Non-directed and unrelated donors were frustrated by 
repetitive questioning of their comprehension of risks and having to 
“convince” the hospital to accept them. Some related donors were not 
worried about being questioned because they felt their motives were 
straightforward.  
Overcoming opposition: “The hardest things” were family opposition or the 
recipient’s reluctance for them to donate. Unrelated donors believed their 
family preferred someone closer to the recipient to donate. Some faced 
disapproval from their religious community, regarding the violation of 
bodily integrity. This left them feeling isolated - “people could not relate to 
me, so I couldn’t talk to them”.  
Undeterred by low-risks 
Worthwhile gamble: Participants, irrespective of time since-donation, felt 
“comforted” by statistics showing “very minimal” risks of morbidity and 
mortality that were no higher than “somebody living with two kidneys”. 
The “very positive” data conveyed that their safety was a “non-issue”. 
Participants felt guilty for prioritising their own safety.  
Inherent invincibility: Unrelated and non-directed donors, in particular, 
felt confident in their safety. They believed they were the “rule, not the 
exception” when considering low-risks of harm - “[if] it’s 1/2000 or 1/500, 
that’s not going to be me”.  
Normalising risks: Participants viewed surgery as a common risk to take, 
equating it to – “the chance you take every time you drive”. Nephrectomy 
was considered a “benign” procedure as they were aware of others who had 
donated safely or were born with one kidney.  
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Medical confidence and protection: The “stringent” medical evaluations 
convinced participants that they were unlikely to face complications. The 
surgeon was “the calming person before the storm” due to their positive 
and authoritative tone. Participants trusted their clinicians to protect 
them from harm – “the [doctors] don’t want to make another patient”. For 
Canadian donors, receiving wait-list priority helped to justify taking the 
risk. 
Mental preparation  
Avoiding regret: Participants were uncertain how they would cope if the 
transplant failed and many expected to feel “devastated”. They 
relinquished control over the ‘gift’ – “It’s like any gift you give. You give 
and you hope for the best”. Others avoided thinking about rejection. Some 
women feared recipient non-adherence would “change the dynamic of their 
relationship”. 
Resolving decisional ambivalence: Some participants were undecided 
about donating, but continued with evaluation while “getting positive 
results”. They appreciated receiving reassurance from the psychosocial 
team, and support from family created a sense that they were not alone. 
They psychological evaluation gave them some “closure”.  
Managing expectations of recovery: Donors sought practical advice to 
prepare for their recovery. Some preferred to hear previous donors’ 
experience of recovery “rather than the aggregate” outcome. Some watched 
videos of surgery and felt reassured by the “simplicity” of the process. 
Websites were used to find statistics about surgical outcomes, but some 
wanted local statistics relevant to their unit.  
Underlying fears for health     
Processing alarming information: It was challenging for participants to 
process information about complications, as this conflicted with their 
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determination to donate. They were confronted by graphic details of 
surgery and had fears “at the back of their minds” about mortality and 
ESKD.  
Unsettling uncertainty: Even small possibilities of harm were troubling for 
some participants, because “you could be an anomaly”. Some participants 
described fears relating to their awareness of gaps in current knowledge of 
living donor outcomes.  
Pre-operative panic: Some participants were overcome with fear just prior 
to surgery, and worried about the consequences for their family, if they 
died. Men believed they had avoided their fears.  
System shortfalls  
Self-advocacy in driving the process: Some participants were surprised 
that they had to drive the evaluation. They had to “do [their] own 
research” to learn their eligibility status, and arrange further tests – “we 
were prompting them every step of the way for dates, times, any scope of 
information”. Some felt they discovered financial support too late, or had 
to “ask for it”.  
Stressful urgency: The “long and exhausting” evaluation, “devastating” 
delays, and “unnecessary” duplication of tests, caused donors to fear their 
recipient would deteriorate on dialysis. Some believed they had to 
pressure the transplant team to progress, and felt they should have been 
“fast track[ed]” through the system.  
Inconsistent framing of safety: Participants were confused by the “highly 
inconsistent” messages from different transplant professionals– “My 
surgeon [will] say, high-five we’re in…you see another surgeon and they 
say, you could die”. The reiteration of dangers and questioning of their 
commitment to donate by the surgeon, and psychosocial team felt like they 
“were trying to convince you not to do it”.  
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Questioning risk information: For some participants, information sessions 
were seen as unrealistically positive regarding post-donation outcomes – 
“everyone’s up there saying this is wonderful”. They were concerned when 
the transplant team could not provide more details about mortality 
statistics, such as the study population. They felt they had no way of 
“checking”, information. Some believed that risk estimates were 
“overinflated” so “you can’t complain later”.  
Unnerving bodily scrutiny: Some participants felt uneasy about becoming 
a “patient”, and exposing their body and lifestyle to examination. 
Abnormal test results and delays in receiving results, caused them to fear 
the worst – “I had myself halfway into palliative care”. Some were shocked 
by their surgeon’s apparent lack of “bedside manner”, and were upset by 
being labelled overweight. They felt they were treated like “just a 
number”, diminishing the “massive thing you are going through”.   
Draining finances: Costs for transport, accommodation and lost income 
accumulated throughout evaluation. Some found the financial assistance 
“wasn’t worth pursuing”. One participant reported being fired due to the 
leave required for recovery. Some Canadian donors had concerns about 
increased costs for health, life and travel insurance post-donation.  
Lifestyle interference 
Living in limbo: Participants felt their “whole life was on hold”, while 
waiting for their surgery date and had to be “ultra-careful with [their] 
body”. Some non-directed donors questioned their commitment to the 
donation with increasing delays. They wanted to be given realistic 
estimates of the work-up timeframe.  
Valuing flexibility: Donors valued the flexibility of the transplant team, in 
organising tests around their work schedule. Workplace flexibility, 
reimbursement of travel expenses and income support alleviated financial 
anxieties, and some felt this made it possible for them to donate.  
Chapter 4: Donors experiences of evaluation  
88 
 
Onerous lifestyle disruption: The evaluation was disruptive to their work 
and lifestyle. Participants travelling long distances to the transplant 
centre would have preferred to undergo tests closer to their home. 
Preparing for the surgery took a lot of organisation, particularly for donors 
with young children. Many had family members to “back [them] up” 
financially, or practically. 
4.5 Discussion 
The emotional investment in giving their organs sustained donors’ 
commitment throughout the evaluation process, despite having underlying 
fears about their health, encountering opposition from others, and 
managing lifestyle disruptions and financial hardship. They were 
determined to improve the recipient’s health and their family life. 
Although information about post-donation outcomes were concerning to 
donors, they trusted their clinicians to protect them from harm. They 
strived to protect their eligibility by adhering to a healthy lifestyle, and 
some concealed their concerns to demonstrate confidence in their decision. 
They also faced expenses and disruptions to their lifestyle in order to 
attend appointments and discovered their need to drive the evaluation 
forward, and find information. Increasing delays and uncertainty left 
donors in a state of limbo, and anxiety, as they feared their intended 
recipient would deteriorate on dialysis, or wanted to avoid the 
commencement of dialysis.   
Some differences in the donors’ perspectives were apparent, particularly 
by donor type, age, gender, and ethnicity. For related donors, the chance to 
improve the recipient’s wellbeing outweighed concerns about their own 
risks, which they regarded as negligible and unjustifiable as a reason to 
not donate. Unrelated and younger donors gave more consideration to 
long-term health outcomes, feeling more vulnerable or distanced from the 
recipient. Non-directed donors had confidence in their safety as they 
believed they were in optimal health. Most donors feared failing their 
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evaluations. Unrelated and non-directed donors described more intense 
questioning of their motivations, suitability and understanding of risks, 
likely reflective of different approaches for evaluating these donors. 
Women described concerns about tensions in their relationship with the 
recipient. Ethnic minority donors faced opposition from their family, and 
religious community, due to beliefs about bodily integrity, which has been 
described previously.22  
Donors were undeterred by low-risks of complications and long-term 
health problems. Some donors recalled ignoring information that 
contradicted their decision to donate. This reflects an analysis of the 
dialogue between potential donors and transplant professionals, which 
found that donors express disinterest in risk information, as their decision 
is ‘entrenched’23. This accords with cognitive dissonance theory, the 
tendency to minimise inconsistency between our thoughts and actions.24 
Clinicians have also expressed scepticism that donors understand risks.25  
Psychosocial support enabled donors to resolve issues causing ambivalence 
or anxiety, for example the possibility of the graft rejection. The need to 
protect their eligibility left some donors unwilling to disclose their 
concerns. Other studies have also found that directed and non-directed 
donors feel anxious about undergoing psychosocial assessment due to their 
determination to donate, and attempt to manage how they are perceived, 
and some conceal experiences that might exclude them.16,23,26 We found 
that some male donors were overcome with anxiety before their operation, 
which supports findings from a study that used self-administered anxiety 
scales.27  
Our multinational study included a large sample of donors with a range of 
demographic and donation characteristics. However, we only included 
English-speaking participants. The applicability of the findings may be 
uncertain in healthcare systems outside of Australia and Canada, 
particularly those without universal access to healthcare and 
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reimbursement programs. In the United States many donors are 
uninsured28, and eligibility for reimbursement is means-tested29. 
Differences are also likely to exist within programs in Australia and 
Canada. However, we achieved saturation within each country, and found 
similar findings to other studies, suggesting the broader relevance of our 
findings.6-8 We also relied on the donor’s recall of their experience. 
However, donors discussed sensitive issues such as ambivalence, which 
they had not expressed prior to donation. Variability in perspectives on 
risks may reflect changes to the messages provided by clinicians. We only 
included participants who had completed donation, and the barriers 
experienced by those who opt-out might be different. Non-donors have 
reported some similar barriers (e.g. financial issues, concerns about risks 
and family opposition).10,30 
Guidelines focus on ensuring psychological suitability, motivation and 
voluntariness, and informing donors of possible outcomes.5,31 Conflicts 
between the goals of clinicians and those of donors may not be addressed 
in guidelines. Comprehensive risk information can be confronting or 
irrelevant to donors.  A ‘cooling-off’ period and requiring donors to drive 
the evaluation ensures donors make a considered decision.12,32 These 
practices can exacerbate stress for donors and prolong lifestyle intrusion. 
Caution to detect coercion and assess risk comprehension can cause donors 
to feel scrutinised and reluctant to express their anxieties. We suggest 
framing a component of the psychosocial evaluation as an opportunity to 
communicate and resolve concerns without feeling under threat of 
jeopardising their eligibility.  
We also suggest the need to provide donors with support to cope with 
anxiety, lifestyle disruption and cultural barriers during evaluation. Some 
donors did not understand that they must drive the evaluation, as the 
transplant team is unwilling to push potential donors to complete the 
testing. Making explicit the expectations and responsibilities of potential 
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donors, providing better information about the process, and expected 
timing-frame, can prepare donors for the commitment of undergoing 
assessment. Transplant centres should also strive to improve efficiencies 
in the evaluation process.11 An independent live donor advocate, social 
worker or patient navigator, could facilitate comprehensive support by 
addressing donors’ needs and concerns as they emerge, assess risk 
comprehension, and provide culturally-sensitive interventions to address 
family conflict.  
Psychosocial interventions are needed to address donors’ fears of surgery, 
mitigate the anxiety of testing, facilitate social and family support and 
prepare them for changes to their relationship, and the possibility of graft 
failure or being ruled out as a donor. For emotional preparation, some 
donors found it useful to discuss their concerns about graft failure and 
relationship problems with psychologists or social workers, and coped by 
relinquishing control over their ‘gift’.  Information about surgery, 
complications and recovery needs to be individualised to donors’ 
preferences (e.g. statistics or narratives of previous donor’s experiences). 
Future studies should include donors from diverse cultural and linguistic 
backgrounds to better understand the challenges of evaluation in these 
groups, particularly given the low rates of kidney donation among ethnic 
minorities.33 The experiences of non-directed donors should be studied 
further. While our study identifies some challenges that may influence the 
retention of donors, there is a need to understand the barriers for donors 
who opt-out.10 Our findings may inform strategies for improving the 
process of evaluation, which would warrant further studies to evaluate 
effective practices (e.g. timing of the psychosocial assessment).  
For potential donors, their emotional investment in the donation 
intensifies during evaluation and drives their perseverance and 
determination to protect their eligibility despite having concerns for their 
health, financial and lifestyle disruption, and facing family and 
Chapter 4: Donors experiences of evaluation  
92 
 
community opposition. Their determination to donate can also limit their 
comprehension of risk information, disclosure of their fears and concerns, 
and thus lead to inadequate mental preparation for donation. Increased 
attention to the psychosocial challenges of evaluation are needed, which 
may include addressing donors’ concerns, preparing for surgery and 
recovery, mitigating lifestyle burdens and anxiety, clarifying donor’s 
responsibilities, and reducing delays in the evaluation. 
4.6 Acknowledgments 
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Figure 4.1. Thematic schema 
Living kidney donors were emotionally invested in the donation, which 
sustained their commitment throughout the evaluation process, despite 
underlying fears and uncertainty about their health, difficulty navigating 
the transplant process, and increasing interference into their work and 
lifestyle. Their desire to help the recipient and improve their own lifestyle 
also led them to view low risks as a worthwhile gamble. Emotional 
support and medical confidence reassured donors of their safety, helped 
them resolve ambivalence, and prepare for their recovery and possible 
disappointment. Difficulties navigating the hospital system to access 
information, psychosocial services and speed up the process left some 
participants feeling unprepared, with unaddressed concerns. Their 
desperation to protect their eligibility prevented donors from seeking 
support and disclosing their apprehensions.  
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Table 4.1. Demographic characteristics of the participants (N=123)  
Characteristics  n (%) 
Gender  
 Female 78 (63) 
 Male 45 (37) 
Country  
 Australia 67 (54) 
 Canada 56 (46) 
Age (years) ^  
 20-29 1 (1) 
 30-39 11 (9) 
 40-49 27 (22) 
 50-59 36 (29) 
 60-69 34 (28) 
 70-79 13 (11) 
Ethnicity^  
 White 100 (81) 
 Asian/South Asian 12 (10) 
 Middle Eastern 5 (4) 
 Other*  6 (5) 
Highest level of education^   
 University degree 59 (48) 
 Diploma/certificate 25 (20) 
 Secondary school: grade 12   24 (17) 
 Secondary school: grade 10 17 (14) 
Total household income per year (AUD) ^ †  
 $0 - $24,079  16 (13) 
 $24,080 - $50,169  29 (24) 
 $50,170 - $80,271  30 (24) 
 > $80,271  42 (34) 
Employment status^  
 Full time 68 (55) 
 Part time/casual 22 (18) 
 Retired/Pensioner 24 (20) 
 Not employed  7 (6) 
Marital status^  
 Married/De-facto relationship 96 (78) 
 Divorced 7 (6) 
 Widowed 6 (5) 
 Separated  6 (5) 
 Single 5 (4) 
 Partner (not living with) 2 (2) 
+Age at time of participating in focus group; ^Total N ≠ 123 due to non-response.; *Includes South 
American, African, Pacific Islander and First Nation (Canada); †As defined by Australian Bureau 
of Statistics 2011 Census Survey (Converted to USD)  
Chapter 4: Donors experiences of evaluation  
95 
 
Table 4.2. Donation characteristics (N=123) 
^Total N ≠ 123 due to non-response; c Includes hyperthyroidism, low blood pressure, kidney stones, gall 
stones, hernia, blood clots, endometriosis, gout, high cholesterol, scleritis and osteoporosis.    
 
 
 
Characteristics  n (%) 
Time since donation (years)^  
    <1  13 (11) 
 1-3  59 (48) 
 4-6  35 (29) 
 7-10  9 (7) 
 >10  6 (5) 
Relationship to recipient  
 Spouse 39 (32) 
 Parent 33 (27) 
 Sibling 23 (19) 
 Friend/colleague  9 (7) 
 Child 6 (5) 
 Other relative (aunt, grandparent, in-law, cousin) 7 (6) 
 Non-directed 6 (5) 
Kidney exchange  
 Yes 19 (15) 
 No 104 (85) 
Post-donation complications  
 Mental health 8 (7) 
 Hypertension 7 (6) 
 Chronic pain 3 (2) 
 Hydrocele 2 (2) 
 Otherc 11 (9) 
Recipient outcome  
 Alive and functioning graft 113 (92) 
 Graft failure or death  10 (8) 
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Table 4.3. Illustrative quotations  
Theme Illustrative quotations  
Emotional investment 
Shame of 
disappointing 
others  
“One thing I thought was wrong…We’re ready to go in virtually the next day and I’m having a psychiatric test.  That should have been the first thing I had and I’ve now 
found out all these things that you didn’t know but someone’s waiting for me and if I was starting to get frightened, I wouldn’t be game at that stage to say, ‘No’. Whereas 
at the start…you can go back home with your head held high and say, ‘It didn’t work out.’  (Female, related donor, Australia, 70s) 
Desperation for a 
normal life 
“I’m glad you say selfish because that’s what drove me, and I can only kind of admit it now. He got admitted into hospital, six times one year. We said our goodbyes so 
many times.  It was just so draining…And then this came up.  I put hand my up faster than anybody in this room.  I was like, “Right, a solution, let’s go and fix it,”. 
(Female, related donor, Australia, 60s).  
“Basically, my doctor told me…because I have a really high case of diabetes in my family, so he was like. I really would prefer not to use you, because more likely than not 
you are going to have diabetes when you are old, but I mean for us there was no choice.” (Female, related donor, Canada, 30s).    
Prioritising the 
recipient ‘s 
health  
“I went in there blind, mean…I didn’t ask questions…I didn’t care. I’d do anything for my family.” (Female, related donor, Australia, 50s) 
“But that was a big barrier, like the unknown for myself …because they say when you donate, there’s a risk that something could happen to you, but in the end, I said to 
myself my brother needs it more than yourself. Because you do have that fear regardless.  Once I put him first everything just pretty much went away. (Male, related 
donor, Australia, 30s) 
“So, if I were to continue as a donor I had to take treatment [for an infection]…But they didn’t tell me that till, about four months on. But by that time I was emotionally 
connected to being a donor, an anonymous donor. I had very personal reasons for doing it. So, it was hard for me to just back out, and kind of give up.” (Female, unrelated 
donor, Canada, 50s) 
Protecting 
eligibility  
“When I was going through the test one of my great fears was that I wouldn’t be able to donate a kidney. I don’t know how that would have affected me because I was so 
committed to wanting to do it. I was sort of nervous right up until they said, you are a match.” (Male, non-directed donor, Canada, 60s).     
“That's a scary one actually, seeing a psych.  It would be awful if I got so far.” (Female, spousal donor, Australia, 50s). 
“They took away my surgery date…I really wanted [this specific person] to get my kidney. So, I basically had to beg to get my surgery date back…it was really hard to 
convince the doctors that I was going to be okay” (Female, non-directed donor, Canada, 40s) 
Overcoming 
opposition  
“Well [my family], honestly, mine weren’t with me but it didn’t make me think twice about it…I’d have put them to the side and thought about my own family. So, it’ a 
hard choice; but in the end you think it’s my choice and my choice only.  That’s what I thought.” (Female, related donor, Australia, 50s).  
“Because of customs of race and religion, people frown upon you…but it didn’t deter me from doing it. I didn’t put race, religion or anything into it… they say it’s God that 
brought you into the world so that you should go to him. But you’re helping, you’re going into the ground anyway, so why not?” (Female, related donor, Australia, 40s) 
“My best friend reacted much like your family. Was probably the only big fight we’ve ever had in about 25 years. At the end of it, I just said, you know what, you don’t get 
a vote. The only one who got a vote was my husband, nobody else got a vote” (Female, unrelated donor, Canada, 50s). 
Undeterred by low risks 
Worthwhile 
gamble  
“They didn't give you any guarantees; they did throw statistics at you. But you could be an anomaly and for whatever reason it doesn't work. But all of us, got to that 
place, where it doesn't matter. If it’s a year, it’s a year. But we have to do something, so we have to try.” (Male, related donor, Canada, 40s).  
“They couldn’t guarantee, even though I ticked all the boxes, that I wouldn’t develop renal failure. But I could have developed it with two kidneys.” (Female, related donor, 
Australia, 60s).  
Inherent 
invincibility  
“I wasn’t really worried about any of the outcomes. I knew I was a healthy individual. I didn’t really have any concerns”. (Female, non-directed donor, Canada, 40s) 
“I mean I haven’t won the lottery yet so I’m the rule, not the exception”. (Female, unrelated donor, Canada, 30s).  
Normalising 
risks  
“The information was that taking my kidney away is not likely to cause any problem. People live very healthy and long, and active lives with one kidney”. (Male, related 
donor, Australia, 60s). 
“She was my inspiration.  I went home and I said to everybody, “I met this lady and son and if that lady can do it.  I can do it.” (Female, related donor, Australia, 50s).  
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Medical 
confidence and 
protection  
“They put you through such a stringent testing process…We don’t go into it thinking ‘Oh my god, am I going to make it?” (Female, related donor Canada, 50s)  
“The surgeon was very reassuring…I think it was more the confidence of how he spoke about the procedures he’d undertaken in his career.” (Male, related donor, 
Australia, 20s).  
“I did ask about life expectancy…He was very careful to tell me the data isn’t really there…So the answer he gave me is basically you have gone through all these tests. If 
something is going to show up it would show up. I guess in my mind I was okay with that answer. (Male, non-directed donor, Canada, 60s).  
“I was paying attention to post-kidney op pregnancy studies…once you’ve passed the two year mark it makes zero difference.” (Female, unrelated donor, Canada, 30s)  
Underlying fears for health    
Processing 
alarming 
information  
“You can’t help but look behind the curtain and start poking around, like, will it hurt?... don’t start trolling the internet looking for these things because you are going to 
find bad stories and they are going to freak you out”. (Male, unrelated donor, Canada, 40s). 
“Well I guess it does give you twinges of qualm as you are told the risks. And it does make you catch your breath maybe.” (Female, spousal donor, Australia, 50s). 
“Your primary motive is that you want to help your person. But simultaneously you’re weighing your own risks.” (Female, unrelated donor, Canada, 30s). 
“They were going to take my mum’s …and my mum’s pretty old, and I said ‘No. Take mine’. That made it easier for me.” (Male, related donor, Australia, 30s). 
Pre-operative 
panic  
“I don’t think it hit me until five minutes before when I was lying on the stretcher going into the operating room.” (Male, related donor, Canada, 70s). 
“A week before the operation, for final check-up, I sat in the park. I suddenly realised ‘I got a family’, what happens if? I don't think I got the support or counselling.” 
(Male, related donor, Australia, 50s). 
Unsettling 
uncertainty  
 “They didn’t follow up with donors for like the last decade really. So, this is all pretty knew”. (Male, related donor, Canada, 50s).  
“He was very careful to tell me the data isn’t really there.” (Male, non-directed donor, Canada, 60s) 
“One of my biggest concerns afterwards was what would be the long-term repercussions because back at the time we did our transplant (10+ years ago), there was no 
ruling data on long term impacts.” (Male, 50s, Sydney). 
Mental preparation  
Resolving 
decisional 
ambivalence  
“I was a little bit anxious.  I didn’t really want to donate at the beginning because I’d met my partner later on, so we hadn’t been really together that long and I kind of felt 
a bit of guilt if my daughter actually got sick…but then after a while, I thought well, she’s healthy.  It’s really an unreasonable fear and yeah.” (Female, spousal donor, 
Australia, 40s) 
“Also going to get all the testing done by myself, I knew that was going to be one of the hard days for me and I did it and I broke down in tears, that was a real moment for 
me to say, ‘Hey can I do it?  Do I want to do it?’  That was kind of one of my hard days.” (Male, related donor, Australia, 40s).  
Avoiding regret  “I very selfishly was worried about how it would affect my marriage. Am I going to feel like he owes me a debt? Is it going to make things weird between us? What if he 
doesn’t treat it properly?…They got me a social worker to talk through this issue…they said, you really need to think of it as a gift. And you know that, but I think 
articulating it out loud made a difference.” (Female, spousal donor Canada, 40s).   
Managing 
expectations of 
recovery  
“They say about risks, maybe they do they generalise it. But they don’t tell you specifically what can happen. So, it doesn’t mean anything.” (Male, related donor, Canada, 
50s) 
“I would like those statistics but later on when you've already said I’ll do it and then you have your tests and you're into it.” (Male, related donor, Australia, 40s).   
“There’s a Facebook page for kidney donors. I would ask the questions there and it was more helpful than the actual hospital. Because it was life experience, so it was 
people that went through it so they knew exactly what it was like.  So, I found it very helpful.” (Female, spousal donor, Australia, 50s) 
System shortfalls 
Unnerving bodily 
scrutiny 
“He didn’t actually use the word ‘fat’, but ‘we won’t take because you’re too overweight’. He was totally unprofessional...My weight has been a sore point” (Female, 
Australia, 50s) 
“I wasn’t even a family member, and it wasn’t even someone I knew very well, they went through it [the risks] so many times…I almost started pulling out the worlds 
tiniest violin.” (Female, non-directed donors, 30s, Canada) 
Self-advocacy in “The amount of information we got was pretty much nil, we were prompting them every step of the way for dates, times, any scope of information we could get.  We were 
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driving the 
process  
pushing for it the whole time.  It was never given freely.  It was never given clearly.  It was just a mess...”  (Male, unrelated donor, Australia, 30s) 
“I got to speak to my surgeon, he said, ‘This whole process is like buying a car.  You have to do the research.  You have to look deeper because you can’t rely on people to 
spoon-feed you the information’…As soon as he said that, every bit of grey just went to black and white…that made everything heaps better for me. (Male, related donor, 
Australia, 20s) 
Stressful 
urgency 
“I do think they could’ve showed a little more zip to the process. I know it’s expensive to do all the screening but, when your loved one is not well and you just see them 
going downhill, and being with them through their dialysis is the most frightening thing I’ve ever seen.” (Male, related donor, Canada, 60s). 
Inconsistent 
framing of safety  
 “The psychiatrist. It’s like they were trying to convince you not to do it. It’s like, ‘You don’t have to do it if you don’t want to.  You could possibly die. This could possibly 
happen.’  And I’m like, ‘No. It’s all right.  My brother’s sick.  He needs it.’  But they kept strumming in your ear, “Are you sure?”. I don’t know if that’s part of the process. 
(Male, related donor, Australia, 30s) 
“I didn’t know if he was trying to scare me to make sure I was going to go ahead with the operation or going to chicken out”. (Male, spousal donor, Australia, 60s). 
Questioning risk 
information  
“Maybe even a resource sheet of valid references…Because a lot of the time I was told information but I didn’t have a way of checking it or validating it …” (Male, 
unrelated donor, Canada, 60s).  
“I think it’s a grey area. I mean, if you start listing complications, no one’s going to donate. I also think, you know, they don’t all tell you the truth. You know, coz they all 
say well people have it nothing happens everything’s okay. But I think that’s also not true.” (Male, spousal donor, Canada, 50s) 
Draining 
finances  
“It was a dent in the career a little bit…I think the financial assistance offered isn’t adequate. That’s just it wasn’t worth pursuing really.” (Male, unrelated donor, 
Australia, 30s) 
“I did research on life insurance. And how it would impact getting life insurance because of course I hadn’t had kidney yet. So, that was in the back of my mind, and that’s 
one of the things that I was researching, looking for studies on” (Female, unrelated donor, Canada, 30s).  
Lifestyle interference 
Living in limbo “My whole life was on hold. I had work and training to do, and I couldn’t do any of that until this was behind us. So, I thought it could have been a quicker. (Male, 
unrelated donor, Canada, 50s) 
“So it was, it was very difficult to stick with it. Because I had other things I wanted to do that I couldn’t get started on because of this whole process and not knowing 
anything about what the date would be…So it was really difficult. I eventually had to tell them “If you don’t tell me a date, like soon, despite all this time, I’m going to 
have to back out”. Because what I wanted to do, what else I want to do was important to me…(Female, non-directed donor, Canada, 60s) 
Onerous lifestyle 
disruption 
“It was more about organising everything around it…organising work, organising kids, organising people.  So, it wouldn’t have stopped us but it obviously took a lot of 
planning…They rang me and said, “Well, we can do it next week,” and, “No, I’m not ready for next week”. (Female, related donor, Australia, 40s) 
“I work casually and I got told one test, allow an hour. When I got there, “Sorry.  Didn’t you get told, it’s A, B, C.” And that happened quite a lot…So, that was one of the 
annoying things I could have changed that shift and not missed financial benefit.  (Female, unrelated donor, Australia, 50s) 
“If there was potential to group all the tests together in a consecutive day, it would be beneficial to a lot people, I think.” (Male, related donor, Australia, 20s) 
Valuing 
flexibility  
“I was fortunate I could use my sick leave and be away from work. But I think for anyone else who didn’t have that, that might be tough.” (Female, related donor, Canada, 
50s) 
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5.1 Abstract 
Background: Wide variations in access to living kidney donation are 
apparent across transplant centres. Such disparities may be in part 
explained by nephrologists’ beliefs and decisions about recipient eligibility. 
This study aims to describe nephrologists’ attitudes towards recipient 
eligibility and access to living kidney donor transplantation.  
Methods: Face-to-face semi-structured interviews were conducted from 
June to October 2013 with 41 nephrologists from Australia and New 
Zealand. Transcripts were analysed thematically.  
Results: We identified five major themes: championing optimal recipient 
outcomes (maximising recipient survival, increasing opportunity, 
accepting justified risks, needing control and certainty of outcomes, 
safeguarding psychological wellbeing); justifying donor sacrifice 
(confidence in reasonable utility, sparing the donor, ensuring reciprocal 
donor benefit); advocating for patients (being proactive and encouraging, 
addressing ambivalence, depending on supportive infrastructure, avoiding 
selective recommendations); maintaining professional boundaries 
(minimising conflict of interest, respecting shared decision-making, 
emphasising patient accountability, restricted decisional power, protecting 
unit interests) and entrenched inequities (exclusivity of living donors, 
inherently advantaging self-advocates, navigating language barriers, 
increasing centre transparency, inevitable geographical disadvantage, 
understanding cultural barriers).  
Conclusions: Nephrologists’ decisions about recipient suitability for living 
donor transplantation aimed to achieve optimal recipient outcomes, but 
were constrained by competing priorities to ensure reasonable utility 
derived from the donor kidney, and protect the integrity of the transplant 
program. Comprehensive guidelines that provide explicit 
recommendations for complex medical and psychosocial risk factors might 
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promote more equitable and transparent decision-making. Psychosocial 
support and culturally sensitive educational resources are needed to help 
nephrologists advocate for disadvantaged patients and address disparities 
in access to living kidney donor transplantation. 
5.2 Introduction 
Living donor transplant programs have been established in more than 80 
countries1 in response to the unresolved shortage of organs from deceased 
donors2. Kidney transplants from living donors now comprise between 28-
36% of all transplants in high-income countries including the United 
States, United Kingdom and Australia.3-5 However, there is concern about 
the significant disparities in access to the living donor pool, particularly 
for patients from ethnic minorities, or who are socio-economically 
disadvantaged, less educated and older.6-13  
Nephrologists play a central role in providing access to kidney 
transplantation, through education, referral to a transplant program, 
completing transplant evaluations, and participating in recipient 
acceptance meetings.14-16 Clinical care and decision-making may be more 
complex in disadvantaged populations who are more likely to present with 
medical and psychosocial risk factors.16-21 Previous research suggests that 
clinician’s interactions with disadvantaged patients may reflect their 
inherent biases regarding patient preferences, their likelihood of finding a 
donor, completing evaluations or adhering to treatment, and the expected 
survival benefit of transplantation compared to dialysis.19,20 Clinicians 
also report difficulties in communicating and establishing trust with 
ethnic minorities, and completing their referral and evaluation 
processes19,22.   
Nephrologists are also uniquely placed to provide insight into the factors 
preventing patients from receiving a living donor transplant that are not 
referred or assessed. The beliefs, attitudes and priorities underpinning 
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nephrologist’s decisions about recipient eligibility for living donor 
transplantation have not been explored in-depth. Further, nephrologists’ 
perspectives regarding the challenges in navigating the complex pathway 
to living kidney donor transplantation are unknown, particularly 
regarding their interactions with disadvantaged patients. Our study aims 
to describe nephrologists’ perspectives on recipient eligibility and access to 
living kidney donor transplantation to inform strategies to mitigate 
disparities and improve equity.  
5.3 Methods 
We followed the Consolidated Criteria for Reporting Qualitative Research 
(COREQ) framework.23  
Participant selection and practice setting  
Nephrologists involved in referral and assessment for living donor 
transplantation in Australia and New Zealand were purposively selected 
to capture a range of years of clinical experience, age, gender and practice 
locations. Nephrologists were chosen because of their ongoing involvement 
across the continuum of recipient care, from education and referral 
through to evaluation and assessment for transplantation. The practice of 
living kidney donor transplantation in Australia and New Zealand is 
similar, as demonstrated by the joint data registries and professional 
societies. In both countries, general and transplant nephrologists assess 
potential recipients for kidney transplantation. While quantitative 
research aims to achieve statistical generalisability with a random and 
representative sample, qualitative research seeks to explore a range of 
diverse viewpoints within a small and diverse sample until reaching the 
saturation of concepts.24-28 Invitations were sent via email and the 
interviews were conducted in clinic offices, meeting rooms or at conference 
venues. A snowballing technique was also employed, whereby participants 
could nominate other nephrologists who they believed might offer a 
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unique or important perspective on this topic. The University of Sydney 
provided ethics approval for the study.  
Data collection  
The interview guide was based on a systematic literature review of 
disparities in kidney transplantation17, and discussion among the research 
team (Appendix C.1). The interview questions focused explicitly on 
recipient eligibility and assessment, and data pertaining to donor 
eligibility and assessment were excluded from analyses.  CSH conducted a 
face-to-face semi-structured interview with each participant from June to 
October 2013. Participant recruitment ceased when theoretical saturation 
(i.e. when little or no new information was being obtained from 
subsequent interviews) was reached. All interviews were digitally audio-
recorded and transcribed verbatim.  
Analysis 
The transcripts were entered into HyperRESEARCH software 
(ResearchWare Inc, United States, Version 3.5.2,), software for qualitative 
data management and coding. Based on adapted grounded theory 
methodology26 and thematic analysis29, CSH coded the transcripts line-by-
line, and translated common and divergent concepts into existing or new 
codes, respectively, as they emerged in the data. Similar concepts were 
then grouped into themes and subthemes. We identified relationships and 
patterns between themes to develop a thematic schema (Figure 5.1). To 
enhance the comprehensiveness and validity of the thematic framework, 
the preliminary findings were discussed among the research team 
(investigator triangulation) and emailed to all participants who were 
asked to provide feedback and any additional opinions (member checking).  
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5.4 Results 
Study participants  
Of the 46 invited nephrologists, 41 (89%) participated in the study from 22 
centres in Australia and New Zealand (11 centres had a transplant 
program). Twenty-three (56%) participants were transplant nephrologists 
and 18 (44%) were general nephrologists. Non-participation was due to 
travel, clinical commitments or non-response. Participant characteristics 
are provided in Table 5.1. On average, each interview lasted 30 minutes 
and was conducted in a hospital office or meeting room, or at a conference 
venue. Participants were from New South Wales (n = 17), Queensland (n = 
4), South Australia (n = 5), Tasmania (n = 1), Victoria (n = 11), Western 
Australia (n = 1), and New Zealand (n = 2).  
Themes  
Five major themes reflecting nephrologists’ perspectives on patient 
eligibility and access to living donor transplantation were identified: 
championing for optimal recipient outcomes, responsibility for patient 
advocacy, justifying donor sacrifice, maintaining professional boundaries, 
and entrenched inequities. Illustrative quotations are provided in Table 
5.2. 
The relationships between themes are depicted in Figure 5.1. Decisions 
about recipient eligibility for living kidney donor transplantation involved 
complex negotiations between achieving optimal recipient outcomes and 
ensuring that the sacrifice to the donor was justified and worthwhile.  A 
willingness to accept justifiable risks was validated by acknowledging 
reciprocal benefits to the donor, but nephrologists were often restricted by 
conservative centre policies or were cautious to protect their professional 
reputation and ensure patients were informed and accepting of possible 
consequences. Nephrologists’ felt powerless to address inequities faced by 
their patients of ethnic minority and low socio-economic backgrounds due 
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to entrenched barriers including poor self-advocacy, the limited 
availability of suitable donors, and uncertainties in facilitating shared 
decision-making.  Arguments for making eligibility decisions and centre 
performance outcomes explicit to patients were met with concerns about 
reinforcing the gatekeeping of high-risk patients by transplant centres.  
Championing for optimal recipient outcomes 
Maximising recipient survival: Living kidney donor transplantation, 
particularly pre-emptive transplantation, was considered the “first line” 
treatment for eligible patients as it offered the best survival and graft 
outcomes and could reduce or avoid time on dialysis. Organs from 
deceased donors were perceived to be of poorer quality due to a longer cold 
ischemic time and an aging donor population.  
Increasing opportunity: Kidney transplantation from a living donor was 
regarded as the “only way to make up for the short-fall of deceased 
donation”, and reduce the burden on the waiting list. Living donation was 
viewed as “the only feasible way of getting a transplant” for complex 
patients, because of the possibility of ABO incompatible transplantation, 
desensitisation therapy or paired exchange.  
 Accepting justified risks: A “relaxed” attitude towards recipients who were 
ineligible for wait listing, due to their age or comorbidities, was justified 
by the safer and more “controlled conditions” compared to deceased donor 
transplantation. Living donation could ensure optimal timing of the 
operation, adequate planning for immunosuppression and more 
predictable graft outcomes. A few participants encouraged leniency for 
young people with previous history of malignancy because of the burden of 
dialysis. Some were willing to accept high-risk recipients with a living 
donor because the “simple contract between the donor and recipient” 
would not unfairly “waste” a community resource.  
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Needing control and certainty of outcomes: Caution to minimise the risk of 
graft failure, patient sensitisation, and perioperative complications led to 
reluctance to pursue high-risk transplants due to fears of “do[ing] more 
harm than good” to the patient.  Some argued that complex procedures 
like ABO incompatible transplantation should only be performed in 
centres with sufficient surgical expertise.   
Safeguarding psychological wellbeing: Some participants believed it was 
necessary to exclude recipients who might not cope with the potential 
psychological challenges after transplantation, including guilt about graft 
failure and donor complications, or donor-recipient relationship problems. 
Others did not consider psychological factors to be contraindications to 
receiving a living donor transplant because the “medical benefit 
supersedes any psychological issues”. 
Justifying donor sacrifice 
Confidence in reasonable utility: There was uncertainty about taking 
chances on recipients who were at risk of graft complications or had a less 
than five-year life expectancy because they needed assurance that the 
donor’s sacrifice was justified by reasonable utility of the kidney. Younger 
patients were thought to gain the most from living donation, whereas 
some questioned the value of the gift to an older recipient. Some preferred 
to waitlist non-adherent patients who had a potential donor, and were 
wary of non-adherence for adolescents, or patients with depression or 
limited social support. However, some nephrologists believed that using 
estimates for patient or graft survival, especially non-adherence and donor 
specific antibodies were “unethical” because of the unreliability of these 
criteria.  
Sparing the donor: To potentially avoid risk to the living donor, some kept 
their patients with “short-wait blood groups” on the waiting list whilst 
simultaneously evaluating their donor. However, others argued that it 
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was unethical to “deprive” someone on the waiting list without a living 
donor available, especially if they were reserving their living donor for a 
subsequent transplant.  
Ensuring reciprocal donor benefit: Some participants believed in 
respecting the autonomy of the donor-recipient dyad, particularly for older 
pairs. For example, they would accept a recipient-donor dyad aged over 
seventy, even when the expected patient survival was less than five years 
as this was justified by a collective improvement in quality of life.  
Advocating for patients   
Being proactive and encouraging: A primary responsibility of 
nephrologists was to proactively educate and facilitate assessment 
(particularly for pre-emptive transplantation). Some stressed the need to 
“sell” living donor transplantation as the ideal treatment, to build patient 
trust and confidence in the transplant team, and to encourage patients to 
“hunt around” for potential donors.  
Addressing ambivalence: Participants acknowledged that the recipient’s 
decision about accepting a living donation involved ethical and 
psychological considerations including guilt, difficulty asking someone to 
donate, family disagreement, concerns for donor safety, financial and 
occupational pressures, and relationship problems due to indebtedness. 
Strategies to address these barriers included identifying an “ally” in the 
patient’s social network to help them find a donor, encouraging patients to 
consider the benefits of living donation from their donor’s perspective or 
involving a multidisciplinary team to provide psychosocial support.  
Depending on supportive infrastructure: Some participants observed that 
patients treated in smaller or private units had “someone in there batting 
for them” because of a stronger doctor-patient rapport, whereas patients 
in larger units often became “lost in the system” due to being seen by 
different consultants. Inefficiency in coordinating assessments was 
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attributed to overloaded clinics, a lack of “streamlining” of evaluations, 
and poor communication between independent donor and recipient 
physicians. General nephrologists faced difficulty coordinating pre-
emptive transplantation, and often delayed discussion about living 
donation because of competing clinical priorities, and limited access to 
resources including transplant education and coordinators. Transplant 
nephrologists felt responsible for improving referrals from non-transplant 
services by educating general nephrologists, to ensure their patients had 
equal opportunity.  
Avoiding selective recommendations: Although it was important to 
participants to convey a consistent message and offer the same 
opportunity to all patients, this conflicted with their reluctance to 
encourage unrealistic expectations in patients who had significant 
comorbidities or were unlikely to have a suitable donor.  
Maintaining professional boundaries  
Minimising conflict of interest: Some transplant nephrologists believed 
they were more “passive” in promoting living donation to potential 
recipients because of their dual responsibility to protect the donor from 
coercion and ensure their long-term safety. The policy for independent 
donor assessment was considered crucial to avoid unwarranted pressure 
on donors. However, they found it difficult to manage competing interests 
in preliminary consultations where family members of the potential 
transplant candidate were present during discussions about living 
donation. Some were willing to provide initial information to potential 
donors, or “allude to the fact that they might be a donor”. Nephrologists 
felt powerless when their patients were unwilling to openly discuss living 
donation with their family, particularly when faced with a young person 
who had a seemingly large potential donor pool.  
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Respecting shared decision-making: Participants highlighted the 
importance of providing balanced information and addressing patients’ 
misconceptions to ensure an understanding of the risks of graft failure, 
donor complications, and possible psychosocial challenges. They respected 
their patient’s moral decision to refuse a living donor, arguing that “we 
shouldn’t try too hard to change their mind” because their concerns were 
often valid and justified. For high-risk patients, transplant nephrologists 
needed to be convinced the patient was accepting of possible risks, to 
protect their professional integrity.  
Emphasising patient accountability: It was difficult for participants to 
encourage patients who they felt were unable to accept their diagnosis of 
ESKD and the need for transplantation to attend education programs, 
undergo assessment, and discuss living donation with family members. 
They believed that patients held some responsibility to ensure they were 
eligible for transplantation, for example, by quitting smoking or making 
lifestyle modifications for weight management. 
Restricted decisional power: Some general nephrologists felt powerless 
because patients they considered suitable could be deemed ineligible by 
the transplant assessment team – “they make their decisions and we need 
to live with them”. Transplant nephrologists believed that democratic 
decision-making or conservative unit policies sometimes prevented them 
from accepting suitable recipients.  
Protecting unit interests: There was a perceived obligation to protect the 
credibility and reputation of their transplant unit by refusing a high-risk 
patient because poor graft or patient survival outcomes “do not look good 
on the hospital statistics”. General nephrologists thought this led to the 
“hyper vigilant” scrutiny and “unnecessary duplication” of the clinical 
assessments they had performed by transplant nephrologists. Some 
general nephrologists were frustrated by an apparent lack of trust in their 
competence. Simultaneously, a competitive drive among transplant units 
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to justify their existence applied pressure on nephrologists to increase 
their rates of transplantation.  Some voiced disappointment that this led 
to the unwillingness of transplant centres to relinquish the care of their 
patients to another unit with unique expertise, such as ABO incompatible 
transplantation.  Some suspected that private physicians might not 
promote pre-emptive transplantation because “every time they lose a 
dialysis patient…they lose income”.  
Entrenched inequities 
Exclusivity of living donors: Socio-economically disadvantaged and ethnic 
minority patients were deemed less likely to have a suitable donor because 
of a higher incidence of obesity, cardiovascular disease, diabetes, high 
blood pressure, end-stage kidney disease (ESKD) and smoking. Some 
believed that these patients were often “pre-judged” regarding their 
likelihood of finding a donor, and that socio-economically disadvantaged 
patients were likely to have a limited social network and thus a small 
potential donor pool or their potential donors could not afford to take time 
off work to donate.    
Inherently advantaging self-advocates: Patients of higher socio-economic 
status were expected to be more likely to receive a living donor transplant 
because they were described as being typically “a good advocate for 
themselves” in terms of their motivation to find a living donor, seek 
information, and achieve weight loss or smoking cessation. Some believed 
that patients from ethnic minority and low socio-economic backgrounds 
were likely to smoke and present with comorbidities, predominantly 
obesity. Patients with lower education or health literacy were thought to 
be “hard to engage” due to often lacking an understanding of their 
diagnosis of ESKD and the benefits of living donor transplantation.  
Navigating language barriers: There were distinct challenges in providing 
access for patients who did not speak English, or those with low health 
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literacy, because of the difficulty in helping them to “understand what is 
quite a complex process”, and relay complicated information onto their 
families. Nephrologists expressed frustration with using interpreters, 
believing that the accuracy and emotional elements of their “delicate” 
dialogue needed to “convince” someone of the safety of living donation 
were not conveyed. Participants observed that some non-English speaking 
patients were not referred for transplantation or failed to complete 
assessments because “it’s more troublesome, more time consuming” due to 
difficulty communicating instructions.  
Understanding cultural barriers: Some participants felt helpless to 
address ethnic disparities because they had a limited understanding of 
cultural barriers. They found it challenging to address patients concerns 
about the spiritual influence of the donor’s kidney, and cultural norms 
pertaining to receiving gifts, asking favours, and family hierarchies.  
Increasing centre transparency: Participants believed that a patient could 
be disadvantaged if they were referred to a transplant unit that had a 
conservative live donor transplant policy or a lower volume program 
because of presumed lesser expertise. While variability across centres was 
deemed acceptable by some, they insisted that centres publicise their 
policies to prevent gatekeeping, so that high-risk patients could be advised 
to seek an opinion from other units. Some also advocated for making 
variations in centre performance known to patients by publicly reporting 
transplantation rates and outcomes, but expressed concerns that this 
might lead to risk aversion by transplant programs.   
Inevitable geographic disadvantage: Delays in coordinating tissue typing 
and transplant evaluations, isolation from family and the financial costs 
associated with travel, accommodation and lost productivity, and a 
reluctance to travel were identified barriers to living donor 
transplantation for patients living outside of metropolitan areas. Rural 
nephrologists were frustrated as they felt these barriers could be reduced 
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by using local tissue typing services, utilizing teleconferencing and 
streamlining and prioritizing assessments to minimize travel. Some 
transplant nephrologists also felt unable to provide the same opportunity 
to rural patients compared to local patients, and wished to increase 
outreach clinics and transplant education programs in rural areas.  
5.5 Discussion 
Central to decisions about recipient eligibility for living kidney donor 
transplantation was maximizing recipient survival and quality of life. 
Simultaneously, nephrologists want to ensure that the donor’s sacrifice is 
worthwhile, and protect their centre’s performance, as measured by 
recipient and graft survival. They struggle to resolve these competing 
responsibilities, particularly when faced with patients who have medical, 
psychosocial and/or behavioural risk factors, and might be ineligible for 
wait listing for deceased donor transplantation. Substantial variability in 
the recommendations of nephrologists may intensify inequity for 
vulnerable patients. Nephrologists also encounter difficulties addressing 
patient ambivalence, supporting patients with donor recruitment, 
achieving shared decision-making and navigating referrals and 
assessments, particularly for patients with limited language proficiency or 
health literacy barriers. However, they primarily attributed ethnic and 
socio-economic disparities to the limited availability of suitable donors, 
and regarded this inequity to be beyond their control.  
Our findings describe the professional attitudes and unit policies that may 
explain the disparities of access to living kidney donor transplantation 
and variability among transplant centres.12,13,30 Nephrologists were 
apparently polarized regarding whether to allow living donor 
transplantation for patients who were older, highly sensitized, non-
adherent, and those with low social support, mental health issues, 
comorbidities, and recurrent disease. Academically affiliated nephrologists 
questioned the fairness of determining access based on estimates of graft 
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survival including donor specific antibodies and non-adherence due to 
their poor predictive value. Mostly older and experienced nephrologists 
encouraged individualized judgments that valued quality of life over graft 
survival, particularly for young patients, and older donor-recipient pairs.  
Inconsistent and inexplicit recommendations may intensify inequity for 
disadvantaged patients. Our findings support suggestions that 
nephrologists’ decisions regarding disadvantaged patients may sometimes 
reflect their inherent biases or assumptions regarding a candidate’s 
expected survival and chances of finding a donor, for example, due to 
expectations of low motivation and poor self-advocacy.19 The hypothesis 
that ethnic and socio-economic disparities are largely caused by a limited 
donor pool due to the higher burden of disease is prevalent in the 
literature, but this evidence is based on single-centre studies.10,11,31,32 Our 
findings also indicate that there may be some reluctance to unnecessarily 
raise patient’s expectations, and uncertainties about communicating risk 
due to language and health literacy barriers. Moreover, nephrologists 
distanced themselves from assisting candidates with donor recruitment to 
avoid a conflict of interest, and this is an important barrier for ethnic 
minorities, uneducated, older and female populations.32-37  
This is the first study to describe in-depth nephrologists’ attitudes toward 
recipient eligibility for living donor transplantation and highlights the 
challenges they encountered in advocating for potential candidates. 
However, there are some limitations. The transferability of some of the 
concepts in our study to other settings is uncertain, particularly to low-
income countries. Our findings are potentially limited by the 
underrepresentation of female participants, although previous research 
suggests that nephrologists’ views regarding transplant eligible are not 
associated with gender, but rather with age, experience in 
transplantation, academic affiliation, and location of practice17;  which are 
broadly captured among participants in our study.  
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Our study has important implications to address disparities in access to 
living kidney donor transplantation, primarily by making more explicit 
and informed decisions concerning recipient eligibility (Table 5.3). 
Implementation of an explicit pathway for patient education and referral 
to transplant services could promote consistent and equitable 
recommendations to patients. Clinical guidelines for transplant eligibility 
fail to address the real uncertainties faced by nephrologists in determining 
risks for older, sensitized, ethnic minority and socio-economically 
disadvantaged patients and emphasis on estimates of graft and patient 
survival inevitably introduce subjectivity.38 Evidence-based 
recommendations to address psychosocial risk factors are needed, 
including non-adherence, depression, and low social support.18,39,40 
Training to improve interactions with interpreters might alleviate 
nephrologists’ uncertainties during shared decision-making with non-
English speaking patients.41,42 There are also concerns that publicized 
centre reports evaluating centre performance based on recipient outcomes 
may encourage risk avoidance strategies among transplant centres, and 
these trends have been observed in the United States.40,41 We support 
recommendations that both patient outcomes and transplant volume 
should be regarded as equally important in quality evaluations, to ensure 
that efforts to maximize outcomes are not maintained at the expense of 
expanding access to transplantation.38  
The assignment of multidisciplinary staff to provide interventions 
targeted to disadvantaged populations may improve patient advocacy. 
Promising interventions include a social worker consultation to identify 
and address individual patient barriers43, peer supporters’ to navigate 
referral and assessment processes44, and culturally-sensitive home 
education45. Strategies to support patients in engaging in discussions with 
potential donors are available43, which should be directed by 
multidisciplinary staff to help minimize nephrologists’ conflict of interest. 
Moreover, the responsibilities and boundaries of nephrologists 
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representing the recipient, in supporting and facilitating donor education 
and recruitment require clarification, and should be restricted to the role 
of the donor advocate.46 Educating patients with a limited donor pool 
about options such as ABO incompatible transplantation, paired exchange 
and unrelated donation might increase their chances of finding a donor.8 
Patients should also be informed about the considerable variability among 
kidney transplant centres in terms of patient outcomes, unit policy, 
expertise and resources such as ABO incompatible transplantation. In 
many countries, hospital performance reports are accessible to patients 
via websites such as Hospital Compare 
(http://www.medicare.gov/hospitalcompare/search.html). Importantly, 
efforts are needed to ensure that patients have the capacity to understand 
centre reports and to travel to an alternative unit47-49, which are likely to 
be challenging for disadvantaged patients and could potentially reinforce 
disparities. 
Nephrologists can offer important insights to address disparities in 
transplantation; therefore it would be beneficial to conduct similar 
research in 1) low-income countries, 2) countries like Japan where living 
donation accounts for the majority of all kidney transplants, and 3) 
jurisdictions where commercial transplantation prevails. Further research 
is needed to develop a broad understanding of cultural barriers, to inform 
educational interventions of potential candidates from diverse 
backgrounds. Our findings can also inform the development of a survey to 
investigate the frequency of opinion among nephrologists and enable 
comparison with other transplant professionals and nephrologists working 
in various settings. Our study did facilitate comparison among 
nephrologists working in rural and urban settings, transplant and general 
nephrologist and years of clinical practice.  The perspectives of 
nephrologists in other countries as well as transplant clinicians involved 
in the multi-disciplinary care of transplant recipients, including surgeons 
and transplant coordinators, should be studied, because their attitudes 
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might differ due to their unique professional responsibilities and settings 
in which they work. 
Decision-making about patient eligibility for living kidney donor 
transplantation involves unique ethical, psychosocial and medical 
uncertainties. Nephrologists weigh opportunities to provide complex 
patients their only chance of avoiding dialysis against their moral and 
professional responsibility to ensure reasonable utility of the kidney 
transplant to justify the donors sacrifice. A preference for certainty of 
graft outcomes and difficulties facilitating shared decision-making may 
contribute to disparities for disadvantaged populations.  Increased 
consensus and standardized practice regarding complex medical and 
psychosocial cases, transparency of centre performance and practice, and 
resources to provide culturally competent care might assist with reducing 
disparities in access to living kidney donor transplantation. 
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Figure 5.1. Thematic schema   
Decisions about recipient eligibility for living kidney donor transplantation involved 
complex negotiations between achieving optimal recipient outcomes and ensuring that 
the sacrifice to the donor was justified and worthwhile.  A willingness to accept 
justifiable risks was validated by acknowledging reciprocal benefits to the donor, but 
nephrologists were often restricted by conservative centre policies or were cautious to 
protect their professional reputation and ensure patients were informed and accepting 
of possible consequences. Nephrologists’ felt powerless to address inequities faced by 
their patients of ethnic minority and low socio-economic backgrounds due to 
entrenched barriers including poor self-advocacy, the limited availability of suitable 
donors, and uncertainties in facilitating shared decision-making.  Arguments for 
making eligibility decisions and centre performance outcomes explicit to patients were 
met with concerns about reinforcing the gatekeeping of high-risk patients by 
transplant centres.  
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Table 5.1: Participant characteristics  
Characteristic (n = 41) n (%) 
Specialty   
    Transplant nephrologist* 26 (56) 
    General nephrologist 15 (44) 
Gender  
Male 33 (80) 
Female 8 (20) 
Age (years)  
30-39 6 (15) 
40-49 15 (37) 
50-59 13 (32) 
60+ 7 (17) 
Clinical experience (years)  
≤ 10  9 (22) 
     11-20 12 (29) 
21-30 13 (32) 
> 30 7 (17) 
Location of practice   
Australia  
     New South Wales 17 (42) 
     Queensland 4 (10) 
     South Australia 5 (12) 
     Tasmania 1 (2) 
     Victoria  11 (27) 
     Western Australia 1 (2) 
New Zealand   
     Christchurch  1 (2) 
     Auckland  1 (2) 
Location of interview   
    Conference venue 10 (24) 
    Hospital office/ meeting room  31 (76) 
*Transplant nephrologists were defined as nephrologists directly involved in the transplant 
assessment team and the immediate post-operative care of transplant recipients  
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Table 5.2. Illustrative quotations  
Theme Illustrative quotations  
Championing for optimal recipient outcomes  
Maximizing 
recipient survival 
From the selfish view of the recipient, it does give them a related transplant or less damaged transplant without a waiting time. (Male, general nephrologist, 50s)  
Every patient should be getting a living, related transplant, or organize one if they can. That would be very much our first line. It just doesn't happen very often. 
(Male, general nephrologist, 50s) 
Increasing 
opportunity 
We all need living donors to try and get our patients off dialysis and give them a half decent life, especially if they're young. (Male, general nephrologist, 50s) 
In our current environment when we have such a low deceased donation rate for a lot of people it's the only feasible way of getting a transplant and the best way. 
(Male, transplant nephrologist, 30s).  
Needing control and 
certainty 
We have people on our live donor recipient list who are transplanted who are older and sicker than the worst patients on the deceased donor list.  And the argument 
we’re putting in terms of the recipient is that the medical milieu in which you’re doing a live donor transplant is somewhat safer than in which you’re doing a 
deceased donor.  You’re doing it electively in perfect daylight prepared, so you can take an older and sicker patient on and believe that they’ll survive. (Male, 
transplant nephrologist, 60s).  
We need to be mindful that we're good at living donation, but with the new ways we have to overcome immunological barriers, we may actually be doing quite high-
risk transplants using living donors…You just wonder what the long-term outcomes of these really heightened risk transplants may be. (Female, transplant 
nephrologist, 40s) 
Accepting justified 
risks  
Some people are very regimented by guidelines, and not necessarily personal patient issues. Sometimes, the longer you've been practicing, the more likely you are to 
consider you can probably get across a problem as opposed to being more junior; you're less likely to take a risk. (Female, transplant nephrologist, 50s).  
I think most practitioners are more relaxed about recipient eligibility for living donor transplantation because it is a simple contract between the donor and 
recipient.  The deceased donor list is the property of the community at large, and decisions made utilizing an organ from the deceased donor pool must benefit the 
community in a way that is completely equitable and transparent.  With living donation, if the transplant doesn't work out, this disadvantages no one else. . (Male, 
general nephrologist, 40s) 
My only negative feeling about it is that everyone’s got their own threshold... Physicians tend to be fairly confident and have very strong opinions that they hold 
quite vehemently. Sometimes we transmit our own ethical beliefs into the clinical situation quite strongly. (Female, general nephrologist, 50s) 
Safeguarding 
psychological 
wellbeing 
There can be some kind of psychological impact on relationships but, generally speaking, I probably, look at things more from a medical point of view.  What's the 
alternative? I think the medical benefit supersedes any psychological issues, quite frankly.  I wouldn't see that as a contraindication. (Male, transplant nephrologist, 
30s).  
I think we often think about matching in terms of blood group, but I think in terms of the relationships and how that's going to impact. (Male, general nephrologist, 
40s). 
Justifying donor sacrifice  
Confidence in If you think someone's going to be non-compliant but you're not really sure… with a deceased donor you might be a bit more likely to just give it a go.  Whereas if 
it's a live donor, you think about the consequences for their relationship if they don't take the pills and they lose their kidneys. (Male, transplant nephrologist, 30s).   
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reasonable utility 
Sparing the donor   If you're waitlisted, you can keep both options open and perhaps in the next six months, if you do get a deceased donor, hoping that it's a good one, then obviously 
that will spare your friend or family member who was going to donate your kidney.  (Male, transplant nephrologist, 30s)  
Ensuring reciprocal 
donor benefit  
What happens if the recipient's only going to live three years?  Well that wouldn't be a good use of a community resource, a cadaveric kidney.  But if the donor 
knows exactly what's going to happen and that person has three good years - that's a good result. (Male, transplant nephrologist, 50s).  
Advocating for patients 
Being proactive and 
encouraging  
You have to be proactive. It's actually about saying your GFR is 20, you are progressing towards renal failure.  You need to find yourself a donor. It's the way that 
you phrase the conversation and the way that you drive things. Otherwise, a different clinician would just sit there saying you are GFR is 20, how are you feeling?   
I think it's personality and its bedside manner but I think it's also about attitude to transplant. (Male, transplant nephrologist, 30s).  
Addressing 
ambivalence 
Perhaps we need to ask a little bit more about when someone says, ‘no, I don't have a donor’, enquire as to…’ is there no-one or do you find it difficult asking?’ So 
maybe digging a little bit deeper.  That might help us help our patients. (Female, transplant nephrologist, 40s).  
I try to motivate it away from just selfish concerns or selfish, in inverted commas; and more trying to say this is the family helping you at very little cost to 
themselves and you being healthy can be a better contributor and less of a burden to your family.  I think we’ve got to sell the family side of things. (Male, general 
nephrologist, 40s). 
Depending on 
supportive 
infrastructure  
There are increasing numbers of units that only dialyze and no matter what you do that places a physical and intellectual barrier. From a mental point of view they 
are dialyzers.  Every thought is about how to dialyze this person better. I know of a doctor who feels people shouldn’t be transplanted till they have been on dialysis 
for a period because when they get their transplant they’ll be more compliant. (Male, transplant nephrologist, 60s).   
It’s the responsibility of the transplanting hub to make sure that these people are getting the same opportunity as their own patients. So we have to get these 
messages out we need to educate the non-transplanting nephrologists about what's important.  (Male, transplant nephrologist, 60s). 
Avoiding selective 
recommendations  
We tend to be a bit paternalistic, take away the decision-making processes a little bit from the patients. It's partly because we give them selective information along 
the way, and biased information. (Male, transplant nephrologist, 60s). 
Maintaining professional boundaries  
Minimizing conflict 
of interest 
I think you have to be careful to not be giving the potential recipient a whole sort of structure to go out there to solicit a kidney. (Female, transplant nephrologist, 
40s).   
We feel that that these are not our patients.  We have no right to be in medical contact with them.  They have their own private lives and we, without being invited, 
would be invading their private life and we won’t do that and doctors don’t go out knocking on doors looking for work.  It’s not what we do. (Male, transplant 
nephrologist, 60s). 
My policy has always been that we should get the potential donor to raise the question…I make sure it is one of my colleagues who hasn’t seen the potential 
recipient yet in the clinic” (Male, nephrologist, 30s). 
Facilitating shared 
decision-making 
But I think the important thing is that the risk is communicated, so you're all taking the risk, not just the doctor taking the risk on behalf of the patient, because 
that is a dangerous position to put yourself in. (Female, transplant nephrologist, 50s).   
I guess as I grow older I do realize that people have their own patient-centred outcomes and sometimes, although they might appear completely bizarre, if they're 
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really competent to make that decision we shouldn't try too hard to change their mind. (Male, general nephrologist, 40s).  
Emphasizing patient 
accountability  
The area where it may fall down is that the recipient really has to be approaching potential living donors within their family group, don't they?  If the recipient isn't 
keen to do that, the nephrologist has no role in being able to facilitate that. So if you don't have the recipient completely on board, then probably those conversations 
may not happen. (Female, transplant nephrologist, 40s).  
Restricted decisional 
power  
The transplant team have a meeting, we’re not invited. They make their decisions and we need to live with them. If we disagree, we either live with it or take our 
business elsewhere. It usually spurs them on to think harder. A lot of the problems we have revolve around moderately obese patients. (Male, general nephrologist, 
50s).  
Rather than have the member of the team who's quite uncomfortable about, we'd err on the side of not doing it rather than doing it. (Male, general nephrologist, 
50s).    
Protecting unit 
interests  
We've had several episodes of threatened closure that influenced attitudes here.  Nothing like hearing on the radio from the Minister of Health that he's been 
advised that your program should be shut down. (Male, general nephrologist, 60s).  
Many centres are not good at what they do, but they keep doing it, because they do it for the centre and not the patient. (Male, transplant nephrologist, 50s).  
There is a strong motivation for transplanting hospitals to protect their credibility and maintain their performance, and to some extent this leads to gatekeeping to 
avoid high-risk patients. The clinical assessments and clinical testing done at other hospitals is scrutinized, as it should be, but this can be, and is often, overdone so 
that there is unnecessary duplication… and can lead to a somewhat adversarial atmosphere for both the patient and referring doctor. (Male, general nephrologist, 
40s) 
Entrenched inequities  
Exclusivity of living 
donors   
The barriers are probably different, just in different communities and different ethnicities. A big Tongan or Samoan family will have lots of potential donors. They 
all get on together and they'll all be willing, but they'll all be pre-diabetic and overweight. (Male, general nephrologist, 50s).  
More valued people in the community are more likely to get offers and that probably equates to higher socio-economic groups. (Male, transplant nephrologist, 60s).  
Advantaging self-
advocating patients 
If they're a professional type person, a good advocate for themselves, then they'll go out and get a donor.  Whereas if they haven't gone to university or haven't 
finished high school then they don't have a social network around them, then actually finding a donor is quite difficult. (Male, transplant nephrologist, 30s)   
There’s a constellation of things that go with poverty. It can be a low IQ, a low education, low motivation, or a combination… Poor people smoke more. They don't 
exercise very much. They get more diabetes. There's a whole stack of things that go with poverty, but they're not all causal. They're all circular. Even when you do 
that multivariate analysis there's this big gap which doesn't explain why they do worse. So the gap is just the intrinsic drive, like conscientiousness. It’s very, very 
hard to actually put a number on and factor in. But you can sense it. (Male, general nephrologist, 50s).  
Navigating language 
barriers  
I think language barriers do play a role as well.  It's a lot easier to convince someone of the benefits of live donor transplants if you can have a full frame 
conversation with them. It's just not the same.  If you're communicating with someone you do it not just at a verbal level. It can be very delicate.  It's very hard to 
have a delicate conversation through an interpreter. (Male, transplant nephrologist, 30s).  
They’re less likely to be referred on, probably because it's more troublesome, more time consuming. Doctor speaks, they don't understand. Or he gives them a piece 
of paper, it says, go and make an appointment, and they don't know where or how to go to make it happen. (Male, general nephrologist, 60s).  
Increasing center 
transparency  
I think the shame is the disparity between units. Both integrated and disintegrated renal services and different doctors have really quite different rates of 
promotion of live donor transplant and if they would voice them, publicize them, I’d be happy. You need to know to move on. Because I think everybody and every 
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institution has the right to do things according to their moral judgment as long as they make it public, that they’re not giving advice based on their own thing. I’m 
very for the concept that units’ habits and outcomes be publicly available. (Male, transplant nephrologist, 60s). 
Different sites might have different policies, for example, about who they'll accept. What tends to happen is once a person gets referred to a particular unit, they’ll 
tend to stay at that unit rather than looking around for different opinions. (Male, transplant nephrologist, 50s). 
So if they happened to be referred to a unit that has a very conservative live donor policy then they might be disadvantaged.  (Male, general nephrologist, 50s)  
Geographical 
disadvantage  
We don't think we do as good a job with [the rural centres], and it's about communication with the teams down there. It's something that we're trying to work on 
now, because we don't think we're providing the same opportunity, and we don't think they're getting as good information. (Male, transplant nephrologist, 60s).   
There's no coordination as a one-stop shop, which there really should be if you're asking people to travel four, five, six hours down to the city to see them, which they 
do, and then make them come back repeatedly for different tests. I think they don't understand the challenges. They don't have a clue actually. To them, the 
patients turn up, everything's done, what's the problem? (Male, general nephrologist, 50s).  
Understanding 
cultural barriers  
We know there are barriers, but we're not the right people to ask, to get that information. They don't tell us. We don’t ask properly. We don’t know how to ask them. 
(Female, transplant nephrologist, 50s). 
To be fair we probably ought to be targeting some of the groups who we’ve cast a fairly jaundiced eye on. (Male, general nephrologist, 30s). 
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Table 5.3. Implications for practice and policy to address barriers and inequity  
Key issues  Suggested research and policy priorities  
Unit variability and 
transparency  
     
 Identify policies and practices associated with higher rates of living kidney donor transplantation  
 Develop national key performance indicators to benchmark and monitor rates of living kidney donor transplantation (including 
pre-emptive transplantation), the rates of referrals, and efficiency of evaluations  
 Develop a platform to publicize transplant centre characteristics (e.g. policies, practices, resources, expertise, rates of 
transplantation) to patients   
Delayed referral to transplant 
services  
 Promote a commitment to living donor transplantation in non-transplant services (e.g. staff education) 
 Provide resources to support the facilitation of referrals to the transplant centre (e.g. transplant coordinators, web-based system to 
monitor patients estimated glomerular filtration rate)  
Inefficiency    Adopt strategies to reduce delays in completing evaluations or operations (e.g. negotiate a higher priority status for operations and 
assessments, utilize private physicians, surgeons and theatres, increase resources for assessment clinics, avoid unnecessary 
duplication of assessments)  
Donor recruitment   Provide counselling to assist patients to engage in discussions about living donor transplantation with potential donors  
 Define the roles and responsibilities of nephrologists in supporting and facilitating donor recruitment and family education  
Disadvantaged populations     Reduce delays for rural patients (e.g. prioritize and streamline appointments at the transplant centre, increase funding for out-
reach clinics, utilize Telehealth services and local medical services for tissue typing and assessments).  
 Identify strategies to counsel potential recipients with low health literacy or English proficiency about donor risks and “high-risk” 
living donor transplants (e.g. family education).  
 Engage with community members to develop strategies to address cultural barriers to living kidney donor transplantation  
 Provide multidisciplinary support to identify and address barriers to transplantation during early stages of renal care  
Psychosocial barriers  Identify strategies to provide psychosocial support to potential recipients to address fears and concerns, denial, non-adherence, 
weight-loss, smoking, alcohol and drug abuse, and promote self-advocacy 
Eligibility criteria  
 
 Develop explicit and shared policies regarding the eligibility of older donor-recipient dyads  
 Develop explicit and shared policies regarding the inclusion/exclusion of non-adherence in eligibility criteria  
 Develop explicit and shared policies regarding the interpretation of donor specific antibodies to determine patient eligibility  
Evaluation procedures   Develop explicit and shared policies regarding cardiovascular screening using coronary angiography and implications for pre-
emptive transplantation  
The suggested research and policy priorities were formulated by participants and discussion among the research team  
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6.1 Abstract 
Background: Living kidney donor candidates accept a range of risks and 
benefits when they decide to proceed with nephrectomy. Informed consent 
around this decision assumes they receive reliable data about outcomes 
they regard as critical to their decision making. We identified the outcomes 
most important to living kidney donors and described the reasons for their 
choices. 
Methods: Previous donors were purposively sampled from three transplant 
units in Australia (Sydney and Melbourne) and Canada (Vancouver). Using 
the nominal group technique, participants identified outcomes of donation, 
ranked them in order of importance, and discussed the reasons for their 
preferences. An importance score was calculated for each outcome. 
Qualitative data was analysed thematically.   
Results: Across 14 groups, 123 donors aged 27-78 years identified 35 
outcomes, with clear regional differences. The five most important donor 
outcomes for Australian participants were impact on family (importance 
score = 0.35, scale 0-1), followed by time to recovery (0.34), donor-recipient 
relationship (0.27), kidney function (0.26) and lifestyle restrictions (0.21). 
The five most important donor outcomes for Canadian participants were 
kidney function (0.57), followed by surgical complications (0.29), kidney 
failure (0.22), life satisfaction (0.20), and time to recovery (0.19). The 
themes identified included worthwhile sacrifice, downplaying risks and 
harms, confidence and empowerment, unfulfilled expectations and 
heightened susceptibility.  
Conclusions: Living kidney donors prioritized a range of outcomes, with 
the most important being kidney health, and the surgical, lifestyle, 
functional and psychosocial impacts of donation. Donors also valued 
improvements to their family life and donor-recipient relationship. Kidney 
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function and kidney failure was more important to Canadian participants, 
compared to Australian donors, perhaps due to the inclusion of non-
directed donors. The outcomes most relevant and meaningful to donors 
should be routinely addressed in research, informed consent, assessment, 
post-donation education, and follow-up care.  
6.2 Introduction 
In 2014, living kidney donor transplants comprised 42% of kidney 
transplants performed worldwide.1 Living kidney donor transplantation 
has been widely advocated to address the global shortage of organs, and 
can offer transplant recipients superior graft and survival outcomes 
compared with a deceased donor transplant.2,3 Whilst there are significant 
benefits for recipients, living kidney donors must accept various risks 
associated with nephrectomy.  
Living donation is considered ethically justified on the proviso that donors 
undergo rigorous medical screening and assessment, provide informed and 
voluntary consent after education about the potential risks and 
uncertainty regarding long-term outcomes, and have access to long-term 
health care.4-6 However, understanding of the risks to living kidney donors 
is evolving, with the progressive publication of more robust long-term 
data.7-9 Recent evidence of small absolute increases in the risk of end-
stage kidney disease (ESKD), hypertension, hypertension in pregnancy, 
and all-cause mortality in donors in the three decades following donation, 
compared to the general or healthy population4,7,8,10-13 reinforces the need 
for ongoing research and follow-up of living kidney donors.  
Living kidney donors experience a broad range of post-donation outcomes 
that span physical and mental aspects of their health, function, 
relationships, wellbeing, and livelihood.14 Current guidelines for informed 
consent and follow up do not consistently or comprehensively address 
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psychosocial outcomes and other donor-reported outcomes.14-17 This study 
aims to identify the impacts of kidney donation that are deemed important 
by living kidney donors, and to understand the beliefs and attitudes 
underpinning the outcomes they value. This can help to ensure that 
research, informed consent and education and follow-up care address 
outcomes and provide information that is meaningful and relevant to 
kidney donors.  
6.3 Methods 
Participant recruitment and selection 
We recruited living kidney donors from three transplant units in Australia 
(Sydney, Melbourne) and Canada (Vancouver). Participants were 
purposively sampled to include a range of demographic (gender, age), and 
donation characteristics (time since donation, relationship with the 
recipient, self-reported complications). All adult kidney donors from the 
past 20 years, at the participating units, who were English-speaking, and 
able to provide informed consent, were eligible to participate. Participants 
were reimbursed AUD/CAD $50 for their travel expenses. Ethics approval 
was obtained from the Western Sydney Local Health District, Monash 
Health and the University of British Columbia/Providence Health Care.  
Data collection 
We conducted focus groups using the nominal group technique. The 
nominal group technique involves structured ‘brainstorming’ to develop 
ideas, followed by individual voting on the list of ideas.18 Group discussion 
was used to identify reasons for individual preferences, as well as 
divergent and similar opinions within the group.19-21  
The two-hour meetings were convened between July 2015 and July 2016 
and included four phases: 1) discussion about the experience of kidney 
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donation; 2) identification of outcomes as a group (which were augmented 
with outcomes from previous groups and research studies7,8,11,14,22-28; 3) 
independent ranking of the relative importance of each outcome (on a 
printed list); and 4) group discussion of the reasons for their rankings (See 
Appendix D.3). Three researchers (CSH, AFR or AT) facilitated the groups 
in a centrally located venue external to the participating hospitals. 
Outcomes were included as distinct options according to the participant’s 
preferences, and there was an effort to maintain consistently in 
subsequent groups. An observer (CSH, AFR, AT, JP) recorded field notes 
during the discussion. Each session was audio-recorded and transcribed 
verbatim. Recruitment was stopped upon reaching data saturation i.e. 
when no new outcomes or concepts were raised in subsequent groups. 
Data analysis 
Quantitative analysis: The ranking from the nominal groups produced 
ordinal data. Some groups did not raise a particular outcome, and some 
participants within a group did not rank all the outcomes on the groups 
list. Therefore, it was not appropriate to calculate means. A measure of 
importance (i.e. importance score) of each outcome was used to prioritize 
the outcomes, based on the rankings attributed by participants. To 
calculate this measure, the distribution of the ranking for each outcome 
was obtained, by calculating the probability of each rank for each outcome 
[𝑃(𝑂𝑗 𝑖𝑛 𝑟𝑎𝑛𝑘 𝑖), i.e., the probability of the outcome Oj being assigned the 
rank first place, second place and so on]. By the total law of probabilities: 
𝑃(𝑂𝑗  𝑖𝑛 𝑟𝑎𝑛𝑘 𝑖) =
=  𝑃(𝑂𝑗 𝑖𝑛 𝑟𝑎𝑛𝑘 𝑖 |𝑂𝑗 𝑖𝑠 𝑛𝑜𝑚𝑖𝑛𝑎𝑡𝑒𝑑) × 𝑃(𝑂𝑗 𝑖𝑠 𝑛𝑜𝑚𝑖𝑛𝑎𝑡𝑒𝑑)
+ 𝑃(𝑂𝑗  𝑖𝑛 𝑟𝑎𝑛𝑘 𝑖 |𝑂𝑗 𝑛𝑜𝑡 𝑛𝑜𝑚𝑖𝑛𝑎𝑡𝑒𝑑) × 𝑃(𝑂𝑗 𝑛𝑜𝑡 𝑛𝑜𝑚𝑖𝑛𝑎𝑡𝑒𝑑) 
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where “nominated” means that the outcome was considered (and given a 
rank) by the participant. We assumed that the 
𝑃(𝑂𝑗  𝑖𝑛 𝑟𝑎𝑛𝑘 𝑖 |𝑂𝑗 𝑛𝑜𝑡 𝑛𝑜𝑚𝑖𝑛𝑎𝑡𝑒𝑑) is 0, because if the participant did not 
rank the outcome 𝑂𝑗, then the probability of any rank is 0.  Therefore, the 
equation is simplified t:  
𝑃(𝑂𝑗  𝑖𝑛 𝑟𝑎𝑛𝑘 𝑖) =  𝑃(𝑂𝑗 𝑖𝑛 𝑟𝑎𝑛𝑘 𝑖 |𝑂𝑗 𝑖𝑠 𝑛𝑜𝑚𝑖𝑛𝑎𝑡𝑒𝑑) × 𝑃(𝑂𝑗 𝑖𝑠 𝑛𝑜𝑚𝑖𝑛𝑎𝑡𝑒𝑑) 
The probability therefore has two components: 1) the importance given to 
the outcome by the ranking and 2) the consistency of being nominated by 
the participants. We computed the weighted sum of the inverted ranking 
(
1
𝑖
) to obtain the importance score. 
𝐼𝑆 = ∑ 𝑃(𝑂𝑗 𝑖𝑛 𝑟𝑎𝑛𝑘 𝑖)
𝑛𝑟 𝑜𝑓 
𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠
𝑖=1
×
1
𝑖
 
The importance score can be interpreted as a summary measure of 
importance of the outcome that incorporates the consistency of being 
nominated and the rankings given by the participants. The ranks are 
inverted so that more weight is given to top ranks and less to lower ranks. 
Higher scores identify outcomes that are more valued by the participants. 
The score can range between zero and one.  This measure has a similar 
motivation to the Expected Reciprocal Rank Evaluation Metric that was 
proposed in a different context.29 The analysis was conducted using the 
software package R version 3.2.3 (R Foundation for Statistical Computing, 
Vienna, Austria). Importance scores for all identified outcomes are 
presented in Appendix Table D.1. 
Qualitative analysis: We entered the transcripts into HyperRESEARCH 
(ResearchWare Inc. www.researchware.com, Version 3.5.2), and used an 
adapted grounded theory approach30 to inductively identify preliminary 
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concepts and themes. Accordingly, CSH conducted line-by-line coding, 
assigning a code to meaningful segments of text. Comparisons were made 
within and across groups, identifying similar and divergent concepts in 
the data to develop preliminary themes. These preliminary findings were 
discussed among the research team (investigator triangulation) to 
consolidate the list of themes and sub-themes, and ensure they captured 
the range and breadth of the participants’ reasons for their rankings.  
6.4 Results 
Participant characteristics 
In total, 123 people aged 27-78 years (mean 55 years) participated across 
14 groups (median = 9 participants per group, IQR = 8-10, min = 5, max = 
12). Sixty-seven participants were recruited in Australia, and fifty-six 
from Canada (Appendix Table D.2). The time since donation ranged from 
two months to sixteen years (mean 3.6 years, standard deviation =3.1). 
Demographic and donation characteristics are provided in Table 6.1 and 
Table 6.2, respectively. Seventy-eight (63%) participants were female, and 
100 (81%) were white. The sample included 101 (82%) related donors 
(spouse, child, sibling, parent), 9 (7%) unrelated donors (colleague, friend), 
and six (4%) non-directed donors, from Canada. Nineteen (15%) donated 
through a kidney paired donation. Thirty-one participants (25%) reported 
mental or physical outcomes which they attributed to the donation (Table 
6.2). No participants reported ESKD. 
Nominal group ranking 
The participants identified a combined total of 35 post-donation outcomes 
and the mean number of outcomes identified by each group was 22 (range 
19-28). The importance scores for donor outcomes across all participants, 
stratified by country, are shown in Figure 6.1. Across all participants, the 
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ten highest ranked outcomes were kidney function (i.e. glomerular 
filtration rate and creatinine levels) (importance = 0.40), time to recovery 
(0.27), surgical complications (0.24), impact on family (0.22), donor-
recipient relationship (0.21), life satisfaction (0.18), lifestyle restrictions 
(0.18), kidney failure (defined as the need for dialysis or transplant) (0.14), 
mortality (0.13) and acute pain/discomfort (0.12) (Appendix Table D.1). 
Differences in ranking between Canadian and Australian participants are 
shown in Figure 6.1.  
Qualitative analysis 
We identified five main themes that explained participants’ ranking of 
outcomes. Quotations to illustrate each theme are provided in Table 6.3. A 
schema depicting the relationship between the themes and participants’ 
ranking of outcomes is provided in Figure 6.2.   
Worthwhile sacrifice 
Primacy of recipient outcome: Participants’ satisfaction with the donation 
depended primarily on the outcome for the recipient. Recipient graft 
failure was expected to feel “similar to a stillbirth”, accompanied by guilt, 
and “helplessness” because “you’ve got no kidney left to give”. Surgical 
complications and lifestyle restrictions were considered “totally worth it”, 
given the observable improvements in their recipient’s health. Donors 
declared they concealed their complications to avoid being “selfish” or 
making the recipient feel guilty. 
Deriving personal and familial benefits: Related donors valued the 
improvement to their own wellbeing, impact on family and relationship 
with the recipient, as this had been a primary motivator to donate. For 
some participants, these positive outcomes were the only impacts they had 
experienced. However, other participants ranked these outcomes lower 
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because they felt these psychosocial benefits were “implicit” or difficult to 
measure - “I think it’s important. But it’s very subjective…I’m answering 
the questions myself, I could be lying to myself.” 
Downplaying risks and harms 
Tolerable burdens and sacrifices: Some participants were less concerned 
with short-term or non-life-threatening outcomes like pain because these 
were expected or they could “tough out those ones”. The ease of their 
recovery surprised some participants, and they wanted these outcomes 
recorded to let potential donors know that “it was not as bad as having a 
broken toe”.  
Irrelevance to self: After full recovery, participants experienced no 
perceptible physical impacts of donating a kidney (“it’s like it never 
happened”) and some believed their health had improved due to their 
adoption of a healthy lifestyle. Therefore, long-term health outcomes 
seemed irrelevant.  
Denying causation: Some participants questioned whether conditions they 
had developed after donation, such as gout, fatigue and hypertension, 
were caused by their lifestyle, pre-existing circumstances or age, rather 
than the donation. Some participants did not believe the nephrectomy 
would increase their risk of developing ESKD, and instead attributed 
these outcomes to a “bad” lifestyle. 
Accepting fate and bad luck: Participants were reluctant to consider 
hypothetical repercussions of their nephrectomy because “there’s no going 
back from [donation]”. Older participants believed that they would 
inevitably develop health complications due to age (“after a certain 
age…stuff’s going to happen”). Surgical complications were viewed as “bad 
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luck” and some ranked this low to avoid “put[ting] people off” from 
becoming a donor.  
Confidence and empowerment  
Power to prevent morbidity: Participants believed that they could actively 
prevent kidney disease, cardiovascular disease and diabetes by managing 
their diet and weight, and medication could keep their cholesterol or blood 
pressure under control. Similarly, some ranked psychological outcomes 
lower because these were “within [their] own control” – “whereas for 
medical outcomes, you need science and technology”.  
Medical reassurance and protection: The “stringent” pre-donation 
assessment gave participants confidence that their health was “not an 
issue” – “I’m not going to second guess medicine”. They recalled “very 
positive” statistics about mortality and long-term outcomes. Participants 
believed that outcomes such as kidney function, fatigue, blood pressure 
and depression were already on the “radar” because they were being 
monitored in follow-up or in the research studies that they participated in. 
The promise of transplant wait-listing priority in Canada somewhat 
reduced participants concerns about ESKD.  
Financial safety net: Many participants had a financial buffer or 
assistance to help them absorb out-of-pocket expenses and replace lost 
income as a result of donation, thus they ranked this lower.  
Unfulfilled expectations 
Misled and unprepared: Some participants ranked time to post-operative 
recovery, surgical complications, and pain highly because they felt “deeply 
disappointed” and “resentful” about enduring a more debilitating and 
protracted recovery than they had been “led to expect”. They considered a 
full recovery to mean “to be back to your life”, and to encompass their 
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mental and physical health. Participants had vivid memories of 
“excruciating” pain. Younger participants had considered themselves 
“bulletproof” and were frustrated by being unable to resume physical 
activity. Younger participants noticed that their self-esteem and sex drive 
diminished, whilst their wound healed.  
Unrecognized anguish: Persistent complications (e.g. chronic pain, fatigue, 
hydrocele and seromas) were considered overlooked by their clinicians. 
Some experienced an unexpectedly difficult emotional recovery due to 
their physical incapacitation, or a sense of loss – “I was surprised by how 
low I felt for a while”. Participants also described anxiety about their 
recipient’s graft function, the devastation of recipient death or graft 
failure, their discomfort with their “hero status” amongst their social 
network, lack of support from some family members, and complexities in 
their relationship with the recipient. Donor psychosocial wellbeing was 
considered a “missing part of the research”.  
Financial loss: Other participants ranked financial impact highly because 
they believed that lost income and out-of-pocket expenses contributed a 
significant barrier to potential donors, and represented an unfair burden 
given their altruistic act.  For younger participants, single parents, and 
the donor who was not a resident and therefore uninsured, the costs were 
“a big hit”, and for some, “an absolute destruction”. The time off work for 
recovery caused some donors to lose their jobs.  
Heightened susceptibility  
Avoiding catastrophic consequences: Surgical mortality, life-expectancy 
and morbidity were important, particularly during decision-making, 
because they considered these to be the “most serious” outcomes which 
would also impact their family. Some were focused on their kidney 
function due to a fear of kidney failure and the impact of reduced kidney 
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function on cardiovascular disease. This was concerning for younger 
donors – “I’m thirty-one, I’ve got a lot of years to come”. However, these 
hypothetical long-term outcomes were “not necessarily the things that 
impacted them the most”, and so sometimes ranked relatively lower. Non-
directed donors explained that “[their] own health was most important” as 
they “didn’t know anything about [the] recipient”.  
Protecting the remaining kidney: In the short-term period after donation, 
some participants felt “paranoid” about their kidney function, and were 
concerned whether their glomerular filtration rate (GFR) was “normal”. 
‘Lifestyle restrictions’ were important because they wanted greater 
understanding on protective and harmful activities, diets and medicines, 
and travel restrictions related to dangerous infectious diseases, so they 
could protect their long-term kidney function. Diabetes and hypertension 
were of concern because they were perceived precursors to kidney failure.  
Disconcerting uncertainty: A few participants, from both countries, 
expressed concern regarding the lack of clear long-term data on ESKD and 
mortality. They considered further research imperative to gain a “longer 
statistical window”, to “confirm” the safety of donation. Participants also 
wanted answers to their unexplained complications, like chronic pain, and 
therefore felt these outcomes were important for research. 
6.5 Discussion 
Post-donation outcomes that were most important to kidney donors 
included long-term health outcomes (kidney function and kidney failure), 
short-term surgical and functional outcomes (post-operative recovery, 
surgical complications, pain, and physical function) and psychosocial 
impacts (impact on family, donor-recipient relationship and life 
satisfaction). Donors are concerned about their health and some were 
disappointed by unmet expectations regarding their recovery, physical 
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function, relationships, and psychological wellbeing. While their priorities 
were largely based on their experience of donation, some donors 
downplayed short-lived problems in light of the improvements to their 
family life, relationship and their recipient’s health. The hypothetical 
long-term risks associated with nephrectomy, including mortality and 
cardiovascular disease was of relatively lower importance. While some 
donors worried about their heightened susceptibility to morbidity and 
mortality, most donors believed their clinicians had ruled out long-term 
risks through screening, and believed they were able to prevent disease 
through a healthy lifestyle and maintaining their kidney function.   
There were some differences observed in the importance of outcomes 
between donors recruited from the Australia and Canada. Canadian 
participants ranked kidney function and kidney failure higher than 
Australian participants, who ranked time to recovery, physical function, 
impact on family, donor-recipient relationship, and financial impact 
higher. A few participants in both countries expressed concerns about 
their heightened susceptibility to kidney failure. This may have been 
ranked higher among the Canadian sample, because of the inclusion of 
non-directed donors, and more unrelated donors, who focus more on their 
own health as they are unaware of the recipient’s outcome, or lack a close 
relationship with the recipient. There may also be an era effect, as most 
Canadian participants were more recent donors, after literature on ESKD 
risk had been published. The transplant clinicians in Vancouver may 
emphasize these outcomes differently to donors. The Canadian cohort also 
had a higher proportion of tertiary educated people. The percentage of 
participants who reported complications was higher for Australian 
participants than Canadian participants (Table 6.2), perhaps explaining 
the higher ranking of physical function and time to recovery. Financial 
impact may have been more important to Australian donors because 60% 
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donated prior to the introduction of the Support for Living Organ Donors 
Program, in 2013. Canadian participants donated after a reimbursement 
program was available in British Columbia.  
Kidney function was the highest ranked outcome, closely linked to donors 
underlying fears of developing kidney failure. Monitoring their kidney 
function gave donors reassurance that they could prevent the onset of 
kidney failure. However, many participants were uncertain whether their 
GFR after donation was ‘normal’ and how to modify their lifestyle and diet 
to protect their long-term kidney function. On the one hand, many donors’ 
felt that they had ruled out any risks of developing kidney failure during 
donor assessment, and were focused on the outcomes they experienced 
rather than hypothetical long-term outcomes. However, some also 
expressed underlying fears about their susceptibility to kidney failure, 
particularly younger and more recent donors. A recent study found that 
concerns for long-term outcomes motivate ongoing health monitoring and 
participation in follow-up among donors.31 Mild anxiety about kidney 
failure has been found to be common among donors within ten years of 
donation.32 
Psychosocial and physical functioning was also highly important to 
donors. Previous studies suggest that only a minority of donors (5-25%) 
report negative psychosocial and physical outcomes.24,33-35 However, we 
found that donors prioritized these outcomes (e.g. relationship problems, 
emotional distress, diminished body image and libido, pain, fatigue, and 
financial hardship) because they were often unexpected and unaddressed 
in follow- up, causing donors to feel unprepared, misled and unsupported.  
We recruited donors from two countries with various donation 
characteristics. A combined quantitative and qualitative methodology 
provided comprehensive data about donors’ priorities, attitudes and beliefs 
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regarding donation outcomes. While surveys with donors are often 
susceptible to social desirability bias, inhibiting discussion of negative 
outcomes24, the focus group enabled open-communication due to the 
shared experiences among participants. However, there are limitations of 
our study. Our sample was limited to English-speaking participants who 
were 81% white and attained a high level of education. Importantly, 
donors from Australia and Canada have access to universal health 
coverage. Therefore, the transferability of our findings may be limited in 
other countries. Due to the semis-structured nature of the nominal group 
technique, each group did not generate the same list of outcomes. Our 
quantitative analysis incorporated both the ranking and the consideration 
of the outcome, but comparisons among participants were not possible. 
The outcomes that are important to donors are also likely to change over 
time for example surgical mortality may be more important prior to 
donation. We included donors, who were 2 months to sixteen years post-
donation, but we were unable to assess how donors’ priorities might 
change over time. Furthermore, donors who are thirty or more years post-
donation may have different perspectives on lifetime risks. 
Our findings suggest there is a need to improve donors understanding of 
long-term outcomes, but also improve education, follow-up care and 
standardized information around the outcomes that are important to each 
individual donor. The recent Kidney Disease Improving Global Outcomes 
(KDIGO) guidelines recommend informing donors of individualized risks, 
benefits including medical, surgical psychosocial and economic outcomes 
during the perioperative period and the remaining lifespan of the donor.6 
They suggest communicating absolute risks, and disclosing uncertainty in 
long-term outcomes.6 An online risk calculator tool to assess the lifetime 
ESKD risk has been developed to help transplant centres evaluate, 
counsel and accept living donors, which may improve donor 
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comprehension of their lifetime risk of ESKD.36 However, donor’s strong 
motivations and the confidence in their safety pose additional barriers to 
comprehending risk information prior to donation.37-39 Continued 
education about donor outcomes and emerging evidence is therefore 
critical after donation.  
The assessment of donor-reported outcomes can provide information to 
help prepare donors for a range of outcomes they may experience and care 
about, and enable follow-up care to be individualized to the donor’s 
needs.40 The Organ Procurement Transplant Network (OPTN) mandates 
the collection of data on a range of post-donation outcomes for two years 
after donation, including two psychosocial outcomes – employment status 
and loss of insurance. A broader scope of psychosocial and functional 
outcomes should be assessed in follow-up. For example, a validated longer-
term measure of recovery is needed, that captures donors’ full recovery.   
Living kidney donors were concerned about their kidney health and the 
surgical, lifestyle and psychosocial impacts of donation that were 
unexpected, debilitating, or unaddressed in post-donation follow-up care. 
They also valued improvements to their emotional wellbeing, impact on 
family and donor-recipient relationship. These findings emphasize the 
importance of identifying donors’ priorities and concerns during the 
informed consent process, and being cognizant of the donor’s confidence in 
the transplant process such that they may readily accept or disregard 
long-term health risks. The assessment of donor-important outcomes 
during follow-up, the collection of more robust data on long-term 
outcomes, and efforts to keep donors updated on emerging evidence on 
donor outcomes and protective lifestyle behaviours could improve donor 
satisfaction and wellbeing after donation, and reduce their anxieties about 
their vulnerability to kidney disease. Our findings can provide a 
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framework to ensure that the outcomes most relevant to donors are 
consistently included research, education, assessment, and follow-up care.  
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Figure 6.1. Importance scores for donor outcomes by country (confidence intervals)  
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Figure 6.2. Thematic schema depicting themes underpinning ranking of outcomes 
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Table 6.1. Demographic characteristics of the participants (N=123)  
Characteristics  Australia, n = 67 (%) Canada, n = 56 (%) All, n = 123 (%) 
Gender    
 Female 41 (61) 37 (66) 78 (63) 
 Male 26 (39) 19 (34) 45 (37) 
Age (years) ^    
 20-29 1 (1) 0 (0) 1 (1) 
 30-39 6 (9) 5 (9) 11 (9) 
 40-49 15 (22) 12 (21) 27 (22) 
 50-59 22 (33) 14 (25) 36 (29) 
 60-69 15 (22) 19 (34) 34 (28) 
 70-79 8 (12) 5 (9) 13 (11) 
Ethnicity^    
 Caucasian 56 (84) 44 (79) 100 (81) 
 Asian 5 (7) 7 (13) 12 (10) 
 Middle Eastern 5 (7) 0 (0) 5 (4) 
 Other* 1 (1) 5 (9) 6 (5) 
Highest level of education ^    
 University degree 25 (37) 34 (61) 59 (48) 
 Diploma/certificate 15 (22) 10 (18) 25 (20) 
 Secondary school: year 12 9 (13) 15 (27) 24 (17) 
 Secondary school: year 10 17 (25) 0 (0) 17 (14) 
Total household income per year (USD)^ †    
 $0 - $32, 135 15 (22) 1 (2) 16 (13) 
 $32,136 - $66, 949  16 (24) 13 (23) 29 (24) 
 $66, 950 - $107,120  15 (22) 15 (27) 30 (24) 
 > $107,120  16 (24) 26 (46) 42 (34) 
Employment status^    
 Full time 35 (52) 33 (59) 68 (55) 
 Part time/Casual 15 (22) 7 (13) 22 (18) 
 Retired/Pensioner 12 (18) 12 (21) 24 (20) 
 Not employed  4 (6) 3 (5) 7 (6) 
Marital status^    
 Married/De-facto relationship 57 (85) 39 (70) 96 (78) 
 Divorced 0 (0) 7 (13) 7 (6) 
 Widowed 5 (7) 1 (2) 6 (5) 
 Separated  1 (1) 5 (9) 6 (5) 
 Single 2 (3) 3 (5) 5 (4) 
 Partner (not living with) 2 (3) 0 (0) 2 (2) 
^Total N ≠ 123 due to non-response. *Includes South American, African, Pacific Islander and First Nation (Canada)†As 
defined by Australian Bureau of Statistics 2011 Census Survey, converted to United States Dollars (USD) using average 
2011 exchange rate
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Table 6.2. Donation and health characteristics of the participants (N=123) 
Characteristics  Australia (n = 67) Canada (n = 56) All n (%) 
Time since donation^     
    <1 year 3 (4) 10 (18) 13 (11) 
 1-3 years 26 (39) 33 (59) 59 (48) 
 4-6 years   16 (24) 19 (34) 35 (28.7) 
 7– 10 years 7 (10) 2 (4) 9 (7.4) 
 >10 years 6 (9) 0 (0) 6 (4.9) 
Relationship to recipient    
 Spouse 28 (42) 11 (20) 39 (32) 
 Parent 17 (25) 16 (29) 33 (27) 
 Sibling 15 (22) 8 (14) 23 (19) 
 Friend/Colleague  2 (3) 7 (13) 9 (7) 
 Child 2 (3) 4 (7) 6 (5) 
 Other relative  3(4) 4 (7) 7 (6) 
 Non-directed (anonymous) 0 (0) 6 (11) 6 (5) 
Kidney paired donation    
 Yes 9 (13) 10 (18) 19 (15) 
 No 58 (87) 46 (82) 104 (85) 
Recipient outcome*    
 Alive and functioning graft   52 (78) 61 (109) 113 (92) 
 Graft failure or death 6 (9) 4 (7) 10 (8) 
Self-reported post-donation complications     
 Any 19 (28) 12 (21) 31 (25) 
 Mental health  5 (7) 3 (5) 8 (7) 
 Hypertension  5 (7) 2 (4) 7 (6) 
 Chronic pain 1 (1) 2 (4) 3 (2) 
 Hydrocele 2 (3) 0 (0) 2 (2) 
 Other† 7 (10) 4 (7) 11 (9) 
^Total N ≠ 123 due to non-response.  
*
The timing of the recipient outcome was not captured   
†
Includes hyperthyroidism, low blood pressure, kidney stones, gall stones, hernia, blood clots, endometriosis, 
gout, high cholesterol, scleritis and osteoporosis. Note that acute pain and fatigue were not reported as 
complications, despite being indicated in qualitative data.  
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Table 6.3. Illustrative quotations 
Theme Illustrative quotations  
Worthwhile sacrifice 
Primacy of recipient 
outcome  
“One of the key ones for me is the success of the donation for the [recipient]. Had it been negative or there had been problems it would have been very 
emotional.” (Female, Canada, 40s) 
“They’re all important it’s just hard to pick one as long as whoever is getting the kidney is okay…but as we all said we’ll do it again no matter what the 
outcome was.” (Female, Australia , 50s) 
“Even now I still don’t get any feeling in my arm when I wake up. It is disturbing. I don’t make a big deal of it because I donated my kidney to my sister and I 
don’t want her to think that my lifestyle has changed. I just want for future reference.” (Female, Canada, 40s) 
“When that fails, you're no longer in control of that person's health, and therefore you would feel a sense of blame, maybe?  And helplessness, yeah.”  (Female, 
Australia, 50s) 
Deriving personal 
and familial benefits 
“My top one was family life, as long as all that’s fine everything else will be fine.” (Female, Australia, 70s) 
“Ever since then we have been travelling all over the world. So freedom! The freedom is amazing so that is really important to us.” (Female, Canada, 50s) 
Downplaying risks and harms  
Tolerable burdens 
and sacrifices 
 “I mean, I am now never going to be a professional kick-boxer. There are some things that you’re taking out of your life as options.” (Female, Canada, 30s) 
“But I’d like the media, or the general public to know that it’s not hard… just the recovery period.” (Male, Canada, 60s) 
“Yeah, just a little bit of the recovery but, you forget about that after a while.” (Male, Canada, 70s) 
Irrelevance to self “You can feel the points; they were six months, twelve months, and then the two years.  And after that it's like it never happened.” (Male, Australia, 60s) 
“I wasn’t really worried about any of the outcomes. I knew I was a healthy individual. I didn’t really have any concerns.” (Female, Canada, 40s) 
“I haven’t lived with [chronic pain]. So it’s hard for me to say because you don’t know what that is until you experience it. So beforehand, I don’t think it 
would’ve made a difference to me”. (Female, Australia, 60s) 
Denying causation “But quite a lot of those things, I’ve got, but it’s nothing to do with my kidney I would think. I think it’s because of my age.  Post-menopausal.” (Female, 
Australia, 70s) 
“But I mean like you could develop it later in life, like type 2 diabetes, if you have like a poor diet or whatever. If you’re going to make poor choices in your 
life, are you going to have a worse outcome if you have one kidney or two kidneys, right?” (Male, Canada, 50s) 
Accepting fate and 
bad luck 
“I got a massive hernia, so I had to go back in for another five days and have that repaired and [I’ve got another one]...But they just said I was just one of the 
unluckiest ones they’d had, so  but it wouldn’t have changed my decision to do it.  It’s just that it was damn unlucky.  Very unexpected.  They got fright too.” 
(Female, Australia, 60s) 
“If it is your time it is your time and you cannot stop it right? You can die crossing the street…When it is your time, it is your time, never thought about it…” 
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(Male, Canada, 40s) 
“Because I read that [risk of kidney failure] in the literature before I had the operation, you know, but at the end of day, you just can’t afford to think about 
that.” (Male, Australia, 70s) 
Confidence and empowerment 
Power to prevent 
morbidity 
“Weighted risk compared to other things like smoking and high blood pressure seems to like, far outweigh the kidney thing, so I wouldn’t be concerned about 
it.” (Male, Canada, 60s) 
“I am actually healthier now just because I have had this on my mind. So I eat healthier, exercise more and so I feel like health wise it has been beneficial.” 
(Female, Canada, 50s) 
“I was of the impression that if you kept your blood pressure down, you didn’t have diabetes and you didn’t have high cholesterol and you have average 
weight that there’d be no problems with kidney function.” (Female, Australia, 50s) 
Medical reassurance 
and protection  
“For the rest, they already screened us, so I think if I was going to be worried about all of these, I’m not because they screened me for it. Like I have enough 
faith in the pre-work that I’m not going to sweat it now. So it’s done, I’m not going to worry about it or second guess medicine.” (Male, Canada, 50s) 
“The longer the years go on, the longer statistical window they have, but the statistics they brought up to me were all very positive. So it was, again, another 
non-issue.” (Male, Canada, 60s) 
“Well I remember the surgeon told me there’s no proof at all that says somebody with two kidneys lives any longer than someone with one.” (Male, Canada, 
50s) 
Financial safety net  “Through the organ donation program, they reimbursed all that which was really good. I didn’t lose any of my long service leave... some people can’t have that 
eight weeks off or they might depend on that one income coming in.  Even though it’s important to donate, there are other things as well…”  (Female, 
Australia, 50s) 
“I guess I had the luxury of all I had to worry about was getting better, work was paid, I had sick leave and if I was allowed that time off work without 
issues.” (Male, Australia, 50s) 
Unfulfilled expectations 
Misled and 
unprepared 
“I don’t regret my decision at all. But I did not have an easy recovery…but I wish I had known it wasn’t as super easy as some people will lead you to believe. 
And that is why the donor blogs were super helpful because there are some people on there who have had truly awful experiences. And I knew that wasn’t 
going to be my experience. There were some people on there who had truly amazing experiences and mine ended up somewhere in the middle.”  (Female, 
Canada, 40s) 
“What would been interesting if there was some sort of follow up as to how long you’re in hospital for, what was your recovery like?  At what report did you 
return to full health?  All that seems like valuable information.  I didn’t really fee that captured at all. If it was recorded in a way that it could be used to 
better inform people or perhaps maybe target different things for different people.  And maybe complications… Information that no one bothers to record.” 
(Male, Australia, 40s) 
“It was really awful and I’ve never had that in my life, and they didn’t warn me about all the digestive stuff. From the nausea to the constipation.” (Female, 
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Canada, 60s) 
“Well lifestyle restrictions. I’ve been healthy all my life, I didn’t have to worry about what I ate or drank or whatever. Now I’m worrying about what 
medications I can take.” (Female, Canada, 50s) 
“I must admit I feel bad sometimes but you would do it again if you had to, I’m so glad I can’t really.  I found it pretty horrible to be honest.  I had partial lung 
collapse and the only way to fix that was to cough.” (Male, Australia, 40s) 
“The main thing for me was my sex drive went completely out the window…It was more just the fact that every time I looked down, my guts were smiling 
back up at me and, it was again, a vanity thing, psychological like, ‘Oh, my God!  Look at that.  It’s horrific.’” (Male, Australia, 30s) 
Unrecognized 
anguish  
“What I’m saying it as a point of study. Not that I have regret. But it would definitely be interesting to see if people have regret after.” (Female, Canada, 50s) 
“It actually surprised me how long it took me to recover. It wasn’t just the physical part of it. It was the emotional and the mental part of it.” (Female, 
Canada, 50s) 
“I focused on the other ones for the entire opposite reason. It’s easier to manage your scientific stuff. It’s really difficult to quantify emotional and relationship 
things, and I think that’s a missing part of the research.” (Female, Canada, 30s) 
“It was like, you know how you get the baby blues? On the fourth day, I just lost it…I don’t know whether it’s because I lost this thing and I just fell to 
pieces.” (Female, Australia, 50s) 
“I think for me after I donated a kidney, I got depression for a few months. It took me probably a year to feel better, and I started gaining a lot of weight and I 
didn’t have any energy. I wasn’t feeling happy. I mean I was feeling happy for my daughter but no, inside me I wasn’t happy.” (Female, Canada, 30s) 
“I was surprised to hear that you suffered depression. I wasn’t told that that could be an impact and I think that’s really crucial. People really need to know 
that that’s a possibility. I don’t remember them saying anything about it… But if it does happen it can be quite, I would imagine, very discombobulating.” 
(Female, Canada, 50s) 
“It seemed to me that stuff like kidney function, cardiovascular disease, end stage kidney disease, diabetes, all those things with a disease on them will 
probably be studied or come up in other studies. It seemed to me that I was choosing stuff that probably wouldn’t necessarily be studied.” (Male, Canada, 60s) 
“If my husband's kidney failed, I'm not sure how I'd react to that. Right now he's doing extremely well.  But if something should happen to him, would I be 
exposed to this depression and anxiety?  That would worry me.” (Female, Canada, 50s) 
“I had a lot of bloating.  I had a lot of pain and that went on years. I think they now know that [the surgeon] cut a nerve.  But all this has really gotten me 
down a lot.” (Female, Australia, 50s) 
“I don’t regret it. But I’m not fine. I’m not 100%. It’s a frustrating position to be in because I don’t fit what the ranges are….I definitely felt there was an 
expectation that I wouldn’t have any needs past 6 weeks. It was a magical number.” (Female, Canada, 40s) 
“Number two would be chronic pain/numbness because I’m still suffering from the after effects of that complication, every day. It’s not serious right now but 
I’m afraid it might get worse. I don’t know what to expect.” (Female, Canada, 50s) 
“I mean I don’t feel good about it, having a medical condition. You know I’m happy to help somebody but I was a healthy person, and now I’m stuck with 
this…Probably not. I wouldn’t have done it…if I’m harming my health and I have to live the rest of my life like this… It’s really quite intense”. (Male, 
Canada, 50s) 
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“For me, what I’d like to know. They are very good at the beginning at telling you this should happen. This should happen. Afterwards, my feeling on it, was 
they didn’t really follow up with you and say did that happen? Did that happen in your case? They said the percentages of whatever, but am I one of those 
percentages?” (Female, Canada, 30s) 
Financial loss “For me it was absolute destruction. Bankruptcy. I was off for a year…But you know, it is embarrassing to tell the family that ...” (Male, Canada, 60s) 
“That had a bit of an impact, we didn’t get any money back for the medication because I had to get medication and whatnot, I had to pay for all that.” (Male, 
Australia, 30s) 
“I was actually fired for the amount of time that I was about to take off…apart from the actual firing itself, I found it very hard after the recovery of about 
two months to get another job.  People just didn’t want to look at me.  It was the weirdest thing ever.” (Male, Australia, 30s) 
Heightened susceptibility  
Protecting the 
remaining kidney 
“'Because there seems to be, just in my mind anyway, some sort of connection between kidneys and particularly diabetes and blood pressure.  And I'm not 
sure which is the chicken and which is the egg?” (Male, Australia, 70s) 
“It’s not so much function. It’s, can you preserve or enhance your kidney health as a result of diet… I just got told to keep doing what I was doing, whatever 
that is…” (Male, Canada, 40s) 
Avoiding 
catastrophic 
consequences  
“Your mortality is not just about yourself, it's about your family or the family that you're going to have.” (Male, Australia, 40s) 
“So, they’re, I suppose, the most serious things… They’re not necessarily the things that impacted me the most but they would be the things that if I was 
looking to donate a kidney, I would want to know that those things are going to be okay.” (Female, Australia, 40s) 
“I mean it was top ten because I have kids…I worry about diabetes because I don’t want both of us going for dialysis. That’s the only reason why I worry, it’s 
not my self-preservation but more for family worry.” (Female, Canada, 30s) 
Disconcerting 
uncertainty  
“We’re all adding to the data pool with our annual lab requisitions, but we don’t hear back as a group on the overall experience. You’ve got a mass of data 
there, it’s easy enough to manipulate, and an incoming donor should have access to that information. Like on average, your GFR will go down to whatever, 
and you can rank that based on the demographic… you’ve got a pool of information that should be mined.” (Male, Canada, 60s) 
“Now that I think on it, one of my biggest concerns afterwards was what would be the long-term repercussions because back at the time we did our 
transplant, there was no ruling data on long term impacts…” (Male, Australia, 50s) 
“Is there any study, is there any data the impact of donation on the life expectancy of donors? Is there any statistic?  Do we know anything about that?  Is 
that one of the things that could be kind of explored so there’s information? It helps towards making an informed decision if people are assessing all sorts of 
things.” (Female, Canada, 70s) 
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Chapter 7: Living kidney donor outcomes reported in randomised 
trials and observational studies 
Hanson CS, Sautenet B, Craig JC, Chapman JR, Knoll G, Reese, PP, 
Tong A. Informative for decision-making? The spectrum and consistency of 
outcomes following living kidney donation reported in trials and 
observational studies. (Submitted to the Journal of the American 
Association) 
This chapter is structured as per the journal article.   
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7.1 Abstract 
Background: Evidence about outcomes following living kidney donation is 
needed both to inform donor acceptance criteria, and to guide the decisions 
of potential donors and their healthcare providers about donation. 
However, the scope and consistency of outcomes reported in research and 
their relevance to decision-making is uncertain. 
Aim: To determine the spectrum and consistency of outcomes reported in 
randomised trials and observational studies in living kidney donors aged 
18 years or over. 
Methods: Electronic databases were searched for randomised trials and 
observational studies reporting outcomes in adult living kidney donors 
published from January 2011 to May 2017. All outcome domains and 
measurements were extracted, and their frequency and characteristics 
were evaluated and reported. 
Results: Of the 268 eligible studies, 14 (5%) were randomised and 254 
(95%) observational. Overall, 136 studies (51%) were short-term (≤1 year 
follow up) and reported 109 outcome domains, of which 51 (47%) were 
classified as clinical, 35 (32%) were surrogate and 23 (21%) were donor-
reported. The five most commonly reported domains were kidney function 
(154, 58%), time to discharge (96, 36%), blood loss (85, 32%), operative 
time (79, 30%) and blood pressure (74, 28%). Quality of life (13%), 
mortality (16%), end-stage kidney disease (ESKD) (10%) and 
cardiovascular events (9%) were reported infrequently. Kidney function 
and pain had 116 and 75 different outcome measures, respectively.  
Conclusions: The outcomes of living kidney donation reported in 
contemporary trials and observational studies are numerous, 
heterogeneous, and often focussed on short-term surgical complications. 
Kidney function was the most frequently reported outcome, but multiple 
measures were used making comparisons across studies problematic. 
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Mortality, ESKD, cardiovascular disease, and donor-reported outcomes 
including recovery, physical function and psychological impact were 
uncommonly reported. Consistent reporting of outcomes relevant to 
decision making is needed to better inform and prepare donors for 
outcomes after donation.    
7.2 Introduction 
Living kidney donor transplantation is the preferred option for most 
kidney transplant candidates due to superior graft and survival outcomes, 
and reduced waiting times.1-3 Living donors now provide more than 40% of 
kidney transplants performed globally.4 As donors voluntarily undergo a 
medical procedure that primarily benefits another person, ensuring the 
safety, wellbeing and informed decision-making of donors is of primary 
concern. Surgical complications, mortality and major morbidity have been 
considered rare following kidney donation.5 However, recent evidence of 
small but important increases in the risks of end-stage kidney disease 
(ESKD), hypertension, and all-cause mortality in donors, compared to the 
general population,  have reinforced the need for ongoing, robust research 
of long-term donor outcomes.6-11 
Progressive publications that comprise long-term data may change 
assessment policies, and will likely also change the information provided 
to donors about post-donation outcomes.12 Donors experience and value a 
broad range of outcomes that span their health, physical function, 
psychosocial wellbeing and livelihood (8-10), but outcomes measured and 
reported in studies of living donor outcomes have had minimal or no input 
from donors.13 Additionally, inconsistencies in outcome measurement 
diminish the ability to combine and compare data on donor outcomes 
across studies, and thus limit the reliability and certainty of available 
evidence.14-21   
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We aimed to determine the spectrum and consistency of outcomes for 
living kidney donors reported in recent randomised trials and 
observational studies. The ultimate goal of the work is to improve the 
relevance and heterogeneity of outcome reporting, and so to better 
understand the outcomes experienced by living kidney donors. 
7.3 Methods 
Selection Criteria 
We searched MEDLINE, Embase, CINAHL and PsychINFO for all 
randomised trials of any intervention (e.g. surgical techniques, analgesia, 
pain control, infection control, psychosocial interventions) and 
observational studies (cohort, cross-sectional, case series) reporting 
biomedical and psychosocial outcomes in living kidney donors aged 18 
years or over. We included articles published from January 2011 to May 
2017 to ensure contemporary relevance (Appendix Table E.1). We excluded 
studies with fewer than 10 kidney donors, or if outcomes of donation were 
not the primary focus (for example, studies that used donors as ‘healthy 
controls’ and diagnostic validation studies).  
Data extraction 
We extracted the following characteristics from each study: first author, 
year of publication, study design, participating countries, sample size, 
follow up period, mean age of participants, year of donation, and all 
outcomes/outcome measures. For randomised controlled trials and 
observational studies evaluating the effects of an intervention, we also 
identified the type of intervention. An outcome measure was defined as 
any measurement or event reported in the results of the study. For each 
outcome measure, we extracted the type of measure (e.g. pain on a visual 
analogue scale), method of aggregation (e.g. mean), specific metric (e.g. 
change) and time frame (from the time of the intervention or donation).13  
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Analysis 
The first author (CSH) categorised all similar outcome measures into 
outcome domains. This was cross-checked by three reviewers and revised 
until a consensus was reached (BS, AT, JCC). All outcome domains were 
categorised as clinical (medical event or comorbidity diagnosed by a 
clinician)22, surrogate (biochemical, imaging, or other markers used as a 
substitute for a clinical outcome)23 or donor-reported (outcomes reported 
by donors that reflect how they feel or function e.g. pain, anxiety)22,24. 
Some domains included measures that could fit into multiple categories, 
and were categorised as clinical, surrogate or donor-reported based on the 
largest proportion of outcomes measures. For example, physical function 
can be measured via self-report or clinical assessment (e.g. gait analysis), 
but was most frequently measured by self-report and thus classified as a 
donor-reported outcome in this study. We calculated the number of studies 
that reported each outcome domain. This analysis was cross-checked by 
three reviewers (BS, AT, JCC). Any differences in opinion were resolved 
through discussion. The dataset was stratified by type of research 
question into treatment and prognosis studies, according to Cunningham’s 
classification of research questions.25 Therapy studies include questions of 
the outcomes of a treatment or exposure (e.g. drugs, surgical intervention, 
psychological intervention).25 A prognosis question assesses the 
progression of a disease or the likelihood of a disease occurring.25 We did 
not stratify by study design because there were a very small number of 
randomised controlled trials. Because of the very large number of 
outcomes, we conducted a detailed analysis of outcome measures (type of 
measure, definition, method aggregation, metric and time point) for the 
three most frequently reported surrogate and donor-reported outcome 
domains.13 Of the clinical outcomes mortality, ESKD and cardiovascular 
disease were chosen for detailed analysis. Statistical analyses (including 
frequencies) were conducted using R version 3.2.3 (R Foundation for 
Statistical Computing, Vienna, Australia, URL http://www.R-project.org/). 
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7.4 Results 
Study characteristics 
We included 268 studies that involved 556,102 (not unique) living kidney 
donors from 35 countries (Figure E1). The study characteristics are 
outlined in Table 7.1. Overall, most studies were conducted in Asia (33%), 
North America (31%) and Europe (29%). Most studies were prognosis 
studies (n=177, 66%) and 91 (34%) were classified as therapy studies. Of 
these 91 therapy studies, 14 were randomised controlled trials and the 
rest were cohort studies or case series.  Interventions included surgical 
techniques (78, 86%), intra-operative analgesia (7, 8%), post-operative 
pain control (3, 3%), infection control (1, 1%), psychosocial support (1, 1%) 
and a haemostatic agent (1, 1%). Of the 177 prognosis studies, 56 (32%) 
were prospective studies. Four (4%) therapy studies included more than 
1000 donors (median 83, interquartile range 43.5-189), compared with 37 
(21%) prognosis studies (median 143, interquartile range 57-588). Of the 
therapy studies, 107 (60%) of studies followed donors up for a maximum of 
12 months. One hundred and thirty-seven (77%) prognosis studies had 
follow up exceeding 12 months, and 37 (21%) exceeding 10 years follow up 
(maximum 32 years).  
Outcome measures and domains 
Across all studies, there were 4513 outcome measures reported which 
were categorised into 109 outcome domains. Overall, 51 outcome domains 
(47%) were clinical, 35 (32%) were surrogate and 23 (21%) were donor-
reported outcome domains (Appendix E.12-E.14). The five most commonly 
reported domains included kidney function (154, 58%), time to discharge 
(96, 36%), blood loss (85 ,32%), operative time (79, 30%) and blood 
pressure (74, 28%) (Table 7.2). Quality of life (13%), mortality (16%), 
ESKD (10%) and cardiovascular event (9%) were reported infrequently. 
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The number of outcome measures per study (including time points of 
measurement) ranged from 1 to 151, with a median of 12 (IQR 7-19). The 
number of unique outcome measures per study (excluding time points) 
ranged from 1 to 78 with a median of 9 (IQR 6-16). The number of studies 
that reported a minimum of one clinical outcome domain was 184 (72%), 
and 172 (64%) and 109 (41%) reported at least one surrogate and donor-
reported domain, respectively.  
Frequency of outcome domains reported in therapy studies 
Across the 91 therapy studies, 1385 outcome measures were reported and 
categorised into 70 outcome domains. Figure 7.1 depicts the proportion of 
therapy studies that reported each of the outcome domains, of which 38 
(54%) domains were clinical, 17 (24%) were surrogate, and 15 (21%) were 
donor-reported (Appendix E.15). The five most frequently reported 
outcome domains were: time to discharge (72, 79% studies), blood loss (66, 
73%), operative time (62, 68%), unspecified donor complications (45, 50%) 
and kidney function (45, 50%) (Table 7.2; Appendix E.15). Recovery and 
mortality were infrequent, reported in 10 (11%) and 9 (10%) of studies, 
respectively.  
Frequency of outcome domains reported in prognosis studies  
Across the 177 prognosis studies, 3128 outcome measures were reported 
and categorised into 100 outcome domains. Figure 7.2 depicts the 
proportion of the prognosis studies that reported each of the outcome 
domains, of which 46 (46%) were clinical, 32 (32%) were surrogate, and 22 
(22%) were donor-reported (Appendix Table E.16). The most frequently 
reported outcome domains were: kidney function (109, 62% studies), blood 
pressure (69, 39%), proteinuria/albuminuria (61, 35%), 
BMI/weight/composition (36, 20%), mortality (33, 19%), pain (33, 19%), 
mental health (31, 18%), physical function (31, 18%) and psychological 
impact (31, 18%) (Table 7.2; Appendix Table E.16). Quality of life (28, 
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16%), ESKD (24, 14%), and cardiovascular events (18, 10%) were reported 
infrequently.  
Outcome measures and time points 
The number of unique outcome measures and time points of measurement 
reported for ten outcome domains (three surrogate domains, four clinical 
domains, and three donor-reported domains) are shown in Figure 7.3. 
These examples were selected based on frequency and to include a range 
of surrogate, clinical, and donor-reported outcomes. 
The clinical outcome ESKD had 18 different outcome measures (34 
including time points), mortality had 23 (27 including time points), and 
cardiovascular event had 21 (25 including time points) (Appendix E.2-E.4). 
The three most frequently reported surrogate outcomes were kidney 
function with 116 different outcome measures (264 including different 
time points); blood pressure with 88 (172 including time points); and 
proteinuria/albuminuria with 29 (93 including time points) (Figure 7.3 
and Appendix E.5-E.7). For the most frequent donor-reported outcomes, 
pain had 75 outcome measures (181 including different time points); 
physical function had 33 outcome measures (67 including different time 
points) and psychological impact had 44 (58 including time points) 
(Appendix E.8-E.10). 
7.5 Discussion 
Recent studies in living kidney donors report an extensive range of 
outcomes, which are mostly short-term clinical or surrogate endpoints, 
with large heterogeneity in the measures used to assess the same 
outcomes. Interventions were predominantly of surgical procedures 
related to nephrectomy, and most frequently reported perioperative 
outcomes with time to discharge, blood loss and operative time each 
reported in more than half of the studies. For prognosis studies, there 
were more outcome domains, of which most were clinical outcomes. 
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However, the most frequently reported domains were surrogate outcomes, 
including kidney function, blood pressure, proteinuria/albuminuria and 
body mass/weight. Across all studies, relevant clinical and donor-reported 
outcomes such as mortality, quality of life and physical function were 
reported in less than twenty percent of studies.   
Feasibility and resource limitations could partly explain the relatively 
high frequency of short-term clinical and surrogate outcomes in therapy 
studies. Time to discharge, blood loss and operative time were the three 
most frequently reported outcomes in therapy studies, and are quality 
indicators that are easily obtained from administrative data. However, 
these outcomes provide limited information to inform donors’ expectations 
of surgical recovery – which, donors have defined as the return to “normal” 
health in terms of their physical and emotional functioning, and 
resumption of their regular roles and activities.26 Surveys and qualitative 
studies suggest that some donors experience an unexpectedly prolonged 
recovery, and report fatigue and pain, up to twelve months after donation 
.20,27 “Unspecified” complications are commonly reported, but these are not 
informative to potential donors or clinicians, without elaboration.  
In prognosis studies, there is a dominance of surrogate outcomes (e.g. 
kidney function, blood pressure and proteinuria/albuminuria) which is 
probably also driven by concerns regarding burden of data collection. 
Surrogate outcomes are routinely collected in follow-up, and changes can 
be detected in short-term assessment.28 Mortality, ESKD and 
cardiovascular events were not measured beyond twenty-five years after 
donation, therefore lifetime risks, particularly for younger donors, are 
uncertain. Most transplant centres have been unable to systematically 
follow up kidney donors.29,30 Some studies suggest donors are emotionally 
invested in donating to the recipient, and thus not focused on long-term 
outcomes of donation during decision-making.31 However, a mild fear of 
kidney failure was found to be common among donors, and concerns for 
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long-term outcomes motivates ongoing health monitoring and 
participation in follow-up.26,32  
While a wide-range of outcomes was reported across studies, donor-
reported outcomes were reported less frequently in both therapy and 
prognosis studies. Donor-reported measures can help donors understand 
and prepare for their recovery, return to work, the financial impact after 
donation and possible changes to their physical and psychological 
functioning after donation.33 It is increasingly argued that clinical trials 
should include patient-centred outcomes and standard measures for 
global, physical, mental and social health are being developed.34 However, 
generic psychosocial assessments may not capture donation-specific 
experiences, particularly interpersonal and emotional benefits, for which 
validated, donation-specific measures may be warranted.15,35 Recent 
guidelines recommend discussing anticipated psychosocial outcomes with 
potential donors including both benefits and risks. Most studies have 
found a minority of donors (5-25%) experience negative psychosocial  
outcomes but it has been difficult to pool data across studies due to 
heterogeneity in outcome measurement.15,36-38 We found that psychological 
impact was reported in 15% of studies, measured in 44 different ways, 
most frequently by the SF-36 instrument. Other psychosocial outcomes 
including mental health, satisfaction with the donation, depression, 
anxiety, donor-recipient relationship, and life satisfaction were also 
reported infrequently.  
A reliance on surrogate outcomes, such as proteinuria, can be problematic, 
as they may not be valid predictors of clinically meaningful outcomes.28 
Equations for estimating glomerular filtration rate (GFR) underestimate 
kidney function in living kidney donors, and are less precise than 
measured GFR.22,39,40 Current guidelines recommend assessing serum 
creatinine measurements and GFR estimation.12 We found that kidney 
function was most frequently measured by estimated GFR and serum 
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creatinine. Blood pressure was the second most frequently reported 
surrogate outcome in prognosis studies. Recent qualitative studies suggest 
that kidney function and blood pressure, despite being surrogate 
endpoints, may be important to donors, as they allow donors to monitor 
their health after donation.26 However, donors were uncertain what their 
absolute level of estimated GFR meant. Their change in kidney function 
over time may also provide meaningful information to donors. The 
importance of other frequently measured surrogates to donors, including 
proteinuria, albuminuria and body mass or composition is uncertain.   
We have also demonstrated heterogeneity in outcome domains and 
measures across studies on living donor outcomes, with 4513 outcome 
measures and time points reported across 109 different outcome domains. 
Surrogate and donor-reported outcome measures have greater 
heterogeneity than clinical measures, because the data routinely collected 
vary across units, and many investigator-developed surveys are used for 
donor-reported outcomes which often lack clear definitions of their 
outcomes.15 Clinical outcomes such as mortality, cardiovascular disease 
and ESKD were reported in using 23, 21, 18 different outcome measures, 
respectively, as they were sometimes reported as composite outcomes or 
identified based on treatment codes. This heterogeneity hampers efforts to 
compare the effectiveness of trials or synthesise data across studies, and 
clinicians’ ability to provide evidence-based recommendations in response 
to donor’s concerns, with certainty. Our findings support the need to 
identify standardised outcomes measures.41,42 To facilitate routine 
collection by transplant centres, researchers, and registries, outcomes 
must also be feasible to measure in large prospective studies and 
registries, which may be particularly challenging for self-reported 
outcomes.43 Identifying the outcomes of critical importance of donors could 
help identify suitable measures.   
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We have provided a detailed examination of the scope and consistency of 
outcome domains and measures reported in recent research on living 
kidney donor outcomes. This analysis has identified problems specific to 
research on living donor outcomes. We did not appraise the risk of bias or 
quality of the included studies, as our analysis was concerned with 
outcome reporting in studies that may inform donor practice and policy. 
Non-English articles were excluded from our search, and most articles 
that were included examined donors from high-income countries. Brazil, 
India, Mexico and Iran do high numbers of living kidney donor 
transplants each year, but publish very little data on donor outcomes1. 
Seventeen (6%) of the studies in our review were from Brazil, India, 
Mexico or Iran. Our search was limited to the past five years, as it was not 
feasible to include all existing studies. This enabled us to comment on 
recent research conduct, and minimise heterogeneity due to changing 
definitions/thresholds for outcomes over time (e.g. hypertension).18  
Among recent studies on outcomes for living donors, surrogates and short-
term clinical outcomes are more frequently reported, while donor-reported 
and long-term clinical outcomes are relatively uncommon. While flexibility 
and creativity in outcome measurement is important for progress and 
innovation, the varied and inconsistent definition and measurement of 
similar outcomes across studies can stifle efforts to synthesise evidence, 
and generate higher quality evidence on living donor outcomes. As 
strategies to collect long-term data on donor outcomes are improved, 
involving donor registries, researchers should seek to include the addition 
of outcomes in their study that are meaningful and relevant to all 
stakeholders, including donors. Improved outcome reporting and 
measurement could ultimately lead to better informed consent practices 
and evidence-based decision-making in living kidney donation
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Figure 7.1. Proportion of therapy studies reporting each outcome domain (total 91 studies, 70 outcome domains) 
Chapter 7: Living kidney donor outcomes reported in trials and observational studies   
174 
 
Categories of outcome:
Clinical outcomes
Donor-reported outcomes
Surrogate outcomes
NB: Proportion expressed 
in a x10 log scale
100%
30%
3%
1%
% of studies
(x10 log 
scale)
10%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. Proportion of prognosis studies reporting each outcome domain (total 177 studies, 100 outcome domains) 
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Figure 7.3. Number of outcome measures (definitions and time points) for selected outcome domains among studies *Number of 
unique time points per measure 
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Table 7.1. Characteristics of included studies (n = 268) 
 Number of studies (%) 
Study characteristics Therapy studies1 
(n =91) 
Prognosis1 studies 
(n =177) 
All  
(n = 268) 
Study design       
 Observational studies2  77 (85) 177 (100) 254 (95) 
 Randomised Trials   14 (15) 0 (0) 14 (5) 
Location    
 Asia 34 (37) 53 (30) 87 (33) 
 North America 21 (23) 62 (35) 83 (31) 
 Europe 28 (31) 49 (28) 77 (29) 
 South America 4 (4) 4 (2) 8 (3) 
 Africa 2 (2) 5 (3) 7 (2) 
 Oceania3 2 (2) 3 (2) 5 (2) 
 Multinational 0 (0) 1 (1) 1 (0) 
Year of publication     
 2011 20 (22) 26 (15) 46 (17) 
 2012 13 (14) 25 (14) 38 (14) 
 2013 16 (18) 20 (11) 36 (13) 
 2014 11 (12) 29 (16) 40 (15) 
 2015 18 (20)  41 (23) 59 (22) 
 2016 9 (10) 27 (15) 36 (13) 
 2017 4 (4) 9 (5) 13 (5) 
Number of participants4    
 0-50 33 (36) 39 (22) 72 (27) 
 51-100 19 (21) 32 (18) 51 (19) 
 101-1000 35 (38) 68 (38) 103 (38) 
 1000-100,000 4 (4) 37 (21) 41 (15) 
Follow up period (years)5    
 ≤1 81 (89)  61 (34) 136 (51) 
 1.1-5 7 (8) 43 (24) 50 (19) 
 5.1-10 2 (2) 44 (25) 46 (17) 
 >10 1 (1) 20 (11) 21 (8) 
Year of earliest donation6     
 1950-1969 1 (1) 11 (6) 12 (4) 
 1970-1989 0 (0) 23 (13) 23 (9) 
 1990-2009 66 (73) 93 (53) 159 (59) 
 2010+ 14 (15) 24 (14) 38 (14) 
1Therapy studies include questions of the outcomes of a treatment or exposure. Prognosis 
questions assess the progression of a disease or the likelihood of a disease occurring.25  
2Includes cohort, cross-sectional and case series  
3Includes Australasia (Australia/New Zealand and neighboring islands in Pacific Ocean, 
Melanesia, Micronesia and Polynesia  
4One study did not report number of participants   
5Fifteen studies did not report follow up. Categories based on mean/median for most studies.  
6The year of earliest donation was not reported in 36 studies   
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Table 7.2. Ten most frequently reported outcome domains 
Domains Therapy1 n = 91 (%) Prognosis1 n = 177 (%) All n = 268 (%) 
Kidney function 45 (49.5) 109 (61.6) 154 (57.5) 
Time to discharge 72 (79.1) 24 (13.6) 96 (35.8) 
Blood loss 66 (72.5) 19 (10.7) 85 (31.7) 
Operative time 62 (68.1) 17 (9.6) 79 (29.5) 
Blood pressure 5 (5.5) 69 (39.0) 74 (27.6) 
Pain 40 (44.0) 33 (18.6) 73 (27.2) 
Proteinuria, albuminuria 4 (4.4) 61 (34.5) 65 (24.3) 
Complication (ns) 45 (49.5) 17 (9.6) 62 (23.1) 
Postoperative complication (ns) 31 (34.1) 12 (6.8) 43 (16.0) 
Mortality 9 (9.1) 33 (18.6) 42 (15.7) 
NS = not specified  
1Therapy studies include questions of the outcomes of a treatment or exposure. Prognosis 
questions assess the progression of a disease or the likelihood of a disease occurring.25 
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Chapter 8: Discussion and Conclusions  
8.1 Summary of findings 
This thesis examined two aspects of living kidney donor transplantation – 
a) patients’, donors’ and nephrologists’ perspectives on different aspects of 
the pathway to living kidney donor transplantation; and b) outcomes for 
living kidney donors, with the overall aim of improving access and 
outcomes in living kidney donor transplantation. 
Specifically, this thesis addressed the following aims:  
1. to identify and describe the beliefs, attitudes and expectations of 
patients with CKD (stages 1-5) regarding living kidney donor 
transplantation (Chapter 3) 
2. to describe living kidney donors’ experiences of the evaluation 
process (Chapter 4) 
3. to ascertain nephrologists’ perspectives on barriers and disparities 
in living kidney donor transplantation (Chapter 5) 
4. to identify living kidney donors’ priorities for outcomes and describe 
the reasons for their choices (Chapter 6), and 
5. to determine the scope and heterogeneity of outcomes reported in 
randomised trials and observational studies in adult living kidney 
donors (Chapter 7). 
Both qualitative and quantitative methods were used to address these 
aims. A systematic review of qualitative studies, focus groups, and semi-
structured interviews was used in Chapters 3 to 5 to describe patients’, 
donors’ and nephrologists’ perspectives on different aspects of the donation 
pathway. In Chapter 6, a mixed-methods approach was used to identify 
and rank a range of outcomes important to donors (nominal group 
technique) and describe the reasons for their priorities (focus groups). 
Chapter 7 is a quantitative systematic review that assessed the scope, 
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consistency, and relevance of outcomes of living donation in recent trials 
and observational studies.  
The findings in the first part of this thesis identified a range of barriers 
and facilitators to receiving a living kidney donor transplantation, which 
may help to explain some of the disparities in access to living kidney 
donation. Several challenges experienced by donors throughout the 
evaluation process were also described. The second part of this thesis was 
focussed on understanding the range of outcomes that are important and 
relevant to living kidney donors, and determining the consistency and 
range of outcomes reported in recent studies. These two studies 
demonstrated some mismatch between the outcomes prioritised by donors, 
and those that are frequently reported in research. The findings from each 
study are integrated and discussed in this final chapter.  
The pathway to living kidney donor transplantation  
The socio-ecological model1, adapted from Bronfenbrenner’s ecological 
systems theory (1998) informed the aims of this thesis. This model 
examines the influence of personal values, family, extended social 
network, health care system, and cultural or societal values on health care 
decision-making and behaviour. The studies in this thesis predominately 
focused on the views of key stakeholders involved in living kidney donor 
transplantation – donors, recipients and clinicians. Other factors within 
this model have also been considered including the health care system and 
family and cultural values.   
Chapter 3: Patient perspectives 
The systematic review and thematic synthesis of qualitative studies 
(Chapter 3) described the perspectives of patients with CKD towards 
receiving a living kidney donation. Three facilitators were identified, 
including prioritising their own health, receiving validation of their 
decision and needing social support. Four themes described barriers 
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including guilt and responsibility, ambivalence and uncertainty, and a 
fear of directly asking someone to donate. Patients’ decisions about 
pursuing or accepting a donation involved a conflict between their 
desperation for improved health and quality of life, and their concerns 
about the donor’s vulnerability to physical harm, coercion and financial 
hardship. While living kidney donor transplantation offered them the best 
health outcomes, they expected to face difficult emotional consequences, 
including guilt, indebtedness to the donor and family conflict.  
Concerns about jeopardising the donor’s health, shortening their life and 
causing burdens and inconvenience, were insurmountable barriers for 
some patients, particularly older patients with younger potential donors. 
Patients were concerned about the risks of perioperative death, shortened 
life-expectancy, kidney failure and fertility and pregnancy complications 
for their donor. Other patients were able to overcome their ambivalence 
and found decisional validation through their confidence and trust in their 
transplant team to protect their donor from harm. Patients also felt they 
could justify accepting a donation from a family member, as they believed 
this would reduce the burdens on their family. Some felt they should 
respect their donor’s desire to donate.  
However, many patients felt unable to communicate and resolve their 
concerns due to receiving insufficient information and lacking emotional 
support. Discomfort and a lack of confidence with asking people to donate, 
and being unable to accept or understand their CKD diagnosis and need 
for transplantation, were also significant barriers to actively pursuing 
living kidney donation.  
Chapter 4: Donor perspectives 
The focus group study conducted in Australia and Canada (Chapter 4) 
identified six themes reflecting donors’ experiences of the evaluation 
process and donation pathway: emotional investment, undeterred by low 
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risks, mental preparation for the surgery and recovery, underlying fears 
for their health, system shortfalls and lifestyle intrusion.  
The emotional investment in giving their organs sustained donors’ 
commitment throughout the evaluation process, despite experiencing fears 
about health risks, encountering opposition from significant others, 
managing lifestyle disruptions and financial hardship, and difficulty 
accessing information and support. They were determined to improve the 
recipient’s health and their family life. However, their commitment to 
donating also prevented potential donors from disclosing their concerns 
and seeking support, for a fear of being deemed ineligible.  
Although post-donation risks were concerning to donors, they trusted their 
clinicians to protect them from harm. This view was also expressed by 
potential recipients in Chapter 3. However, some felt that their 
determination to donate had limited their ability to comprehend and 
process information about risks prior to donation. They described 
themselves as going into donation “blind”, ignoring information that 
contradicted with their decision to donate. This was particularly evident 
among non-directed donors, who felt confident they were in good health, 
and therefore deemed the risks of donation and complications of surgery to 
be overstated or irrelevant to them.  
Chapter 5: Clinician perspectives 
Nephrologists provided insight into the barriers and disparities that 
impact recipient eligibility and access to living kidney donor 
transplantation. The semi-structured interview study with clinicians 
(Chapter 5) identified five major themes. These included championing 
optimal recipient outcomes, justifying the donors sacrifice, advocating for 
their patients, maintaining professional boundaries, and entrenched 
inequities. Nephrologists’ decisions about recipient suitability for living 
kidney donor transplantation aimed to achieve optimal recipient 
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outcomes, but they felt constrained by competing priorities of ensuring 
reasonable utility of the transplant to justify the donors sacrifice, and 
protecting the integrity and reputation of the transplant program.  
Nephrologists struggled to resolve these conflicting priorities when faced 
with patients with medical, psychosocial and/or behavioural risk factors, 
but who might not be eligible for deceased donation due to the strict 
eligibility criteria for waitlisting. Specifically, variable views were 
expressed among nephrologists regarding whether to allow living donor 
transplants for patients who were older, highly sensitised, non-adherent, 
and those with low social support, mental health issues, comorbidities, 
and recurrent disease, because they were uncertain of achieving 
reasonable graft outcomes and being able to justify the donor’s sacrifice.  
Nephrologists described needing to be proactive in encouraging potential 
recipients to search for a donor, providing education and counselling, and 
facilitating assessments and referrals early, particularly to enable pre-
emptive transplantation (prior to dialysis). The clinicians recognised many 
of the concerns raised by patients in Chapter 3. However, they found it 
difficult to advocate for their patients because of limited psychosocial and 
educational resources available to them, and their perceived conflict of 
interest in actively helping their patients find a donor. They also 
emphasised that patients were accountable for ensuring that they were 
eligible for transplant (e.g. by demonstrating adherence).   
Chapters 3-5: Ethnic and socio-economic disparities  
The triangulation of donor, recipient and nephrologist perspectives 
provided greater understanding of disparities in living kidney donor 
transplantation. Nephrologists largely viewed inequities as entrenched, 
and felt powerless to facilitate access for their patients of ethnic minority 
backgrounds due to a lack of culturally-sensitive resources. These patients 
were deemed less likely to have a suitable donor because of a higher 
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incidence of obesity, cardiovascular disease, diabetes, high blood pressure, 
ESKD and smoking. Some believed that patients from ethnic minority 
groups were often “pre-judged” regarding their likelihood of finding a 
donor, and that socio-economically disadvantaged patients were likely to 
have a limited social network and thus a small potential donor pool, or 
their potential donors could not afford to take time off work to donate. 
Nephrologists also believed that the living donor transplant pathway 
inherently advantaged patients with the resources and skills to advocate 
for themselves, due to the difficulty of coordinating work up and referrals.  
In Chapter 5, nephrologists practising in Australia described their ethical 
responsibility to distance themselves from assisting potential recipients 
with donor recruitment to avoid a conflict of interest. However, this was 
found to be an important barrier for patients from ethnic minority groups, 
in Chapter 3. Patients described cultural values that created a reluctance 
to discuss donation with their family and social network, including the 
impropriety of discussing illness, rules of family hierarchy in identifying a 
potential donor, and unfamiliarity with living kidney donation among 
their community. Patients also mentioned some potential religious 
barriers; for example, the notion of bodily integrity (i.e. being buried 
whole), or concerns that interfaith or unrelated donation might be 
condemned by their religious community. Some patients described their 
culture as passive information seekers, and believed their family members 
would be unwilling to attend information sessions with them. In chapter 4, 
donors of ethnic minority background described opposition from their 
family and community regarding their decision to donate, also mentioning 
bodily integrity. 
Financial considerations were a barrier for donors and recipients 
(Chapters 3 and 4). Patients were reluctant to pursue living kidney donor 
transplantation because they did not want to cause financial burdens to 
the donor, including out-of-pocket expenses and career disruption. During 
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evaluation, donors described the significant and accumulating costs for 
transport, accommodation, and lost income, and struggled to access 
adequate financial assistance.  
Outcomes important to living donors and the relevance of 
outcomes reported in trials and observational studies 
The nominal groups held with donors from Australia and Canada 
identified the outcomes of donation that are most important to donors and 
their perspectives on a range of possible outcomes (Chapter 6).  The ten 
highest ranked donor outcomes were their kidney function (i.e. glomerular 
filtration rate or creatinine levels), followed by time to post-operative 
recovery, surgical complications, impact on family, donor-recipient 
relationship, life satisfaction, lifestyle restrictions, kidney failure, 
mortality and acute pain/discomfort. The themes underpinning their 
priorities included: unfulfilled expectations; heightened susceptibility; 
confidence and empowerment; downplaying risks and harms; and 
worthwhile sacrifice.  
From a range of possible and experienced outcomes associated with kidney 
donation, the outcomes that were most important to donors included 
kidney health, short-term surgical and functional outcomes, and 
psychosocial impacts. The long-term risks associated with nephrectomy, 
for example, mortality and cardiovascular disease, were of relatively lower 
priority. While some donors were concerned about their heightened 
susceptibility to kidney disease or a shortened life expectancy, most 
believed their clinicians had minimised long-term risks through the 
screening process, and they could prevent disease through a healthy 
lifestyle and maintaining their kidney function.  Kidney function was the 
highest ranked outcome, because of underlying fears of developing kidney 
failure in their remaining kidney, uncertainty regarding a ‘normal’ post-
nephrectomy glomerular filtration rate, and worry about avoiding 
nephrotoxic products.  
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Recent observational studies and trials (Chapter 7) in living kidney donors 
reported an extensive range of outcomes, which were mostly surrogate or 
biochemical parameters, and short-term clinical endpoints, with large 
heterogeneity in measures used to assess the outcomes. Therapy studies 
(i.e. RCTs and observational studies testing the effects of surgical and 
post-operative interventions) frequently reported short-term surgical 
outcomes (e.g. time to discharge, blood loss and operative time), and non-
specific complications. The three most frequently reported outcome 
domains in prognosis studies were all surrogate end-points (including 
kidney function, blood pressure and proteinuria/albuminuria). Important 
clinical and donor-reported outcomes including mortality, quality of life, 
cardiovascular events, and ESKD, were reported in less than 20% of 
prognosis studies. The review also demonstrated heterogeneity in outcome 
domains and measures across studies, with the 268 studies reporting 109 
different outcome domains. Surrogate and donor-reported outcome 
measures had greater heterogeneity of measures than clinical outcomes. 
ESKD, a clinical outcome, was reported in 18 different ways.  
There was a mismatch between the outcomes frequently studied, and 
those described as relevant and important to donors, in Chapter 6. Donor-
reported outcomes were included infrequently, limiting the relevance of 
these studies to help donors understand and prepare for their recovery, 
return to work, deal with the financial impact after donation and possible 
changes to their physical and psychological functioning after donation. 
Time to post-operative recovery was the most important outcome to 
donors; however, this is typically reported as time to discharge from the 
hospital. In the focus group study (Chapter 6), donors defined their 
recovery as their return to normal health in terms of their physical and 
emotional functioning, and resumption of their regular roles and 
activities. Also, some donors described experiencing fatigue, pain, and 
psychosocial problems for a few years after donation, and they believed 
they were not informed or adequately prepared for these outcomes, and 
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they were not addressed in follow-up care. These outcomes were rarely 
reported and only followed up in the short-term (for a maximum of twelve 
months in most studies). The positive psychosocial impacts of donation 
that donors experienced and valued (Chapter 6), which motivated their 
decision to donate (Chapter 4) were rarely reported. An awareness of these 
positive impacts also provided decisional-validation to potential recipients 
(Chapter 5), and nephrologists (Chapter 5).   
Mortality, ESKD and cardiovascular events were not measured beyond 25 
years after donation. Most donors did not expect to be at an increased risk 
of long-term health outcomes, and they believed that these risks had little 
influence on their decision to donate (Chapter 4). However, kidney failure 
and mortality were still of interest to some donors, particularly after 
donation, and motivated their participation in life-long self-care, including 
monitoring their kidney function (Chapter 6). Surrogate end-points such 
as kidney function and blood pressure were important and relevant to 
donors as they used these to monitor their health after donation (Chapter 
6). Other frequently measured surrogates, including proteinuria, 
albuminuria and body mass or composition, were also frequently 
measured but were not identified as highly important to donors in 
Chapter 6. 
8.2 Strengths and limitations  
The strengths and limitations of the studies are provided in more detail in 
the relevant chapters. This section will focus on the overall strengths and 
limitations of the thesis.  
This thesis is comprised of a systematic review of qualitative studies, a 
focus group study, a semi-structured interview study, a nominal group 
technique study, and a review of the scope and consistency of outcomes 
reported in recent research. The qualitative and quantitative methods 
used were complementary, and the qualitative methodologies enabled 
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stakeholders’ beliefs, attitudes, and priorities to be elicited. The 
systematic review and synthesis of qualitative studies on patients’ 
perspectives of living kidney donation pooled together existing evidence 
from different health care contexts and populations, and enabled the 
identification of knowledge gaps and the development of a new analytical 
framework to understand recipient perspectives on living kidney donor 
transplantation. The triangulation of different stakeholders’ perspectives 
generated a more comprehensive understanding of different aspects of the 
transplant pathway2. The studies sought to understand both barriers and 
facilitators to living kidney donor transplantation, and contextual 
understandings to develop implications for policy and practice.  
A multi-centre perspective was gained by recruiting donors from three 
centres cross Australia and Canada, and nephrologists from twenty-two 
centres in Australia and New Zealand. The quantitative component of the 
nominal group technique provided an understanding of donors’ relative 
priorities. The systematic review of trials and observational studies on 
donor outcomes enabled a comparison between donors’ priorities and the 
outcomes that are frequently reported.   
Across all the qualitative studies in this thesis there were limitations 
regarding the selection and inclusion of specific subgroups. Participating 
donors were all English-speaking, and mostly Anglo-Saxon, and had 
achieved a high level of education; although, this reflects the majority 
donor population in the included countries. Despite providing 
reimbursement to participants for travel costs, rural and remote donors 
are typically more difficult to recruit to focus group studies. All interviews 
and groups were conducted face-to-face, due to the difficulty of 
establishing rapport and managing the interview dynamic over telephone 
or Skype interviews. A purposive sampling strategy was used in each 
study to achieve a diverse sample. Data saturation was achieved in each 
study. The transferability of these findings to other settings beyond the 
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participating sites is uncertain. However, some complementary and 
similar findings to other studies conducted in other regions have been 
demonstrated, which suggest broader transferability of the results.  
Brazil, India, Mexico and Iran do high numbers of living kidney donor 
transplants, but publish very little data on donor outcomes.3 There were 
very few studies from these countries in our qualitative and quantitative 
systematic reviews.  
Qualitative methods were used to elicit a range and depth of beliefs, 
attitudes and perspectives. Across these studies, steps were taken to 
demonstrate rigour. The author was trained to conduct interviews, focus 
groups and nominal groups by an experienced qualitative researcher and 
supervisor. Across the fourteen groups there was a learning curve, such 
that the author’s skills with prompting elaboration and facilitating the 
direction of the discussion improved with experience. For example, donors 
were often focused on the recipient and would discuss their concern for 
recipient wellbeing more readily than their own outcomes.  A range of 
techniques was used (e.g. directing questions to individuals or shifting 
attention using eye contact and body language) to keep the discussion on 
topic and minimise undue individual dominance of the discussion and to 
encourage all members to contribute.4 Being present at all the focus 
groups, the author used the knowledge gained from previous groups to 
prompt wider or more detailed discussion in subsequent groups. Living 
kidney donors have been found to be reluctant to reflect negatively on 
their experience5, and may not feel comfortable expressing this to 
researchers. To encourage open discussion, time was spent building 
rapport with participants, and it was emphasised that the discussion was 
confidential and would be de-identified. The group format enabled 
participants to feel comfortable discussing the difficult and challenging 
experiences of donation, due to their shared experience. Donors whose 
recipient had died or experienced graft loss have been found to be difficult 
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to recruit to research, and only a few such donors were included in the 
studies.5 As for the clinician interviews, it was also challenging to ensure 
clinicians felt comfortable disclosing their personal attitudes and beliefs, 
particularly if they differed from the status quo or from the principles and 
approach of their unit.   
Qualitative researchers need to demonstrate the confirmability of their 
findings; i.e., that their interpretations reflect the participant’s 
perspective rather than the researcher’s predetermined ideas. Reflexivity 
is one such way that researchers can recognise any undue influences on 
their interpretations of the data.  
I was not involved in the assessment and clinical care of living kidney 
donors or recipients. However, the insights I had gained through my 
research, and my personal background may have influenced the 
information elicited during data collection and my interpretations adopted 
during analysis. To minimise this, multiple researchers were involved in 
the analysis (investigator triangulation) to ensure the findings and 
conclusions were directly linked to a participant’s data and captured the 
full range and depth of the data. Member checking was conducted for the 
clinician study, whereby participants were provided with feedback on the 
preliminary findings to ensure the range of opinions was captured. 
Inductive coding also ensured that the themes were developed from the 
data.   
8.3 Comparison with other studies 
The studies in this thesis provided new insights and addressed knowledge 
gaps in living kidney donor transplantation.  
Pathway to living kidney donor transplantation  
Patient perspectives 
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Surveys of transplant candidates’ attitudes towards living kidney donor 
transplantation have consistently found that concerns about graft failure, 
and about the future health of the donors are the most common barriers 
for patients.6-8 The qualitative systematic review reported in Chapter 3 
described recipients’ beliefs and attitudes that help explain these 
concerns. It is noted that potential recipients understood the risks to the 
donor to be low, but felt they were potentially catastrophic and therefore 
patients may prefer to wait for a deceased donor transplant. The 
possibility of graft failure or donor harm was expected to cause unbearable 
guilt, and patients expected that the donor may regret their decision. The 
conceptual schema depicts how recipients persevere with living kidney 
donor transplantation, despite their fears and concerns, through receiving 
emotional support, education and decisional validation.  
Reticence to initiate discussions with potential donors is one of the most 
frequently reported barriers among patients waitlisted for 
transplantation.6,9 Insufficient information about living donor outcomes, 
uncertainty about donor eligibility criteria, and doubt and discomfort 
about asking someone to donate prevented patients from considering 
living kidney donation further. The reluctance among potential recipients 
to ask someone to donate was multilayered, underpinned by a 
determination to avoid coercion, a preference for a donor to initiate the 
discussion, and a need to avoid the disappointment of rejection. Patients 
also lacked confidence in how to ask someone to donate.  
Previous studies have found that patients from minority ethnic 
backgrounds are less likely to initiate discussions with potential living 
donors than non-minority patients.9,10 In the systematic review in Chapter 
5, patients emphasised various cultural values which underpinned their 
reluctance to seek potential donors, including the impropriety of 
discussing illness, rules of family hierarchy, and suspected community 
unfamiliarity with living donation, perceiving it as “strange”. A sense of 
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medical urgency and desperation mobilised patients to initiate discussions 
with potential donors, but some did not accept or understand their 
diagnosis of CKD, or need for transplant. Previous studies suggest this 
may be more common among patients of ethnic minority backgrounds.9-13 
Patients may also feel uneasy about incorporating a living person’s kidney 
into their own body. This may be due to concerns about how transplanted 
organs can influence their recipients’ personality and thoughts.14   
Donor perspectives 
In previous studies, donors have described being highly motivated to 
donate, and attempted to manage how they are perceived during the 
psychosocial evaluation, to protect their eligibility.15 Other studies have 
reported that both directed and non-directed donors feel anxious about 
undergoing psychosocial assessment due to their determination to donate, 
and some are reluctant to disclose experiences that might exclude them 
from donating.15-17 Uncertainty about their eligibility status whilst 
waiting for test results, long delays, and navigating an unfamiliar 
healthcare system, has been identified as a considerable source of 
emotional strain during evaluation.18-20 In addition to confirming these 
previous findings, the focus group study in Chapter 4 illuminated this 
concept of emotional investment that underpins donor perseverance 
despite the challenges of assessment, and an intense need to protect their 
eligibility.  
Surveys have shown that donors have a higher acceptance of risks of 
mortality, kidney disease, hypertension, cardiovascular disease and 
hypertension, compared to transplant recipients and transplant 
professionals.21,22 This study provides some potential explanations for the 
higher acceptance of risk among donors. Donors felt invincible, trusted 
transplant professionals to protect them from harm, normalised surgical 
risks, and believed that it would be reprehensible to deny the recipient the 
opportunity for live-saving and life-improving transplant based on a 
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minimal and theoretical risk to the donor. While donors have previously 
been found to be accepting of risks to themselves23, some donors conveyed 
concern for health risks and uncertainty regarding long-term outcomes 
(Chapter 4). The findings in Chapter 6 suggest that, for many donors, 
concerns about health risks may arise or become more prominent after 
donation. Underlying concerns about long-term health risks have been 
found to be a strong motivator for donor participation in follow-up care 
with their general practitioner or transplant unit.24 Mild anxiety about 
developing kidney failure was found to be common among people who have 
donated a kidney.25 However, many donors continue to be unconcerned by 
health risks and lack a patient or ‘sick’ identity after donation, and regard 
follow-up care as unnecessary.24  
Nephrologist perspectives 
Nephrologists’ perspectives on recipient eligibility and access to living 
kidney donor transplantation had not been comprehensively studied. A 
number of studies have shown that nephrologists may have inherent 
biases or assumptions regarding a transplant candidate’s expected 
survival, motivation, adherence and chances of finding a donor.26,27 26 
These attitudes may result in subconscious differences in the way 
nephrologists make decisions and discuss transplantation options with 
patients of ethnic minority backgrounds or socio-economic disadvantage. 
The hypothesis that ethnic and socio-economic disparities are largely 
caused by a limited donor pool is prevalent in the literature, but evidence 
is based on single-centre studies.13,28-30 These beliefs were also held by 
some nephrologists in this study (Chapter 6), who expressed a reluctance 
to unnecessarily raise the expectations of patients when they felt it was 
unlikely they would find a suitable donor.   
Nephrologists also believed that there were centre factors that influence 
access to living kidney donor transplantation. Epidemiological studies 
have found that a patient’s chance of receiving a living donor kidney 
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transplantation is higher if they are treated at a centre that has a higher 
annual volume of transplants overall, a higher volume and percentage of 
living kidney donor transplantation, and longer waiting times for deceased 
donor transplantation.31-35 Transplant centres with a higher-volume of 
living kidney donor transplantation performed a higher proportion of 
donations from unrelated donors, and they offered programs to overcome 
biological incompatibility.32-34 The nephrologists in this study did not refer 
to these factors, but felt they depended on education, timely referrals, 
streamlining of evaluations, and effective communication between the 
independent donor and recipient physicians. Nephrologists believed that 
their patients often became “lost in the system”, and discussion about 
living kidney donation and referrals for pre-emptive transplantation were 
often delayed because of competing responsibilities. In addition, they 
reiterated that the transplant team had to build a strong culture of living 
kidney donation by promoting this option positively, encouraging their 
patients to find potential donors and building trust and confidence in the 
transplant team.  
Donor outcomes  
Donors’ perspectives on a range of post-donation outcomes were explicitly 
and systematically studied, and these outcomes were compared to those 
that have been measured in recent trials and observational studies 
(Chapters 6 and 7). Previous qualitative studies of donors motivations’ and 
their experiences of donation have suggested that donors value highly the 
psychosocial benefits of donation.23 Post-donation problems including 
fatigue, pain, anxiety about their kidney function and difficulties in their 
relationship with the recipient have been described in qualitative 
studies.23 Surveys suggest that only a minority of donors (5-25%) report 
negative psychosocial and physical outcomes5,36-38, yet, these were among 
the highest ranked outcomes for donors. Improvements in family life and 
emotional wellbeing were rated highly because they were the things that 
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many donors benefited from the most, personally. Others ranked negative 
psychosocial and functional outcomes highly as they felt they were 
unrecognised by transplant professionals and inadequately addressed in 
follow-up care. 
Surrogate outcomes are frequently measured because they are easier to 
collect and detect short-term changes, but offer limited information to 
inform decision-making as they may not be valid predictors of clinical 
outcomes.39 Recent studies have shown that equations for estimating 
glomerular filtration rate (GFR) underestimate kidney function in living 
donors.40-42 Kidney function was most frequently measured by estimated 
GFR. The nominal group study found that donors were focused on their 
GFR, and wanted some clarity whether their level of function was normal. 
A recent qualitative study found that kidney function and blood pressure 
may be important outcomes to donors, as they allow donors to monitor 
their health after donation, and provide reassurance about their health.24 
Therefore, some well-known surrogates may be meaningful to patients, 
despite providing limited information about long-term clinical outcomes. 
However, it was also found that donor outcomes are reported 
heterogeneously across studies. This has proved difficult to combine and 
compare data on donor outcomes across studies, and thus limits the 
reliability and certainty of evidence available donors to help with decision-
making.5,43-49   
8.4 Implications for clinical practice and policy 
Major innovations in transplantation policy and practice have improved 
access and outcomes in living kidney donor transplantation; however, 
numbers have decreased in recent years and ethnic and socio-economic 
disparities are apparent.50 Overall, the studies in this thesis identified 
limitations of current guidelines, education, informed consent, pre-
transplant psychosocial support and long-term follow up care (Figure 8.1). 
Addressing these could lead to more equitable access to living kidney 
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donor transplantation, improved satisfaction with the donation process 
and improved wellbeing for donor-recipient pairs.  
Improving access to living kidney donor transplantation and the 
donation pathway  
The fulfilment of living kidney donor transplantation is a complex process, 
influenced by individual, familial, social, ethical, societal and health care 
centre and system aspects.31 In the qualitative systematic review (Chapter 
3), potential recipients described the inherent psychosocial and ethical 
challenges implicated in asking another person to accept risks on their 
behalf, as well as coping with guilt, responsibility, indebtedness and 
family resistance. Uncertainties about living kidney donor outcomes, and 
asking someone to donate, were major obstacles for potential recipients. 
Therefore, this study identified the need for specific pre-transplant 
education, psychosocial support and counselling for patients that 
addresses: 
 guilt, ambivalence, decisional-conflict and interpersonal problems 
 engaging in discussions with potential donors  
 potential risks and outcomes for donors 
 acceptance and understanding of their diagnosis 
 benefits of pre-emptive transplantation, and 
 cultural values and family opposition. 
Few psychosocial interventions have been assessed in the pre-transplant 
setting. A RCT found some promising results with quality of life therapy, 
which aims to identify specific areas of patient dissatisfaction and 
problem-solving strategies.51 The intervention resulted in improved 
quality of life and psychological functioning for patients awaiting 
transplantation. The findings in Chapter 3 indicated that recipients 
choose not to discuss their concerns with their family or potential donor, 
for example, that they will feel eternally indebted to the donor, or the 
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donor will try to ‘control’ them. This highlights the need for mediated 
communication between patients, their family and potential donors to 
resolve interpersonal issues. This could also help facilitate family support, 
provide decisional validation and reassurance.  
There have been efforts to develop and evaluate interventions to support 
patients in identifying potential donors. The Talking about Living Kidney 
Donation Educational and Social Worker intervention encourages patients 
to identify and resolve self-identified barriers to discussing and pursuing 
pre-emptive living kidney donor transplantation.57,60 This intervention 
increased discussions about living kidney donation with family and 
clinicians, and the identification of potential donors.52,53 Indirect 
discussions about donation in this type of intervention, rather than direct 
requests to donate, may be effective for donor recruitment54, and could 
alleviate patients’ concerns about disrespecting or pressuring potential 
donors. Model conversations52 and role-playing exercises could be offered 
to potential recipients to help them make donation requests, directly. It is 
recommended that patients be provided with access to counselling to cope 
with the disappointment of refusal to donate and to develop resilience for 
making subsequent requests. 
Pre-transplant education about donor outcomes may be somewhat 
overlooked for recipients. Evidence-based information about the potential 
risks and benefits should be communicated to patients.  Informing 
patients about efforts to safeguard donors, such as the use of independent 
donor advocates, reimbursement schemes, psychological evaluation, and 
rigorous donor acceptance criteria, may provide reassurance to patients.  
Family-oriented education may be particularly effective for culturally and 
linguistic diverse patients to facilitate social support, improve 
comprehension of information and address family ambivalence.52,53 A 
randomised controlled trial found that a culturally-sensitive home-based 
family education  program improved patients’ knowledge and willingness 
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to discuss living kidney donation, decreased patients’ concerns, and led to 
increased donor inquiries, completed evaluations and actual living kidney 
donation rates.55,56  
The nephrologist interview study (Chapter 5) primarily identified the need 
to ensure nephrologists make more explicit and informed decisions 
concerning recipient eligibility for living kidney donor transplantation. 
Additionally, improved resources to address patient barriers are required. 
Therefore, the main recommendations from this study included: 
 improving consensus and standardised practice regarding 
candidates with complex medical or psychosocial issues 
 developing an explicit pathway for patient education and referral to 
transplant services 
 using evidence-based guidance for addressing psychosocial risk 
factors, including non-adherence, depression and low social 
support18,39,40 
 ensuring transparency of centre performance and policies 
 educating patients with a limited donor pool about options such as 
ABO incompatible transplantation, paired exchange and unrelated 
donation34 
 providing culturally competent educational and psychosocial 
resources to facilitate shared decision-making and address barriers, 
and 
 clarifying the responsibilities and boundaries of nephrologists in 
the role of caring for potential recipients.  
There is limited research evaluating and implementing interventions to 
address psychosocial barriers to living kidney donor transplantation.57,58 
Promising interventions to help patients through the pathway to living 
donor transplantation include a social worker consultation to identify and 
address individual patient barriers52, peer support to navigate referral 
and assessment processes59, and culturally-sensitive home education.56 
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Training to improve interactions with interpreters might alleviate 
nephrologists’ uncertainties during shared decision-making with non-
English speaking patients.60,61  
Nephrologists distanced themselves from assisting candidates with donor 
recruitment to avoid a conflict of interest. Some transplant nephrologists 
also felt they were more “passive” in promoting living donation to patients, 
because they wanted to protect donors from coercion and unnecessary risk. 
This may prevent patients from receiving adequate information and 
counselling regarding living kidney donor transplantation. Therefore, 
separation of the donor and recipient teams or clinicians is imperative. 
Moreover, the responsibilities and boundaries of nephrologists 
representing the recipient, in supporting and facilitating donor education 
and recruitment, require clarification. With mechanisms protecting the 
donor from coercion, nephrologists may feel more comfortable in providing 
advice to their recipients about donor recruitment.  
Strategies are also needed to resolve the tensions nephrologists felt 
between advocating for their patients and protecting the reputation of 
their transplant program. Trends of risk avoidance for patients with less 
certain graft outcomes have been observed in the United States.40,41 This 
study supports recommendations that both patient outcomes (graft and 
patient survival) and transplant volume be regarded as equally important 
in evaluations of centre performance, to ensure that efforts to protect 
outcomes are not maintained at the expense of expanding access to 
transplantation.62 Patients should also be informed about the considerable 
variability among kidney transplant centres in terms of patient outcomes, 
unit policy, expertise and resources such as ABO incompatible 
transplantation. However, many patients are unable to choose a different 
centre due to financial and geographical constraints.63-65  
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The focus groups with living donors (Chapter 4) demonstrated that more 
attention is needed to address the psychosocial challenges of live donor 
evaluation. This includes:  
 identifying and addressing fears/concerns and psychosocial issues 
(e.g. fears of surgery, social support, family conflict, donor-recipient 
relationship problems and coping with possibility of graft failure) 
 mitigating the anxiety of testing (e.g. possibility of being ruled out) 
 minimising financial burdens and lifestyle interference, and 
improving efficiencies in the evaluation process 
 preparing potential donors for surgery and recovery (individualised 
to donor’s preferences) 
 improving comprehension of risk, and 
 clarifying donors’ responsibilities in driving the evaluation process. 
Since 2007, the Organ Procurement and Transplant Network in the 
United States has required an independent living donor advocate to assist 
with informed consent by providing education, support and advocacy to 
potential donors.66 An independent live donor advocate, social worker or 
patient navigator could facilitate more comprehensive support throughout 
evaluation by addressing donors’ needs and concerns as they emerge, 
limiting lifestyle intrusion, assessing risk comprehension, and providing 
culturally-sensitive interventions to address family conflict. It is worth 
noting that a reluctance to burden and intrude on the life of others was a 
strong deterrent for patients considering living kidney donation. 
Therefore, limiting the burdens of evaluation may encourage both donors 
and recipients to be more accepting of living kidney donor transplantation.    
Current practice in living kidney donation may prevent many donors from 
openly discussing their fears, concerns and uncertainties. Guidelines  
focus on ensuring psychological suitability, motivation and voluntariness, 
and informing donors of possible outcomes67,68, rather than providing 
evidence-based strategies to address these issues. Caution to detect 
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coercion and assess risk comprehension can cause donors to feel 
scrutinised and become reluctant to express their anxieties. Therefore, it 
is recommended that a component of the psychosocial evaluation be 
framed as an opportunity to communicate and resolve concerns without 
feeling under threat of jeopardising their eligibility. Similarly, deliberately 
delaying the evaluation process and requiring donors to drive progress of 
their assessments to ensure donors are motivated can exacerbate delays, 
burdens and uncertainty. These cautionary measures may be practised 
more often or intensely in the case of non-directed donation. Overall, 
greater transparency regarding the purpose and process of donor 
evaluation could resolve uncertainties, confusion and stress during donor 
evaluation. 
Improving understanding and treatment of living donor outcomes  
Living kidney donor candidates accept a range of risks and benefits when 
they decide to proceed with nephrectomy. Informed consent around this 
decision assumes they receive reliable data about outcomes they regard as 
critical to their decision. The nominal group technique study provided a 
framework to ensure that the outcomes most relevant to donors are 
consistently included in education, informed consent, assessment and 
follow-up care. The main recommendations from these studies include: 
 improving donor education on long-term outcomes and information 
about outcomes important to the individual 
 assessing and addressing donor-important outcomes during follow-
up, and 
 keeping donors updated on emerging evidence on donor outcomes 
and providing advice on protective lifestyle behaviours. 
These findings emphasise the importance of identifying donors’ priorities 
and concerns during the informed consent process, and being cognisant of 
the donor’s confidence in the transplant process such that they may 
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readily accept or disregard long-term health risks.  The recently published  
Kidney Disease Improving Global Outcomes (KDIGO) guidelines 
recommend informing donors of individualised risks, benefits including 
medical, surgical psychosocial and economic outcomes during the 
perioperative period and the remaining lifespan of the donor.69 The 
guidelines suggest communicating absolute risks, and disclosing 
uncertainty in long-term outcomes.69 However, the donor’s strong 
motivations and confidence in their safety pose additional barriers to 
comprehending risk information prior to donation.15,21,22 Donors may also 
be overwhelmed by information.15 It remains unclear how to tailor 
education to  donors’ varying stages of readiness, learning preferences and 
health literacy to improve recall and comprehension.70,71 Therefore, 
continued education about donor outcomes and emerging evidence is 
critical after donation.  
The assessment of donor-reported outcomes can provide information to 
help prepare donors for a range of outcomes they may experience and care 
about, and enable follow-up care to be individualised to the donor’s 
needs.72 The Organ Procurement Transplant Network (OPTN) mandates 
the collection of data on a range of post-donation outcomes for two years 
after donation, including two psychosocial outcomes – employment status 
and loss of insurance. A broader scope of psychosocial and functional 
outcomes should be assessed in follow-up. For example, a validated longer-
term measure of recovery is needed, that captures donors’ full recovery.   
Kidney function was the most important outcome to donors, as monitoring 
their kidney function could provide reassurance that they are not at risk 
of kidney failure. However, there was some uncertainty whether their 
GFR was at a normal level, given that they only had one kidney. 
Equations for estimating GFR underestimate kidney function in living 
kidney donors, and are less precise than measured GFR.40-42 The recent 
KDIGO guidelines recommending routine assessment of both estimated 
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GFR and serum creatinine during donor follow-up care.69 This should be 
explained and emphasised to donors during follow up and may provide 
greater reassurance about their kidney health and reduce anxieties about 
their vulnerability to kidney disease.   
 
Figure 8.1: Summary of the recommendations derived from this thesis 
8.5 Implications for research  
The studies in this thesis identified several recommendations for 
increasing access to living kidney donor transplantation, and improving 
the donation process. There are some important research gaps that were 
not addressed in this thesis, and additional research questions were 
identified from these studies.  
Improving the pathway to living kidney donor transplantation  
Patients and donors from various ethnic minority groups should be 
studied to develop a better understanding of cultural barriers, and inform 
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educational resources about living kidney donation specifically targeted to 
Hispanic patients and their families.73,74 There is limited evidence 
available to inform culturally sensitive interventions in Australia where 
about 30% of the population was born overseas. Further research is also 
needed to study:  
 the perspectives of patients of low socio-economic backgrounds so 
as to understand financial barriers  
 recipient perspectives on pre-emptive transplantation and non-
directed donation 
 the experiences of non-directed donors during evaluation and their 
perspectives of risk  
 the perspectives of donors who opt-out of donation during or prior 
to evaluation, as the barriers they experience may be different to 
those described included in the focus group study75 
 the perspectives of surgeons, transplant coordinators, psychiatrists 
and allied health professionals, as they may have different 
perspectives on barriers and challenges along the pathway to living 
kidney donor transplantation, including informed consent, 
education and psychosocial assessment, and 
 the perspectives of nephrologists practising in low-income countries 
and health care contexts with different regulations and policies for 
living kidney donor transplantation. 
Additional research questions have been developed from the findings of 
this thesis, including:  
 conducting a survey of practices and policies for living kidney donor 
transplantation across transplant units 
 conducting a survey to assess the frequency of opinions among 
nephrologists to enable comparison across transplant professionals 
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 conducting a longitudinal study of donors changing priorities for 
outcomes over time (e.g. prior to donation, in the perioperative 
period and short-term and long-term follow up) 
 developing and evaluating interventions to improve informed 
consent, psychosocial support and education (including culturally-
competent interventions), and 
 developing validated screening tools to assess psychosocial and 
functional outcomes during evaluation and after kidney 
donation/transplantation.  
Outcomes of living kidney donor transplantation  
Improved reporting and measurement of donor-relevant and clinical 
outcomes would ultimately lead to better informed consent practices and 
evidence-based decision-making in living kidney donation. Heterogeneity 
in outcome measurement has stifled efforts to pool data across studies.5,36-
38 This makes it difficult to provide donors with reliable data on the 
outcomes that matter to them. It is increasingly argued that clinical trials 
should include patient-centred outcomes; standard measures for global, 
physical, mental and social health are being developed.76 To facilitate 
routine collection by transplant centres, researchers, and registries, these 
measures must also be feasible to measure in large prospective studies 
and registries, which may be particularly challenging for self-reported 
outcomes.77 Generic outcome measures like the SF-36 are frequently used 
and reported in studies, but provide limited meaningful information to 
donors and may not capture donation-specific psychosocial experiences e.g. 
conflict in the donor-recipient relationship. At a minimum, researchers 
should include meaningful outcomes that are of critical significance to 
donors, in addition to the outcomes intended to be studied.  
Time to recovery was the second most important outcome to donors, yet is 
infrequently reported in short and long-term studies on the outcomes of 
donation. Time to discharge was the most frequently reported outcome in 
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therapy studies, which is routinely collected and easily obtained from 
administrative data. This measure provides limited information to inform 
donors’ expectations of surgical recovery – which, donors defined as the 
return to “normal” health in terms of their physical and emotional 
functioning, and resumption of their regular roles and activities. A 
patient-reported outcome measure is needed that captures their concept of 
recovery and allowing for long-term assessment. A brief post-operative 
recovery index (PORI) self-report instrument has been developed, that 
assesses the quality of recovery across domains, including psychological, 
physical activity, general symptoms, bowel symptoms and appetite 
symptoms.78 However, this would need to be adapted and validated for 
longer-term assessment (i.e. beyond 30 days) and include participation in 
the patient’s regular roles and activities. This may provide more useful 
data to better prepare donors for their recovery and understand their 
needs after donation. 
Donor outcomes are central to the decisions of nephrologists and potential 
recipients and their acceptance of living kidney donor transplantation. As 
strategies to collect long-term data on donor outcomes are improved, 
involving donor registries, it is critical that the outcomes reported are 
useful to all stakeholders, and measured in a more consistent way. 
Therefore, this study should lead to further work to identify standardised 
outcome measures which are meaningful and relevant to all stakeholders, 
including recipients, donors and clinicians.79,80 
8.6 Conclusion  
In conclusion, the studies that form this body of work provide a 
comprehensive and in-depth understanding of the perspectives and 
experiences of key stakeholders involved in living kidney donor 
transplantation. These studies highlight the inherent psychological, 
cultural and social implications of living kidney donor transplantation, 
and the importance of identifying and developing interventions to address 
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these issues. The findings also highlight the need for culturally sensitive, 
family-oriented, educational and psychosocial support to resolve recipient 
ambivalence and help patients find an acceptable approach to engaging in 
discussions with potential donors. There is a need for greater consensus 
and standardised practice regarding complex medical psychosocial 
transplant candidates, and greater transparency on the part of centre 
practices. The psychosocial challenges of live donor evaluation must be 
addressed, including efforts to ensure donors can express their fears and 
concerns and adequately prepare for donation. Understanding of the risks 
and benefits of undergoing living kidney donation was shown to be central 
to the decisions of donors, recipients and nephrologists. Improved 
reporting and measurement of donor-relevant and long-term clinical 
outcomes could lead to better informed consent practices and evidence-
based decision-making in living kidney donation. Overall, the 
acknowledgement of stakeholder perspectives in guidelines, education, 
research and practice could ensure equitable decision-making, alleviate 
barriers and disparities, and improve satisfaction and outcomes for 
recipients and their donors. 
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APPENDICES  
 
Appendix A: Supporting data for Chapter 3  
A.1. Search strategy  
OVID Medline 1948 - 19th February 2013 
exp Adult/ or exp Young Adult/ 
exp Patients/ 
exp Renal Insufficiency/ 
exp Renal Dialysis/ or exp Dialysis/ 
exp Peritoneal Dialysis/ 
exp Peritoneal Dialysis, Continuous Ambulatory/ 
(haemodialysis or hemodialysis).tw. 
peritoneal dialysis.tw. 
exp Kidney Transplantation/ 
kidney transplant recipient$.tw. 
exp "Quality of Life"/ 
exp Psychology, Social/ 
exp Adaptation, Psychological/ 
exp Stress, Psychological/ 
exp Depression/ 
anxiety/ 
mental health/ 
social support/ 
social adjustment/ 
communication/ 
emotions/ 
interpersonal relations/ 
satisfaction/ 
family/ 
exp Marriage/ 
Life Change Events/ 
exp Qualitative Research/ 
qualitative.tw. 
interview$.tw. 
focus group$.tw. 
exp Living Donors/ 
(live donor$ or living donor$ or live donation or living donation).tw. 
(liv$ adj kidney).tw. 
 
Embase 1996 - 18th February 2013 
1996 - 18th February 2013 
adult/ 
exp patient/ or exp chronic patient/ 
exp chronic kidney failure/ 
exp dialysis/ 
exp peritoneal dialysis/ 
exp continuous ambulatory peritoneal dialysis/ 
(haemodialysis or hemodialysis).tw. 
peritoneal dialysis.tw. 
exp graft recipient/ or exp kidney transplantation/ 
kidney transplant recipient$.tw. 
"quality of life"/ 
social psychology/ 
adaptation/ or adaptive behavior/ 
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mental stress/ 
depression/ 
anxiety/ 
mental health/ 
social aspect/ or social support/ 
self-esteem/ 
interpersonal communication/ 
patient satisfaction/ 
marriage/ or family/ 
lifestyle/ or lifestyle modification/ 
life event/ 
decision making/ 
qualitative.tw. 
interview$.tw. 
focus group$.tw. 
exp living donor/ 
(live donor$ or living donor$ or live donation or living donation).tw. 
(liv$ adj kidney).tw. 
 
PsycINFO 1809 - 13th February 2013 
exp Kidney Diseases/ 
exp Dialysis/ 
(haemodialysis or haemodialysis).tw 
peritoneal dialysis.tw 
kidney transplantation.tw. 
kidney transplant recipient$.tw. 
exp “Quality of Life”/ 
qualitative$.tw. 
(interview$ or focus group$). tw 
 
CINAHL 1959 to Week 3 2011 
TX chronic kidney disease OR TX dialysis OR TX transplantation 
Qualitative research (clinical queries – best balance) 
TX living donor OR live donor OR living donation 
TX live kidney OR living kidney
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Appendix B: Supporting data for Chapter 4  
B.1. Focus group question guide 
Questions We would first like you to think about your experiences 
leading up to the donation:  
1.  What were the factors that made it easier for you to donate and 
complete the evaluation process? (Information, education, 
psychosocial and financial support, family support).  
2.  Were there any barriers or challenges that you had to overcome? 
How did you overcome them? (Risk information, fears and concerns, 
eligibility, family opposition, religious and cultural values) 
3.  Did you have any concerns about outcomes of donation for yourself? 
(Medical, lifestyle, psychological, social financial) What helped you 
to donate, despite your concerns? 
4.  What were your experiences of the informed consent process? What 
did you think were the goals of informed consent? How effective was 
this process?  
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Appendix C: Supporting data for Chapter 5 
C.1. Interview guide 
Introduction 
Briefly, could you describe your role in transplantation?  
Beliefs about living kidney donation  
What are 2-3 things that you personally consider to be the main benefits of living kidney 
donor transplantation? Do you have any concerns about any aspect of living kidney donor 
transplantation?  
Compared to your colleagues, would you describe yourself as being more liberal, or 
conservative, with regards to recipient eligibility for living kidney donor transplantation? 
Why?   
In terms of a patient’s eligibility for living kidney donor transplantation, are there any 
additional or different considerations compared with deceased donor transplantation – 
why?  
Do you think the proportion or number of kidney transplants from living donors should 
be higher or lower on a national level? 
To what extent do you think that living donor transplantation needs ‘promotion’ in 
Australia?  
Barriers and disparities in living kidney donation (patient, clinician, centre 
factors)  
What do you believe are the main barriers to a patient receiving a living kidney donor 
transplant?  
Do you believe there are any disparities in access to kidney transplantation in Australia 
– why?  
Do you think that any factors relating to the specific nephrologist a patient sees might 
impact upon their likelihood of considering living kidney donor transplantation?  
Can you speculate why some Australian transplant centres have higher rates of living 
kidney donor transplantation than others?  
Suggestions for policy and practice 
Do you have any suggestions for changes to policy or practice to: 
Address barriers and disparities? 
Increase access to living kidney donation? 
Improve discussion and patient education around living kidney donor transplantation?  
Close 
Do you have any other thoughts about living kidney donation that you would like to add?  
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Appendix D: Supporting data for Chapter 6 
D.1. Individual ranking of all outcomes 
Rank 
Position 
Outcome Importance 
score 
N groups 
listing 
outcome 
N donors 
ranking 
outcome 
Rank 
position 
Australia 
Importance 
score 
Australia 
Rank 
position 
Canada 
Importance 
score 
Canada 
1 Kidney function 0.40 14 120 4 0.26 1 0.57 
2 Time to recovery 0.27 14 115 2 0.34 5 0.19 
3 Surgical complications 0.24 14 120 6 0.20 2 0.29 
4 Impact on family 0.22 11 87 1 0.35 19 0.07 
5 Donor-recipient 
relationship 
0.21 14 112 3 0.27 8 0.15 
6 Life satisfaction 0.18 13 102 7 0.17 4 0.20 
7 Lifestyle restrictions 0.18 12 97 5 0.21 6 0.15 
8 Kidney failure 0.14 10 81 19 0.07 3 0.22 
9 Mortality/survival 0.13 12 97 11 0.12 7 0.15 
10 Acute pain/discomfort 0.12 12 99 9 0.15 16 0.10 
11 Blood pressure 0.12 14 111 13 0.11 9 0.14 
12 Physical function 0.12 9 83 8 0.16 18 0.08 
13 Surgical mortality 0.11 13 101 12 0.12 14 0.10 
14 Fatigue 0.11 12 94 18 0.08 10 0.14 
15 Diabetes 0.10 13 107 15 0.09 11 0.12 
16 Financial impact 0.10 14 107 10 0.13 20 0.07 
17 Cardiovascular disease 0.20 14 112 14 0.09 13 0.10 
18 Depression 0.09 12 94 16 0.09 15 0.10 
19 Anxiety 0.09 13 91 17 0.09 17 0.09 
20 Chronic pain/discomfort 0.08 11 84 22 0.06 12 0.11 
21 Pregnancy 0.06 14 97 23 0.06 21 0.06 
22 Weight 0.05 9 64 25 0.05 22 0.05 
23 Caregiver responsibilities 0.05 3 27 21 0.09 23 0.03 
24 Cholesterol 0.04 5 45 20 0.07 28 0.00 
25 Fertility 0.03 7 58 24 0.06 - - 
26 Career impact 0.02 3 27 32 0.02 24 0.03 
27 Insurance 0.02 4 35 26 0.04 - - 
28 Gout 0.02 5 43 27 0.03 - - 
29 Self-esteem/body image 0.02 3 24 28 0.03 - - 
30 Anaemia 0.02 1 15 29 0.03 - - 
31 Bone issues 0.02 4 31 30 0.03 - - 
32 Intimacy/sex drive 0.01 2 19 31 0.02 - - 
33 Kidney stones 0.01 1 7 - - 25 0.02 
34 Urinary tract infection 0.01 1 7 - - 26 0.01 
35 Length of stay 0.01 1 8 - - 27 0.01 
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D.2. Location and number of participants in each nominal group 
Group ID City Participants (n = 123) 
1 Melbourne 7 
2 Melbourne 9 
3 Melbourne 9 
4 Melbourne 10 
5 Sydney 5 
6 Sydney 10 
7 Sydney 8 
8 Sydney 9 
9 Vancouver 12 
10 Vancouver 9 
11 Vancouver 11 
12 Vancouver 9 
13 Vancouver 9 
14 Vancouver 6 
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D.3. Focus group run sheet 
Time Details Notes 
 
Phase 1 – Welcome and introductions, ice-breaker and objectives  
 
10mins Welcome 
Good [morning/afternoon] everyone. Thank you for attending this focus group to 
discuss your experiences and perspectives of living kidney donation. My name is 
______ from the University of Sydney.  
Introduction 
We have invited you here because you have experience with living kidney 
donation.  For this session, we would like you to reflect on your experiences after 
living kidney donation. This will help us to understand how donating a kidney 
has impacted on you, and what aspects of your experience may be more 
important, and those that may be less important to you. We want you to share 
insights from your own personal experiences and we encourage you to listen and 
consider other members’ views, and engage in a conversation with each other. 
The goal of this session is to identify outcomes that are important to you, and to 
understand the reasons why they are important to you. We want future research 
to focus on outcomes that are most important to you, as well as information and 
support that is provided to donors. 
Confidentiality and voluntary participation 
What you tell us will be recorded but will be kept confidential. Nothing you say 
will be traced back to you or your name. Also, what you say will not impact the 
level or type of care you receive. Please note that we are unable to provide clinical 
advice about your health. You are free to leave at any time without providing a 
reason. We would also appreciate it if you could please keep this discussion 
confidential, to respect the other members in the group.  
Ice breaker  
To get to know you a bit better, could you introduce yourself by telling us: 
a) Your name 
b) The first thing that comes to your mind when I say “kidney donor” 
 
 Phase 2 – Focus group discussion 
 
30 mins Experiences/impact of living donation  
We would now like to invite you to share your ideas and experiences of donating a 
kidney: 
 Has donating a kidney impacted on your life - in what ways?  
 Did anything happen to you after kidney donation that was unexpected? 
 What outcomes are most challenging to deal with - why and how do you 
cope with it? 
 
 Phase 3 – Nominal group Technique (Part 1) 
(40 minutes)  
40 mins Now we are going to have a more focused discussion and an activity to find out 
what outcomes of kidney donation matter to you most and why. 
Let me give you a bit of context. There are a variety of outcomes that might be 
experienced by kidney donors. That is, anything that arises or changes, directly 
as a result of donating a kidney, be it a positive or negative impact. There are 
research studies being conducted worldwide that are looking to determine the 
impacts of donating a kidney. For example, they might look at whether kidney 
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donation impacts on the long-term kidney function of donors. We want to know 
what outcomes matter most to you, so that we can ensure that research focuses 
on those outcomes.  
I am going to ask you a question and get you to write down three ideas: What 
outcomes do you suggest that researchers should include in their study, if they are 
looking to explore the impact of donating a kidney? 
Please write down your 3 ideas now and then we will share them with each other. 
Now, I would like you to share your ideas. I am going to go around the table and 
ask each of you to give me one or two ideas from your worksheet. After the entire 
list is on the board, we will discuss and clarify the ideas.  
We are now going to include some outcomes [impacts] that other patients told us 
in the past, or outcomes that have been included in recent research studies. 
[write on whiteboard, read them out, and clarify]  
Are any of the outcomes unclear to anyone? If not, we will take a short break 
while we print out the list of outcomes. We will then rank these items from most 
important to least important.   
 Break 
(10 minutes)  
10 mins Break 
Print list of outcomes for ranking.  
 Phase 3 – Nominal group Technique (Part 2) 
(30 minutes)  
30 mins  Now we are going to look at all the ideas raised by the group and I will ask you to 
rank them in order of most important to least important to you.  If you find it 
difficult to rank the whole list, please try to rank the top 20.  
Now we will have a discussion to discuss any similarities and differences in 
ranking.  
What did everyone put as: number 1, number 2, number 3, least important? 
Would anyone like to explain why they ranked (22) or how they made their 
decisions about ranking? 
Why do you think most people ranked (22) high/low? 
Why do you think there are differences in ranking of (22)? 
 
 Wrap up 
(1 minute)  
1 min Wrap up 
Wrap up, acknowledgement. 
Thank you and closing remarks. 
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Appendix E: Supporting data for Chapter 7 
 
E.1. Search results  
MEDLINE
2537 citations 
Embase
5111 citations
PsycINFO
70 citations 
CINAHL
849 citations
citations
8570
Title and abstract review
Excluded (n = 8150)
Duplicate articles
No living kidney donors (recipient, other solid organ/tissue donor, multiple organ donor, deceased)       
Conference abstracts 
Non primary research (reports, reviews, editorials, guidelines, protocols, policy statements, ethics)
Pre-2011 studies
Non clinical research (prevalence of donors, economics, information quality, practice variations)
Pre-donation donor characteristics
Validation studies (surveys, outcome measurement)
Qualitative study
Surveys of knowledge/attitudes
Basic science, genetics and animal research
Descriptive studies (surgical technique, anatomical variation)
Full text analysis
Excluded (n = 152)
Case reports (< 10 participants) 
Non primary research (letter, reviews, editorial, protocol) 
Non study population (recipient, graft biopsy, donors used as ‘healthy controls’, terminally ill)
Descriptive study (donor characteristics, anatomy)
Non-English publication
Outcome measurement validity study 
Conference abstracts 
Economic study 
Modeling study
citations
420
Included in systematic review 
268 studies
(n = 556,102)
Other sources
3 citations  
39
39
29
17
12
8
6
1
1
3218
1616
1057 
867
487
267
185
154
115
110
75
11
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E.2. Frequency of outcome measures (definitions and time points) among trials reporting mortality (42 studies, 23 outcome measures). 
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E.3. Frequency of outcome measures (definitions and time points) among trials reporting cardiovascular event (24 studies, 21 outcome 
measures). 
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E.4. Frequency of outcome measures (definitions and time points) among trials reporting ESKD (26 studies, 18 outcome measures). 
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E.5. Frequency of outcome measures (definitions and time points) among trials reporting kidney function (154 studies, 116 outcome 
measures). 
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E.6. Frequency of outcome measures (definitions and time points) among trials reporting blood pressure (74 studies, 88 outcome 
measures). 
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E.7. Frequency of outcome measures (definitions and time points) among trials reporting proteinuria/ albuminuria (65 studies, 29 
outcome measures). 
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E.8. Frequency of outcome measures (definitions and time points) among trials reporting pain (73 studies, 75 outcome measures). 
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E.9. Frequency of outcome measures (definitions and time points) among trials reporting physical function (42 studies, 33 outcome 
measures) 
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E.10. Frequency of outcome measures (definitions and time points) among trials reporting psychological impact (39 studies, 44 outcome 
measures). 
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E.11. Search Strategy  
MEDLINE 
January 2006 - May 2017 
Embase 
January 2006 - May 2017 
PsycINFO 
January 2006 - May 2017 
Liv$ donor nephrect$ 
Liv$ kidney donor$ 
Living Donors/ and Kidney/ 
Liv$ donor nephrect$ 
Liv$ kidney don$ 
Living donor/ kidney/ 
Liv$ donor nephrect$ 
Liv$ kidney don$ 
 
Appendix E 
235 
 
E.12. Proportion of studies reporting each clinical outcome (268 studies, 51 outcome domains) 
Domains (clinical outcomes) All (n = 268) 
Time to discharge 96 (35.8) 
Blood loss 85 (31.7) 
Operative time 79 (29.5) 
Complication (unspecified) 62 (23.1) 
Postoperative complication (unspecified) 43 (16.0) 
Mortality 42 (15.7) 
Surgical site infection 41 (15.3) 
Conversion to open surgery 40 (14.9) 
Hospital readmission 31 (11.6) 
Perioperative injury 29 (10.8) 
ESKD 26 (9.7) 
Postoperative bowel function 26 (9.7) 
Cardiovascular event 24 (9.0) 
Hernia 24 (9.0) 
General infection 23 (8.6) 
Reoperation 23 (8.6) 
Intraoperative complication (unspecified) 21 (7.8) 
Diabetes 20 (7.5) 
Pulmonary event 18 (6.7) 
Genitourinary function 16 (6.0) 
Thrombosis/embolization 15 (5.6) 
Appearance of incision 13 (4.9) 
Wound complication 12 (4.5) 
Chylous ascites 11 (4.1) 
Nausea/vomiting 11 (4.1) 
Gastrointestinal disorder 9 (3.4) 
Fat necrosis/seroma 7 (2.6) 
Fever 7 (2.6) 
Paresthesia/hypoesthesia 7 (2.6) 
Oedema 6 (2.2) 
Cancer 5 (1.9) 
Nephrolithiasis 5 (1.9) 
Pruritus 5 (1.9) 
Dehydration 3 (1.1) 
Fertility 3 (1.1) 
Gout 3 (1.1) 
Pregnancy complications 3 (1.1) 
Skin  3 (1.1) 
Lymphatic fistula 2 (0.7) 
Thyroid disease 2 (0.7) 
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Fracture 1 (0.4) 
Hydrocele 1 (0.4) 
Liver disease 1 (0.4) 
Lupus  1 (0.4) 
Metabolic syndrome 1 (0.4) 
Osteoarthritis 1 (0.4) 
Postoperative epigastric function 1 (0.4) 
Septicemia 1 (0.4) 
Tuberculosis 1 (0.4) 
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E.13. Proportion of studies reporting each surrogate outcome (268 studies, 35 outcome 
domains) 
Domains (surrogate outcomes) All (n = 268) 
Kidney function 154 (57.5) 
Blood pressure 74 (27.6) 
Proteinuria, albuminuria 65 (24.3) 
BMI/weight/composition 37 (13.8) 
Lipids 29 (10.8) 
Anaemia/haemoglobin/iron 21 (7.8) 
Glucose metabolism 16 (6.0) 
Uremic toxins and uric acid 14 (5.2) 
Cardiovascular function 13 (4.9) 
Inflammatory markers/oxidative stress 12 (4.5) 
Kidney morphometry 12 (4.5) 
Calcium 9 (3.4) 
Phosphate 9 (3.4) 
PTH 9 (3.4) 
Urea 9 (3.4) 
Bone metabolism 8 (3.0) 
Vitamin D metabolism 5 (1.9) 
Blood pressure regulating hormone 4 (1.5) 
Kidney biomarker 4 (1.5) 
Liver function 4 (1.5) 
White blood cells 4 (1.5) 
Calcification 3 (1.1) 
Endothelial function 3 (1.1) 
Kidney pathology 3 (1.1) 
Kidney physiology 2 (0.7) 
Sodium 2 (0.7) 
Adrenal function 1 (0.4) 
Calcium x phosphate 1 (0.4) 
Cpk 1 (0.4) 
Kidney hemodynamics 1 (0.4) 
Magnesium 1 (0.4) 
Medication (unspecified) 1 (0.4) 
Potassium 1 (0.4) 
Respiratory function 1 (0.4) 
Vitamin A metabolism 1 (0.4) 
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E.14. Proportion of studies reporting each donor-reported outcome (268 studies, 23 
outcome domains) 
Domains (patient-reported outcomes) All (n = 268) 
Pain 73 (27.2) 
Physical function 42 (15.7) 
Psychological impact 39 (14.6) 
Mental health 37 (13.8) 
Quality of life (global) 35 (13.1) 
Social functioning 33 (12.3) 
Fatigue/energy 27 (10.1) 
Satisfaction with donation  17 (6.3) 
Recovery - global return to activity 17 (6.3) 
Cosmetic satisfaction 16 (6.0) 
Depression 16 (6.0) 
Financial impact 15 (5.6) 
Employment 13 (4.9) 
Anxiety 11 (4.1) 
Donor-recipient relationship 9 (3.4) 
Sexual function 4 (1.5) 
Sleep 4 (1.5) 
Muscle weakness 3 (1.1) 
Spiritual impact 3 (1.1) 
Life satisfaction 2 (0.7) 
Caregiver burden 1 (0.4) 
Cognition 1 (0.4) 
Education attainment 1 (0.4) 
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E.15. Frequency of all outcome domains reported in therapy studies (91 studies, 70 outcome 
domains) 
Outcome domains 
Number of 
studies 
% (/91 studies) Classification 
Time to discharge 72 79.1 Clinical 
Blood loss 66 72.5 Clinical 
Operative time 62 68.1 Clinical 
Donor complication (unspecified) 45 49.5 Clinical 
Kidney function 45 49.5 Surrogate 
Pain 40 44.0 Donor-reported 
Conversion to open surgery 34 37.4 Clinical 
Donor postoperative complication (ns) 31 34.1 Clinical 
Surgical site infection 27 29.7 Clinical 
Perioperative injury 25 27.5 Clinical 
Postoperative bowel function 19 20.9 Clinical 
Donor intraoperative complication (ns) 18 19.8 Clinical 
General infection 16 17.6 Clinical 
Hernia 16 17.6 Clinical 
Hospital readmission 16 17.6 Clinical 
Reoperation 15 16.5 Clinical 
Appearance of incision 13 14.3 Clinical 
Cosmetic satisfaction 13 14.3 Donor-reported 
Physical function 11 12.1 Donor-reported 
Thrombosis/embolization 11 12.1 Clinical 
Recovery - global return to activity 10 11.0 Donor-reported 
Fatigue/energy 9 9.9 Donor-reported 
Mortality 9 9.9 Clinical 
Pulmonary event 9 9.9 Clinical 
Chylous ascites 8 8.8 Clinical 
Psychological impact 8 8.8 Donor-reported 
Social functioning 8 8.8 Donor-reported 
Anaemia/haemoglobin/iron 7 7.7 Surrogate 
Genitourinary function 7 7.7 Clinical 
Nausea/vomiting 7 7.7 Clinical 
Quality of life (global) 7 7.7 Donor-reported 
Wound complication 7 7.7 Clinical 
Cardiovascular event 6 6.6 Clinical 
Fat necrosis/seroma 6 6.6 Clinical 
Mental health 6 6.6 Donor-reported 
Blood pressure 5 5.5 Surrogate 
Fever 5 5.5 Clinical 
Oedema 4 4.4 Clinical 
Paraesthesia/hypoesthesia 4 4.4 Clinical 
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Proteinuria, albuminuria 4 4.4 Surrogate 
Satisfaction with donation  4 4.4 Donor-reported 
Employment 3 3.3 Donor-reported 
Financial impact 3 3.3 Donor-reported 
Gastrointestinal disorder 3 3.3 Clinical 
Sexual function 3 3.3 Donor-reported 
Anxiety 2 2.2 Donor-reported 
ESKD 2 2.2 Clinical 
Fertility 2 2.2 Clinical 
Kidney biomarker 2 2.2 Surrogate 
liver function 2 2.2 Surrogate 
lymphatic fistula 2 2.2 Clinical 
Pruritus 2 2.2 Clinical 
Skin 2 2.2 Clinical 
Adrenal function 1 1.1 Surrogate 
Blood pressure regulating hormone 1 1.1 Surrogate 
BMI/weight/composition 1 1.1 Surrogate 
Creatinine phosphokinase (Cpk) 1 1.1 Surrogate 
Dehydration 1 1.1 Clinical 
Depression 1 1.1 Donor-reported 
Glucose metabolism 1 1.1 Surrogate 
Hydrocele 1 1.1 Clinical 
Inflammatory markers/oxidative stress 1 1.1 Surrogate 
Lipids 1 1.1 Surrogate 
Postoperative epigastric function 1 1.1 Clinical 
Pregnancy complications 1 1.1 Clinical 
Respiratory function 1 1.1 Surrogate 
Septicaemia 1 1.1 Clinical 
Sodium 1 1.1 Surrogate 
Uremic toxins and uric acid 1 1.1 Surrogate 
White blood cells 1 1.1 Surrogate 
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E.16: Frequency of all outcome domains reported in prognosis studies (177 studies, 100 
outcome domains) 
Outcome domains 
Number of 
studies 
% (/177studies) Classification 
Kidney function 109 61.6 surrogate 
Blood pressure 69 39.0 surrogate 
Proteinuria, albuminuria 61 34.5 surrogate 
BMI/weight/composition 36 20.3 surrogate 
Mortality 33 18.6 clinical 
Pain 33 18.6 donor-reported 
Mental health 31 17.5 donor-reported 
Physical function 31 17.5 donor-reported 
Psychological impact 31 17.5 donor-reported 
Lipids 28 15.8 surrogate 
Quality of life (global) 28 15.8 donor-reported 
Social functioning 25 14.1 donor-reported 
ESKD 24 13.6 clinical 
Time to discharge 24 13.6 clinical 
Diabetes 20 11.3 clinical 
Blood loss 19 10.7 clinical 
Cardiovascular event 18 10.2 clinical 
Fatigue/energy 18 10.2 donor-reported 
Complication (unspecified) 17 9.6 clinical 
Operative time 17 9.6 clinical 
Depression 15 8.5 donor-reported 
Glucose metabolism 15 8.5 surrogate 
Hospital readmission 15 8.5 clinical 
Anaemia/haemoglobin/iron 14 7.9 surrogate 
Surgical site infection 14 7.9 clinical 
Cardiovascular function 13 7.3 surrogate 
Satisfaction with donation  13 7.3 donor-reported 
Uremic toxins and uric acid 13 7.3 surrogate 
Postoperative complication (unspecified) 12 6.8 clinical 
Financial impact 12 6.8 donor-reported 
Kidney morphometry 12 6.8 surrogate 
Inflammatory markers/oxidative stress 11 6.2 surrogate 
Employment 10 5.6 donor-reported 
Anxiety 9 5.1 donor-reported 
Calcium 9 5.1 surrogate 
Donor-recipient relationship 9 5.1 donor-reported 
Genitourinary function 9 5.1 clinical 
Phosphate 9 5.1 surrogate 
PTH 9 5.1 surrogate 
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Pulmonary event 9 5.1 clinical 
Urea 9 5.1 surrogate 
Bone metabolism 8 4.5 surrogate 
Hernia 8 4.5 clinical 
Reoperation 8 4.5 clinical 
General infection 7 4.0 clinical 
Postoperative bowel function 7 4.0 clinical 
Recovery - global return to activity 7 4.0 donor-reported 
Conversion to open surgery 6 3.4 clinical 
Gastrointestinal disorder 6 3.4 clinical 
Cancer 5 2.8 clinical 
Nephrolithiasis 5 2.8 clinical 
Vitamin D metabolism 5 2.8 surrogate 
Wound complication 5 2.8 clinical 
Nausea/vomiting 4 2.3 clinical 
Perioperative injury 4 2.3 clinical 
Sleep 4 2.3 clinical 
Thrombosis/embolization 4 2.3 clinical 
Blood pressure regulating hormone 3 1.7 surrogate 
Calcification 3 1.7 surrogate 
Chylous ascites 3 1.7 clinical 
Cosmetic satisfaction 3 1.7 donor-reported 
Intraoperative complication (unspecified) 3 1.7 clinical 
Endothelial function 3 1.7 surrogate 
Gout 3 1.7 clinical 
Kidney pathology 3 1.7 surrogate 
Muscle weakness 3 1.7 donor-reported 
Paresthesia/hypoesthesia 3 1.7 clinical 
Pruritus 3 1.7 clinical 
Spiritual impact 3 1.7 donor-reported 
White blood cells 3 1.7 surrogate 
dehydration 2 1.1 clinical 
Fever 2 1.1 clinical 
Kidney biomarker 2 1.1 surrogate 
Kidney physiology 2 1.1 surrogate 
Life satisfaction 2 1.1 donor-reported 
Liver function 2 1.1 surrogate 
Oedema 2 1.1 clinical 
Pregnancy complications 2 1.1 clinical 
Thyroid disease 2 1.1 clinical 
Calcium x phosphate 1 0.6 surrogate 
Caregiver burden 1 0.6 donor-reported 
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Cognition 1 0.6 donor-reported 
Education attainment 1 0.6 donor-reported 
Fat necrosis/seroma 1 0.6 clinical 
Fertility 1 0.6 clinical 
Fracture 1 0.6 clinical 
Kidney hemodynamics 1 0.6 surrogate 
Liver disease 1 0.6 clinical 
Lupus  1 0.6 clinical 
Magnesium 1 0.6 surrogate 
Medication (unspecified) 1 0.6 surrogate 
Metabolic syndrome 1 0.6 clinical 
Osteoarthritis 1 0.6 clinical 
Potassium 1 0.6 surrogate 
Sexual function 1 0.6 donor-reported 
Skin  1 0.6 clinical 
Sodium 1 0.6 surrogate 
Tuberculosis 1 0.6 clinical 
Viral hepatitis 1 0.6 clinical 
Vitamin A metabolism 1 0.6 surrogate 
 
 
 
 
 
 
 
 
 
 
